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Abstract 
Nadyah Y. A. H. Alayadhi 
Establishing an Essential Medicine List for the State of Kuwait  
Keywords:  Essential Medicine List, Rational drug use, Pharmacovigilance, 
Transparency, GCC health profile and economy, Standard Treatment 
Guidelines, selection criteria. 
 The Health Sector at the state of Kuwait is facing many challenges. 
One of which is public expectations in health are high, and thus, the Ministry 
of Health (MOH) in Kuwait has amplified the health expenditure by 86% 
since 2007. And since the medicine budget represents half of the total MOH 
budget, it is proposed that the development in health policy might be a 
suitable tool to control the inflation within the health budget. This thesis 
examines the opportunities and challenges of introducing an EML in Kuwait 
and the factors influencing its effectiveness. A mixed-methodology approach 
has been used to enhance and validate the data, in the form of interviews, 
comparative studies and questionnaires. One major limitation to the research 
was the lack of previous data relating to this work, and the information should 
be gathered in person in the form of hard copies, and later, the data was 
analysed using qualitative and quantitative approaches.    
 It has been attained that, the EML might be a valuable tool if adopted 
and implemented appropriately, EML adjustment to country health situation 
is crucial for successful utilisation and fulfilling the concept objectives. 
 Standard Treatment Guidelines are fundamental part of EM selection 
process, in Kuwait there were lack in the uniformity of the local STG, but 
fortunately, there is an eagerness to innovate, and the medicine situation 
might benefit from a type of organisation, overall, if the EML implemented 
efficiently in Kuwait, it might help in improving the general health and control 
the inflation in MOH budget.  
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Chapter 1 
 INTRODUCTION 
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1.0 Introduction 
 The collaborative work of healthcare professions is aimed generally in 
one direction, to provide the best possible healthcare services to all of the 
population. The prescribing and dispensing of medicines, the work of the 
healthcare professionals, the operation of healthcare facilities and the use of 
diagnostic tools should all be designed to work in collaboration. However, to do 
this they all need to work in harmony and connect together, otherwise they are 
likely to cause incomplete levels of healthcare and the patient consequently 
may not receive the full healthcare support which is needed and thus may not 
fully recover. For this reason, there should be development of the programme to 
use the Ministry of Health’s budget efficiently and they should consider all 
aspects related to healthcare, through planning the use of the budget and the 
funding from a government, rather than spending most of the budget on just one 
aspect, which could result in another part suffering and lead to an overall 
inappropriate healthcare service. In some cases, where governments and 
health ministries have been shown to over-spend on one aspect, the tendency 
is often that in the next period, in order that other aspects of healthcare will not 
suffer, there is a tendency to compensate by increasing the request for a higher 
health budget. For this reason, a large debate often occurs at government 
ministerial meetings which try to assess how much should be spent without 
being excessive or going the other way and being insufficient (Waddell, 2010).  
 The World Health Organisation (WHO) during World Health Assembly 
meetings acknowledged this situation arising and has made suggestions on 
what is considered as appropriate health expenditure. In 1981, the WHO first 
made a recommendation and stated that countries should consider spending no 
more than 5% of national income on healthcare services. Following this 
proposal, Savedoff, in 2007, discussed the issue further and debated in more 
detail the question of how much a country should be spending on Healthcare 
Services (Savedoff, 2007).  
 In his proposal, Savedoff suggested that a country should firstly consider 
the overall financial position of a country in accordance with the per capital 
health spending and that they should take this into account, alongside the WHO 
statement that ‘countries should spend, not more than 5% of national income on 
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health care services’ (Savedoff, 2007). However, Savedoff suggested that there 
was still some confusion around the 5% figure and that it only appeared in WHO 
documents in 1981 as an indicator, that should be monitored, but not as a 
strictly recommended level of health spending. He suggested however that in 
recent years it may be the case that researchers, journalists, and policymakers 
have transformed this figure into a firm recommendation. 
 The 5% figure is however being regularly surpassed in many countries 
and the question which should be answered at this stage is why the growth is 
still rising? However from knowledge gathered it can be suggested that the 
answer is far from being straightforward, because healthcare is a very complex 
system, and is known to be governed by multi-factors. It is proposed that it can 
involve not only the budget of the country but also the life-style and the 
expected standards of living of the population, the quality of the healthcare 
providers, the standard of the healthcare facilities and what diagnostic tools are 
available and in operation within a country.  It is proposed that all these aspects 
should work in collaboration to enhance the health of the population. But in 
introducing an improved Healthcare System there is the possibility of increasing 
cost. But it is expected that through increased efficiency in service and 
reduction of health issues increased costs can be controlled and may be 
reduced in the future. 
 
                             
 
 
 
 
 
Fig 1.1: Satisfactory Healthcare Chart 
Source: created by author based on data from the WHO 
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 The diagram above is one way of summarising what aspects need to be 
available to provide a satisfactory health service. But a major key point is having 
suitable financing in place, to ensure aspects of health and living are up to the 
standards expected in the country. From this financial basis, a country can have 
reasonable resources to include quality medicines, good regulatory control, and 
choice of medicines. These are likely to give a good impact on the efficiency of 
the diagnostic tools and the healthcare facility quality, and of course it is likely to 
ensure that the patient will receive high quality medicine. But in practice, 
unfortunately, that is not always the case, as it has been suggested by a 
number of agencies including the WHO that more than 50% of medicines 
worldwide may be being prescribed, dispensed, or sold inappropriately (WHO, 
2015).   
 An approach has been suggested by Hogerzeil (2004) in an attempt to 
come up with solution to control a medicine budget and provide good 
prescribing practice.  His suggestion was that the more affluent and countries 
with gross national income (GNI) of more than $12,476, should follow in the 
footsteps of the less fortunate countries, and adopt a more systematic way of 
controlling the cost of medicines. He suggested that this is important to prevent 
a future uncontrollable increase in health cost leading to a crisis in health 
management. It can be suggested from past evidence to be a reasonable 
approach but it needs to be borne in mind that each country’s experience is 
unique to that specific country and a careful deliberation needs to be adopted in 
a suitable manner. It is considered important when looking at the escalating 
health budget to look at the reason behind this increase and try to locate the 
source of inflation, whether it’s using too expensive medical technologies, over 
prescribing or even the tendency to preferentially prescribe a newer more 
expensive medicine.  This medicine may not have established an advantage to 
other previously available medicines.  From this short overview, it can be seen 
that there are many other sources of health fund drainage and as a result each 
country that have an interest in rationalisation should approach changes 
carefully (Hogerzeil, 2004).   
 Hogerzeil, 2004 in his study also suggests that there are a number of  
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alongside an increase of medicines cost. Taking one of the developed countries 
as an example in the SCRIP report which is an English International 
Pharmaceutical news, analysis and data service no (1974:21) it is indicated that 
there was an increase in medicine cost by 93% between 1987 and 1993 in 
Canada. It is then stated that 33% of this increase was due to the medicine 
price elevation, 15% due to increased quantities of medicines dispensed per 
prescription, and 55% was a direct result of prescribing new medicines (SCRIP, 
1994).  
 From this report, it can be suggested that medicines can play a major 
part in increasing the healthcare budget, and control of this part of the budget is 
very important when developing Health Policy.  
 In providing a basis for a Policy this major issue can be tackled by 
carefully observing other countries methods in controlling the limited health 
budget that is available.  
 In developing and low income countries it has been proposed that, 
because of the limited financial resources, the predicament has always been 
how to get the best medicine with reasonable quality within the limited budget 
available. As an indicator it has been reported that this approach was followed 
by many developed and high income countries, as a mean of controlling the 
inflation in health expenditure.  Typically Australia developed the practice of 
pharmaceutical reimbursement (Drummond, 1992), which is based on a limited 
list of medicines and also around the same time the United States of America 
introduced a restricted list of medicines for reimbursement (Lipton et al, 2000) 
(Gold et al, 1995).  
 In 2006, according to a publication by the WHO referred to as Contact 
(No 183, 2006), developed countries, were shown to spent roughly between 
10% and 20% of their national health budget on medicines and in contrast 
developing countries, the range was higher and was shown to be between 20% 
and 40%.  This development in spending of a high percentage of national 
income on healthcare has been noted by the OECD (Organisation for Economic 
Co-operation and Development), across the world. According to OECD (2011), 
the growth of health spending, which includes spending by both public and  
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private sources on medical services and goods, public health and prevention 
programmes and administration, (OECD, 2011) has suggested that spending 
has risen faster than the average GDP over the past 50 years. According to 
their figures it escalated from 4% of GDP in 1960 to 17% of GDP in 2009 
(OECD, 2011). 
 
 In practice the actual percentage of a country’s spending on healthcare 
does vary; as is shown on the following chart which represents Total Health 
Expenditure as a share of GDP in 2009 across a range of countries (OECD 
2011). 
 
Figure 1.2: Total health expenditure as a share of GDP, 2009 (or nearest year) 
Source: “Health at a Glance 2011: OECD Indicators- © OECD 2011” 
 
 The figure reveals that the USA spends over 17% on Healthcare, which 
can be explained partly by the various insurance schemes that are available to 
the public that allows physicians to prescribe more expensive treatment 
regimens, if the patient is covered by an elite health insurance scheme. There 
was a study in 2013 conducted by the Commonwealth Fund which however 
revealed that spending a large amount in healthcare in the USA did not 
necessarily provide better health to the population. The report indicated at that  
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time that the USA had the worst outcome in chronic diseases, obesity and infant 
mortality in comparison to the other high income countries that have undergone 
the study (Squires and Anderson, 2015). The report demonstrated that in the 
USA the patient receives an average of 2.2 medicines per prescription and that 
could contribute to higher spending on healthcare, alongside other reasons. 
 Therefore, the presence of these reports appears to indicate that over 
prescribing of expensive medicines does not necessarily guarantee good 
health.  It can be proposed that a certain level of investigation into the source of 
funding wastage and the strategies which should be implemented to review and 
address this wastage of health and financial resources should be carried out to 
try to come up with solutions. Such solutions could aim mainly to enhance the 
general health and provide a reasonable and practical control over spending. 
This situation is similar to Kuwait’s Healthcare situation; because Kuwait is a 
country with excellent access to all kind of health-related resources and large 
fund availability.  But unfortunately, it suffers from the lack of good 
managements of these resources and funds, as has been discussed earlier and 
it became clear following the study conducted by the Commonwealth Fund that 
the availability of cutting edge medical technologies and expensive medicines 
does not indicates better health and doesn’t guarantee good utilisation of these 
resources.  With this comment Kuwait total health expenditure as a share of 
GDP is low, it is only 3.9%, explaining this figure is not very easy because of the 
lack of data related to Kuwait and the lack of evidence to support this 
information.  
 The following figure demonstrates the fluctuation of Kuwait’s Health 
expenditure as a percentage of the total GDP from 1995 until 2014, sourced 
from the World Bank Publications, it is apparent that in the nineties the total 
health expenditure was higher than what it is currently then it went down in the 
beginning of the millennium and started increasing again slowly (world Bank, 
2015).  
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 The situation can be partly explained that the fluctuation is based on 
what the Kuwait Ministry of Finance allocates to the MOH, and as a result the 
MOH needs to work within this budget, however there are some exceptions 
when the budget requires intensification, but that is a different process.  
 In the previous discussion above relating to the Commonwealth Fund 
study, the position in the USA and Australia is referred to.  But to get a balanced 
viewpoint it should be worthwhile to look at the attempts made by other 
countries with lower levels of funding for health resources and try to extract 
suitable indicators.  These could be considered for Kuwait and it would be 
beneficial to try to find successful countries, where it has been used to control 
their health budget, and could be considered for implementation in the 
outcomes of this research. 
 As shown in figure 3 mentioned above, the overall cost of medicines can 
be high and therefore any developments in restricting the List of Medicines 
could generally benefit a Health Service.  Therefore, it is proposed that there is 
an urgent need to control medicine use and promote rational drug use, which 
would lead to improved medicine access and decreased cost. This in turn could 
lead to important decreases in morbidity and mortality. It is proposed that the 
main way to have a better management of the healthcare situation is to 
implement a well-established and tested policy; where the strategy should be to 
aim to improve rational drug use, promote cost effectiveness and accommodate 
the health needs of the population.  
1995 1998 2000 2004 2006 2008 2010 2012 2014
% GDP 3.1 3.5 1.9 2.2 1.8 1.5 2.3 2.2 2.6
0
0.5
1
1.5
2
2.5
3
3.5
4
%
Figure 1.3: Kuwait Health Expenditure, Public (% of GDP)
Source: based on data from Kuwait Health publication, 2015
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 However, it is important to be realistic and flexible and within a country it 
is important to ask whether a country should have a structured Medicine Policy?  
The response could be that a well-organised policy gives a framework for 
healthcare professionals to work within, in order for them to achieve adequate 
patient oriented care, to bear in mind the quality of the services provided and 
have a well-balanced budget (WHO, 2016).  
 The programme for Essential Medicine Lists, which was started in 1977 
after discussions at the World Health Authority’s meeting was then taken up by 
the WHO, It is a good example today of a structured, time-tested system that 
can provide the accurate requirement of medicines that satisfies the health 
needs of a population.  
 It is over forty years since the World Health Assembly discussed the 
need for recommendations of an organised ‘list of medicines’ and proposed this 
should be investigated further.  The history behind the current list started in 
1975 when Resolution WHA28.66 from the World Health Authority instructed 
the WHO to assist countries in the selection and procurement of essential 
drugs. The first list was published in 1977, but it faced criticism from prescribers 
because it suggested restrictions on some medicines which were in countries 
and commonly in use. But in 1978 the Alma Ata, Kazakhstan conference 
confirmed the agreement for the importance of the Essential List concept and in 
1981 it was recognised as an important management requirement by the first 
edition of Managing Drug Supply. (R. Laing Et al 2003).    
1.1 Aims: 
The aim of this research is to examine the opportunities and challenges of 
introducing an EML in Kuwait and the factors influencing its effectiveness. 
To achieve this aim, the following research questions have been formulated: 
1.2 Research Questions which should be answered are: 
 What is an Essential Medicine List and why do countries need it? 
 What are the characteristics of an effective EML Programme? 
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 To what extent have other countries succeeded in their 
implementation of an EML? 
 What are the contextual factors in Kuwait which would assist or 
hinder effective implementation of EML? 
1.3 Study objectives 
 Identify the concept of the Essential Medicines.  
 To find out if it is possible to implement the EML concept in Kuwait.  
 What might be the required steps to introduce it successfully.  
 An attempt to detect the source of drainage in relation to the 
medicines budget. 
 Try to recognise other beneficial characteristic for the EML concept, 
such as the reorganisation of the medicines situation in the Kuwait 
Public sector, it might promote rational drug use, increase patient 
trust and confidence in the healthcare services at the state of Kuwait 
and to promote healthier population. 
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Chapter 2 
Critical Literature Review 
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2.1 Introduction to Literature Review (LR) Methodology  
 The review was carried out to extract knowledge on the subject of 
Essential Medicine Lists (EML) from the literature, to try to understand the 
importance of an EML and the basis of setting up an EML and summarising the 
impact an EML can have in a constructive manner. The LR was carried out in a 
systematic manner and focused on research questions, which would try to 
identify the basis of EML’s, evaluate their value and to examine relevant and 
high-quality studies that were available and related to the topic and the research 
questions. The purpose in mind while conducting the LR would be to present 
the value of an Essential Medicine List and relate the concept of the EML to 
past and present experiences, then to introduce the fundamental elements of 
the PhD research programme and link this to Kuwait’s health profiles. 
 The LR would attempt to focus on giving an unbiased approach, by 
reviewing the work of many researchers from different countries and from 
different backgrounds and to try to make the approach as thorough and 
transparent as possible. The LR was carried out at the very early stages of the 
research and was carried on throughout the research period by adding new 
material. By doing so, it was proposed that it would enhance the methodology 
and contextualise the findings.    
 It was conducted in a systemic manner to increase efficiency and reduce 
time consumption. This meant, basically, that the literature review focuses on 
the studies and previous research, related mainly to an EML and to Kuwait’s 
health profile and includes examples from other neighbouring countries that 
have a similar health profile to Kuwait’s and already have an established EML.    
2.1.1 Time Frame of Literature Review (LR) 
 It was started in early February 2013 and continued until the end of the 
research; in total the LR work was concentrated on the first year, and then 
carried on parallel with the research. 
 2.1.2 Aim 
To identify information regarding:  
 Past/present Essential Medicine List programmes in similar countries. 
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 The elements and criteria, of an Essential Medicine List. 
 Exploration of each criterion associated with the EML. 
 The relationship between Kuwait and the Gulf Co-op Council in terms of 
the demography and health indicators. 
 
2.1.3 Purpose of the Literature Review    
 The LR was conducted; in order establish why is an EML is needed, to 
become more acquainted with all elements of an EML. This could include 
aspects such as the history of the EML, when was it started, who launched the 
idea of an EML, who has adopted EML’s, and has the EML or generally a 
restricted medicines list been a success. 
 It was expected that as the LR search progressed, there may be an 
opportunity to find information on whether the EML concept has expanded with 
time and how has the selection criteria on the EML evolved or remained the 
same.   
 Through studying the literature from the LR it could lead into an 
explanation of the popularity of the concept and whether there has been an 
expansion into many countries, worldwide. The LR may demonstrate the 
advantages and disadvantages of an EML programme and give an insight into 
what hindrances might be expected when starting the programme.  In addition, 
it could explain the evolution of the list from 1977 until its current form today.  
Each concept of establishing a list, which needs to be considered when 
launching the programme, would be reviewed.              
 As the overall major research aim, is to discuss the basis for introduction 
of an EML programme for the State of Kuwait, in developing the background to 
the programme, it was considered vitally important to research into the basis of 
the health sector of Kuwait and the surrounding countries that share a similar 
health profile to that of Kuwait. An example is the countries which make up the 
GCC countries, this is an abbreviation for the Gulf Co-operative Council which 
is a political and economic alliance of six Middle Eastern countries—Saudi 
Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman. The GCC 
was established in Riyadh, Saudi Arabia, in May 1981, the GCC countries that 
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were studied are the ones with an Essential Medicine List. In the LR the health 
burdens experienced by the GCC region would be considered, as well as the 
health cost, health budget and expenditure, and the demography of the GCC 
region.   
2.1.4 Key Words 
 Several key words been used to research the literature, the following list 
represents them; 
 Essential Medicine List. 
 Rational drug use. 
 Pharmacovigilance. 
 Transparency. 
 GCC health profile and health economy. 
 Standard Treatment Guidelines. 
 Essential Medicines selection criteria. 
 
2.1.5 Search Protocol 
 Many search engines and scientific website that published related 
articles were included in the LR research the following is the list of the site being 
used for the research; 
 Google Scholar. 
 Pubmed/Medline. 
 Athens/SCOPUS/Sciverse/Bradfinder. 
 WHO site. 
 GCC library. 
 Arab Planning institute (Arabic language search). 
 National Electronic Library for Medicines. 
 ISI web of Knowledge. 
 Global Health. 
 International Pharmaceutical Abstract. 
 CoChrane Library. 
 CINAHL. 
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 World Bank Web. 
2.1.6 Date of Search 
 Ranges from 1975 until the research thesis submitted. 
2.1.7 Language of Search 
 The search language was mainly an English and Arabic search, but there 
was important requirements to include a few articles in French which are 
translated into English using google translate, the reason is because in 
countries like Morocco, Tunisia and Algeria, the official language being used 
and dealt by the majority of the population is French.        
2.1.8 Exclusion Criteria   
 The first criterion for exclusion was based on the irrelevance of the title to 
the LR research questions, some titles did not includes the EML as a main topic 
and only included small section in the article itself, therefore, such articles have 
been excluded, there were a large number of articles that were excluded based 
on the fact that they appeared in more than one journal, Many articles were 
excluded because when going through them they were irrelevant to the concept 
of the EML and introduced no significance to the LR.  Another exclusion 
criterion was based on the fact that some journals were inaccessible or required 
a very expensive subscription fees to access them, and Journals that were 
published in different languages other than Arabic, and English were also 
excluded, except as indicated above a few articles in French that required 
google translate to explain literature relating to the North African Arabic 
countries were written in French.  
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  The following diagram represents a brief indication on how the LR was 
conducted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1:  Exclusion and inclusion criteria in the literature Review 
  
Article search  
(Essential medicine List, Rational 
Drug use, Pharmacovigilance, 
transparency, GCC health profile and 
economy, standard treatment 
guidelines) 
 
n= 2,803,761  
Articles Identified in Arabic and 
English 
n= 3,065 
Articles relevant 
n= 2,800,696 
Excluded based on irrelevance of 
the title 
n=   2,801 article excluded 
Some articles multi-published in separate journals 
Others excluded in bases of irrelevance 
n= 1,495 inaccessible  
n= 300 articles published in different language  
N= 264 
Article met the criteria 
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 The references that met the required criteria of the research were close 
to 300 references, they were in published journals, government publications and 
books. 
 Most of the references relating to the concept of Essential Medicines List 
were sourced from the WHO library, few were published by various researchers 
in the field, a large number of the figures, percentages and statistics were 
sourced from the World Bank, the WHO surveys, and each individual countries 
official government Data.  
2.1.9 Limitation of the Literature Review 
 Information in relation to Kuwait’s healthcare situation were very limited, 
and very few studies have been conducted to explain the actual healthcare and 
medicines situation in Kuwait.  A similar situation was noted in other Gulf Co-
Operative Countries and for this reason the information was collected in person 
through field-trips to the countries from various government departments. 
 Another limitation was related to the language, and as there were a few 
related articles published in French and it took a very long time to be translated.  
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2.2.0 The Essential Medicine List   
 The Essential Medicine List, programme as first proposed in 1977 by the 
WHO, is still discussed and developed in the similar initial manner when it’s first 
launched, with regular meetings of the medicine selection committee every two 
year, and from experience and knowledge it appears to be a good example 
today of a time-tested system that provides the efficient method of proposing a 
suitable List of Medicines that can satisfy the health needs of a population. The 
WHO EML concept has initially targeted countries with limited resources and 
poor medicine access; the EML’s were published as a starter point and as a 
guideline to aid these countries.  The list was never meant to be adopted in the 
exact form and adjustment is key, to be able to adopted a successful EML, and 
work and research is required to establish whether the EML concept is suitable 
to a certain country’s healthcare situation, and further research is required to try 
to discover the most appropriate adaptation method.  
2.2.1 Essential Medicine List 
 A strong healthcare system would not be considered a success without 
adequate availability of medicines. To ensure a well-established Medicine 
Supply Policy many factors are involved, from appropriate human resources, 
sustainable and logical financing, co-ordinated healthcare partners and 
institutions, and a comprehensive information system. These aspects are 
discussed more fully later in this Chapter, along with information on the 
development tools suggested by the WHO which could be appropriate in some 
cases to assess medicine supply (WHO, 2012). 
 It is proposed that a limited range of carefully selected Essential 
Medicines appropriate for each country can lead to better health care, better 
drug management and lower health costs (Hans V. Hogerzeil, 2005). This 
statement proposes that if there is a means to have a practical number of 
reasonably priced medicines to prescribe to patients, this might results in better 
prescribing practice in terms of assessing the quality of medicines more 
efficiently.  This could ensure enhanced supply of these medicines and better 
patient access to them, the cost would be known beforehand, and all this could 
lead to a better and effective fund control.  The number of medicines that can 
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be considered as being essential would then be related to a specific country 
health setting and needs.  The cost of these medicines would be related to 
health needs and cost.  
 In terms of the number of drugs/medicines proposed by the WHO in the 
Essential Medicine List programme which started in 1977; it identified 208 
individual medicines which they suggested together could provide safe, 
effective treatment for the majority of communicable and non-communicable 
diseases (WHO, 2013).  It was proposed to keep it up-to-date with these 
medicines by introducing new and possibly more efficient medicines, by revising 
the list every two years. One of the programme aims is to improve access of 
medicines to all patients. But the medicines need to be of proven quality, they 
should be affordable, and suitable to the health needs of the population.   
 It is however, in reality a delicate process and requires a careful and 
thoughtful system of choice. When the WHO first introduced the list, it gave a 
model guide to what medicines could be considered as essential medicine but 
in practice the final decision lies in the hands of the local healthcare workers to 
decide what is suitable to the health needs of the population. But it was 
suggested there should be a reasonably high level of relative cost- 
effectiveness. 
 One point that has come out of the early literature and assessment 
studies in this research is the very important consideration in the assessment of 
medicines that the individuals responsible for Essential Medicines selection 
should have a wide knowledge of health issues and medicines generally and 
that they should be chosen carefully and their proficiency and knowledge is very 
important in ensuring the delivery and a suitable and successful selection 
process.    
 In these respects the WHO Model EML has been a good starter point for 
many countries, but it is pointed out through this background searching and 
research that individual countries health requirements varies respectively, and 
what is appropriate to one country health situation might be irrelevant to 
another.  Therefore following the WHO guideline precisely and attempting an 
exact implementation of the WHO Model EM List was found early in these 
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studies not to be appropriate and best practice, and might have a reverse 
effects and worsen medicine access rather than enhancing it, especially that the 
WHO EML is designed to countries with poor sanitation and low standard of 
livings that results in more medicines to treat diseases such as malaria, tropical 
diseases and infectious diseases.  This situation is not applicable in countries 
like Kuwait, because Kuwait has a high income and has good access to quality 
housing and clean water and food, and has a good standard of living.   From the 
early studies, some general points of concern to health in Kuwait is related to 
the inflated medicine budget and the lack of skills to appropriately manage the 
MOH general Budget and the Inflated medicine budget.  
 An important consideration need to be acknowledged and considered 
when attempting to select medicines, is the racial variances. Ethnicity is one 
factor that may account for the observed differences in both pharmacokinetics 
(PK) and pharmacodynamics (PD) of drugs, resulting in variability in response 
to drug therapy (SU Yasuda, 2008). The following table describes some 
examples of the variances in medicine potency in regards to the ethnicity 
variation. 
Table 2.1 : Examples of the effect of the ethnic differences in allele frequencies for 
selected enzymes, transporters, and pharmacologic targets 
Enzyme substrates Alteration 
in function 
Allele frequencies (%) 
White Black Asian Chinese 
CYP2A6 Nicotine Reduced 
or virtually 
absent 
0.7 1.1 - 0.4 
CYP2B6 Cyclophosphamide 
Efavirenz 
Nevirapine 
Bupropion 
Methadone 
Increased 6 2 4 - 
CYP2C8 Repaglinide 
Paclitaxel 
Reduced 0.4 18 - - 
CYP2C9 Warfarin, Phenytoin 
Tolbutamide 
Reduced 10 
13.3 
14.9 
3 
1 
3.6 
Absence - 
CYP2C19 Omeprazole 
Diazepam 
Non-
functional 
13.6 
15 
17 - 29.7 
Table sourced from SU Yasuda et al, 2008 
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To examine Kuwait’s Healthcare position, it was important to have the 
correct background information to the country’s healthcare situation and the 
actual fund that is required to support this concept.  Also, to examine and 
consider the level of competency of the human resources that would carry the 
concept forward. It was therefore considered important to clearly identify all the 
relevant aspects that are required to implement a suitable and relevant policy. 
In this regard, Kuwait’s Healthcare situation is rather unique because Kuwait it 
appears to have the capability to fund the healthcare services fully. But from the 
early studies and from personal experience of working as a senior pharmacist in 
the public sector it may lack the suitable organisation and competent expertise 
and the professional skills to run the healthcare services efficiently, which may 
be revealed in the research undertaken.   
 For these reasons, it was considered important to establish a full 
knowledge of the healthcare system and situation in Kuwait and to gain good 
skills to examine the concept of EML and try to view it from several prospective.  
By doing so it was expected that it would help in accurately establishing how 
suitable this concept would be to Kuwait’s healthcare situation.  
 At this point it was considered to be useful to attempt to understand an 
Essential Medicine List fully and try to view whether the EML concept is suitable 
to Kuwait’s Healthcare situation, by carrying a suitable level of research and 
knowledge to the implementation processes carried out by several international 
and also neighbouring countries, and this could be useful to finds ways in which 
this concept can be altered to suit Kuwait healthcare requirements. 
2.2.2 Definition   
The Essential Medicines are defined by the WHO as being  
‘Those that satisfy the priority health care needs of the population. They are 
selected with due regard to disease prevalence, evidence on efficacy and 
safety, and comparative cost effectiveness. Essential medicines are intended to 
be available within the context of functioning health systems at all times, in 
adequate amounts, in the appropriate dosage forms, with assured quality, and 
at a price the individual and the community can afford. The implementation of 
the concept of essential medicines is intended to be flexible and adaptable to 
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many different situations; exactly which medicines are regarded as essential 
remains a national responsibility.’ (WHO, 2002) (Hans V Hogerzeil, 2004). 
 The concept is however very general and doesn’t explain any particulars, 
when the WHO indicates that the medicines are essential, there is no indication 
to the implication of this term and the method in which a medicine can be 
considered as essential or not, the only information given is the fact that the 
medicines should be related to the health needs of a population, this is a valid 
point but unfortunately, it is very broad and there could be a large number of 
medicines that treat similar illnesses, and the cost can be closely related.  
 The definition indicates that a medicine would be considered as being 
essential if there is evidence of its quality and safety, again this notion is valid 
and important, but the concept and the actual lists when they were initially 
launched, was aimed at countries with limited resources.  For instance, in many 
of the low-income developing countries, how such countries can ensure the 
quality of a medicines when there is no appropriate Quality Control and Quality 
Assurance laboratories to establish the quality of medicines is unclear.  
Furthermore, in such cases the cost would be high to retest and reassess the 
available medicines and to establish the quality of the newly procured 
medicines. This could be an added cost a country might need to consider if a 
country decided to adopt the Essential Medicine Concept. There are many such 
aspects which need to be considered in introducing an EML, as discussed more 
fully in the work carried out in this Thesis.   
 The definition also states that to make a proper medicine selection, it is 
important to consider the health needs of the population. This is another aspect 
which needs to be considered through this study, as it requires an efficient 
system of data collection to establish an accurate knowledge of the diseases 
pattern, and such processes.  When an appropriate healthcare system does not 
exist, this knowledge is difficult to achieve, and the solution at this point might 
be that the selection committee will end up depending on their own initiative to 
figure out the disease profile, and this method will not be very accurate.  
 In other words, having a list of medicines doesn’t always guarantee 
treating patients and giving better health, and the healthcare facilities may need 
23 
 
to be re-organised to provide appropriate treatments. Therefore, having an EML 
might enhance procurement practice, and might have a positive effect on prices 
and cost, the reason for this, is because when buying in bulk, the suppliers can 
give better price.  
 The initial reason for the WHO to come-up with the EML is to provide 
low-cost access to quality medicines for low-income countries, for this reason, 
only low priced medicines were initially included in the list. Currently the concept 
generally of cost-effectiveness has been introduced both by many countries of 
the world and in the WHO List and some expensive medicines are included due 
to the benefit/cost ratio, (such medicines are the antiretroviral medicines). It’s 
been declared that antiretroviral medicines are essential to control the 
spreading of viral conditions, such as HIV, and should be on the national EML, 
where the health issue is of concern. The WHO Model EML, 2002 first included 
medicines for the prevention and treatment of HIV/AIDS (WHO EML. 2002). 
 When considering the EML concept overall, it is however defined slightly 
differently from country to country as the interpretation of the definition terms 
varies between countries and complies within individual countries where there 
are available funds to support the concept.  This includes areas such as the 
health requirements and the clinical capabilities of each country, but overall the 
introduction of an Essential Medicines List as indicated above is a complex 
process requiring a considerable level of research.  
 But the groups-countries involved all seem to agree on the main outline 
concept, that the list should contain a manageable number of medicines with an 
established clinical relevance and proven quality, which are affordable at the 
standards of living of a particular country. In carrying this general definition 
through another of the early problems in choice of suitable medicines for a 
particular country was that information on post-market surveillance of medicines 
was limited and the information accessibility was often inadequate. But in the 
present times it is more advanced and accessible and for this reason the 
selection of medicines for the list moved from an experimental based system 
into evidence-based in the early part of this century (Report to WHO Executive 
Board, 2002). 
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 Coming back to the WHO as an organisation it was established to assist 
particularly developing countries to introduce areas of Health 
Development.  The WHO came about to give support to the poorer countries.  
In addition, it included in its support not only financially poor, but information 
poor countries, which may to a certain extent include some areas of health 
organisation in Kuwait, because Kuwait can be considered from some directions 
to be a developing country.  These aspects will be part of the studies 
undertaken in this research Thesis and at the initial stages it can be proposed 
through experience that Kuwait may have a very high access to all kinds of 
resources but may lack the appropriate managerial skills to utilise the resources 
efficiently.   
 Whether this is the case, then the research study may establish or 
propose the need for adjustment/change, such as investigation into restructure 
and reinstate a more organised healthcare that might reflect positively on the 
general health and the general MOH budget.  But these comments are only 
through work experience as a senior manager and are still to be established in 
this study. 
 Generally speaking, the basis for the introduction of an EML came about 
because it was clear at the World Health Authority Conferences that many of 
the Developing Countries had difficulty putting together Health/Medicines 
requirements and information from the information produced by other 
Regulatory Agencies, particularly in High Income-Developed Countries where 
the majority of medicines were/are discovered and developed and from the 
Pharmaceutical Companies on medicines which were appropriate for health 
areas such as tropical and obscure diseases. Access to low cost medicines 
know as Generic Medicines was also an issue, and required deliberation.  
Initially, the EML were more appropriate to countries with limited income level, 
but in the recent years, EML changed and became more suitable to wider range 
of countries with various income levels.  
 The EML moved into a List more suitable to countries needs and for 
health and current diseases, financial position, Government strategies, 
educational developments, population changes and many other developments. 
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 Therefore, the EML which is almost forty years old has been very helpful 
to many countries.  The information about the Medicines on the List comes from 
the Companies, the developed countries and their Regulatory Agencies and 
increasingly from Databases to include the Uppsala Database linked to the 
WHO (and other Databases). 
 
2.2.3 Essential Medicine List Progress 
 Countries with limited access to healthcare resources, has tried to come 
up with solution to enhance medicines access in a financially suitable means. 
The limited income countries realised that medicines are costing the country a 
great deal and medicines access was an issue, for this reason several countries 
tried to have a form of a list of medicines that is required by the general public, 
this is a form of a strategy to enhance medicine access and control medicine 
budget, one of these countries were Peru, in 1960 it created a list of basic 
medicines as an attempt to enhance medicines access, later in 1971 it started a 
basic programme to promote the basic list of medicines as a method of 
improving the general health and reduce cost (WHO, 2016).  
 Similar situation was observed in Tanzania in 1970, where the first non-
official Essential Medicine List was created by Tanzania, and the country’s 
Health Service directed their efforts in trying to enhance the medicine supply in 
their healthcare facilities, to control the expenditure and provide quality 
medicines. This attempt was carried out by the Tanzania Healthcare services as 
their own effort; the Tanzanian List of medicines was designed before the WHO 
launched the Model list of EM (Bartle, 2014).  
 Mozambique is another country that solely attempted to organise 
healthcare and medicines situation by creating a restricted list of medicines, the 
list was created few months prior to the WHO Model List of Essential Medicines, 
and according to a survey carried out by the WHO in 2006, stated that 
medicines access increased from only 10% of the total population in 1975 into 
80% by the year 2007, the survey did not indicates whether this tremendous 
enhancement in medicines access can be referred to the efficient use of the 
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restricted List of medicines or due to some other strategies been adopted by the 
healthcare services in Mozambique (Medicines and health products, 2007).   
 The WHO started the processing of the first EML in 1975, and World 
Health Authority in 1975 (Resolution WHA28.66) called on the WHO to assist 
member states to select and procure essential drugs of good quality and at 
reasonable cost (Laing, et al, 2003).   
 Seven years after Tanzania launched their own national none-official 
EML, the WHO announced and published a list of 205 medicines and 
considered them as essential to general health needs. This publication however 
raised an accusation that the WHO, by announcing the EML, was trying to 
restrict prescribers from the freedom of prescribing. However, the list was 
welcomed by many organisations, and was considered as one of eight 
components of primary healthcare, this was identified by the Alma Ata 
conference in 1978. And the first edition of Managing Drug Supply identified 
drug selection as an essential management requirement in 1981.  A year later 
Bangladesh adopted the concept (Laing, et al, Lancet 2003). 
 The World Health Assembly in 1984 gained further support for the EML 
concept from all the delegations, the USA had their own version know as 
Medicaid preferred drug lists since 1965, to provide healthcare services to low-
income individuals (Kaiser Family Foundation Medicaid Facts, 2009), and in the 
case of the UK, they introduced a Restricted List of Medicines.   
 The philosophy of an EML was widely spread by 1991, and more 
countries adopted the idea of a list including NGO (Non-Governmental 
Organisations), however, there were still some concerns on the basis of 
justifying the medicine choices, and as a result the choices moved from just 
experience based choices into evidence-based submissions, and this was 
finally agreed in 2000/01, although the list were widely adopted by several 
countries, it still came with some issues, the model list is a good starter point 
but it requires several adjustments and changes to be suitable to a certain 
country healthcare situation, the adjustment requires in depth research and 
knowledge to the actual level of healthcare services and medicines situation, it 
is important to identify clearly the process of introducing a new concept or 
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policy, what is required to support a successful implementation process, the skill 
level and actual knowledge of the working power, it might be important to 
identify the funds that are available to support the policy or the concept, the 
selection criteria could be different than what have been suggested by the 
WHO, and this might be true due to the fact that Kuwait cost-effectiveness 
approach might differ than other countries, for this reason careful medicine 
selection approach and well-thought of adaptation plan  is required, 
furthermore, it might be useful to identify the current health and diseases profile 
to support a successful medicine selection tactic.      
 In addition to increase access to medicines, suggestions were made at 
the Seattle, USA WTO (World Trade Organisation) meeting to subject the WHO 
EML to automatic compulsory licensing; this meant countries could manufacture 
medicines without seeking the consent of the rights holder, but instead pay the 
rights holder a set fee for the license. 
    With all these efforts to ensure a successful EML, discussion took place 
with the USA and others and the final version of the revised procedure was 
adopted by the WHO Executive Board in January, 2002. As a result a modified 
form was published. Several changes and additions to the EML were included, 
such as including several antiretroviral drugs under patency, alphabetical and 
anatomical therapeutic chemical (ATC) classifications and translations into four 
languages appeared within months, and the development of web-based EM 
Library.  
 In 2007, the world health sector, in general, and the WHO in particular, 
had noticed that children are more sensitive to some types of medications and 
require specific attention, for this reason the WHO published the first WHO 
Model EML for Children (EMLc). This approach is wise, kids requires special 
consideration, because they are still at the body developing stage and healthy 
kids will eventually results in a healthy and strong community.   
 The WHO now has a specific department to deal with the Essential 
Medicine List programme; this department is called The WHO Essential 
Medicines and Health Products (EMP). The objective of this department is to 
ensure the continuation of the concept, it aims to update it and keep it up to 
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speed with the continuous advances in medicine technology. Its main duty is to 
collaborate with countries to aid them in gaining reasonable access to quality 
medicine information and guide member states in the medicine selection 
process. The department was founded over three main fundamentals; access, 
innovation and regulations together with other duties such as education, training 
and technical support. 
 The concept of the Essential Medicine List has become popular and the 
work of the WHO is significant, which is evident because by 2008, 81% of the 
WHO members have a form of the Essential Medicine List and 65% of countries 
have updated the list in the past 5-10 years (WHO 2015). These figures 
indicates countries adopting the concept with modification to suit each country 
healthcare situation, but doesn’t indicates the level of success of the 
implementation process and whether adopting the EML concept helped to 
enhance medicine access.  
 In the early years of the concept, the selection criteria was based upon 
experience (Laing. 2009), as the world developed and access to information 
became easily reachable, the selection criteria moved towards evidence based 
and post-market confirmation of medicine efficacy.  
 The WHO Essential Medicine List has gone through a lot of changes 
throughout the years; the following table represent the changes that occurred 
since 1998 until 2011.  
 
Table 2.2: Deletion and Addition of Medicines on WHO Model EML 
 1998 2000 2002 2003 2005 2007 2009 2011 
Deletion  13 6 0 12 17 3 4 21 
Addition 31 14 12 4 9 22 16 27 
Duplication 50 51 52 52 57 56 81 87 
Source: WHO website, WHO EML from 1998-2011 
 
 As it can be seen, changes do take place and it is considered important 
to keep the list updated, otherwise the list can become outdated and unsuitable 
to the current health requirements, this continues follow up of the medicines on 
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the EML and continuous updates might demonstrate the expert committee 
commitment and interest in keeping the concept of EML efficient and the 
medicines on the list are suitable to the advancements in the field of 
pharmaceuticals.    
 The concept when first came out and launched, it designed to help the 
less fortunate countries that has limited access to quality medicines, but years 
after the utilisation by the limited income developing countries, the more middle 
and high income countries became interested in the concept, and some of 
these countries has actually started following the footsteps of the less fortunate 
countries.  
 The EML as proposed by the WHO is not accepted as the best way of 
developing access to medicines in Kuwait, because Kuwait has the potential 
both financial and structurally to introduce a system that is specifically 
structured to benefit Kuwait patients. The WHO EML is a baseline, but Kuwait 
has bypassed the fundamentals of the WHO EML, the research aims in taking 
the underlying concept of the EML proposed by the WHO back in 1977 and 
producing an overall development programme based on an EML that provides 
Kuwait with medicines and health support , which is affordable, provides 
relevant medicines for the illness faced by Kuwait population, handles the 
public/ private interface, controls the introduction of medicines to Kuwait 
patients on clinical needs-cost effectiveness-medical-effectiveness program.  
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2.2.4 EML Concept in Relation to Higher Income Countries 
 High incomes countries are defined by the World Bank, as countries with 
are those with a GNI (Gross national income) per capita of $12,476 or more. 
The developed countries and the high income developing countries such 
as the Gulf Co-operation Council countries are faced with new challenges in 
health; this is due mainly to diet and the sedentary life style that gave rise to 
modern life chronic diseases such as cardiac problems, cancer, respiratory 
diseases and some mental illnesses. Countries with good access to health 
resources ended up with more aging population and that resulted in old-age 
conditions that require more attention and care. This entire situation gave rise to 
an increase in health cost and more demands on healthcare and medicines.  
 Hogerzeil, 2008, support the previous discussion and has indicated in his 
study that the inflation of a medicine budget is generally due to an aging 
population, general elevation in medicine costs and the continued introduction 
of new medicines, which may have little extra benefit, but add to the overall high 
cost. In contrast the aim of a Ministry of Health in a low-income country is 
generally to obtain quality medicine with a suitable cost.  
 Currently the same concept is being adopted by mid and high income 
countries, as a tactic to fight the ever-increasing medicine costs. example of 
that is found in Australia and New Zealand, two countries with an advanced 
healthcare system and at some times in the nineties had the lest cost of 
medicines is currently faced with a rapid medicine inflation, and both countries 
took very strong measures to come up with solutions for the situation, one 
solution was to establish a national EML and bases medicines procurements 
and reimbursements on it. The success of this approach is yet to be confirmed, 
there are no significant studies or data to indicate the outcome of the utilisation 
of the EML concept in Australia and New Zealand (Clement FM et al, 2009) 
(Stafinski T, Menon D. 2003) (Lexchin J, Mintzes B. 2008). 
 If high income countries adopt the concept of an EML, the effect can 
have an impact on a variety of healthcare areas, including; the promotion of 
rational prescribing, more focused healthcare professional training and follow-
up training. It can also lead to improved prescriber’s knowledge of medicines, 
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often because there may be limited medicines used, reduction in adverse drug 
reactions and this is achievable because the drugs on the list are better 
documented and acknowledged.  In addition, there can be many other 
improvements in the medicine supply cycle involving procurement, storage and 
distribution, and when procuring large quantities of medicines this often results 
in price reductions. Overall however, the major advantage of introducing the 
concepts of an EML, can be that a country should have a continuous supply of 
medicines at all times, ensures patients have access to their own medicines, 
and these can lead to improvements in patient compliance, improved patient 
health, and as a result improvements in the overall health of the population 
(WHO, 2013).    
 Because of all the facts and suggestions mentioned above, it can be 
suggested that the Essential Medicine List has delivered more than it was 
initially suggested it would achieve, providing there is a proper follow-up and 
transparency in the procurement policy which practiced. Therefore the List 
might be beneficial in multiple areas not only in cutting cost but also in providing 
better healthcare, and that is a major requirement for any country and any 
community regardless of the standard of living and how wealthy it is.  
 In the state of Kuwait, the medicine budget is alarmingly high. The 
following table shows an actual breakdown of the MOH expenditure from 2006 
until 2010. 
Table 2.3: Financial data from the general budget department of the MOH 
Kuwait, (2005-2010) 
Item 2005/2006 
(KWD 
million) 
2006/2007 
(KWD 
million) 
2007/2008 
(KWD 
million) 
2008/2009 
(KWD 
million) 
2009/2010 
(KWD 
million) 
Approved 470 555 639 1048 877 
Executed 448 538 589 1020 837 
% Executed 95.3 97.0 92.2 97.3 95.4 
Expenditure 
per capital 
143 158 172 213 230 
% of MOH 
budget from 
the country 
budget 
6.7 5.3 6.2 5.6 7.6 
Source: Population Statistics – Public Authority of Civil Information 
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The next table represents the percentage of medicine cost to the Kuwait MOH 
total budget. 
Table 2.4: The percentage of medicines cost from the total Kuwait MOH 
budget.  
Category Total amount in 
% 
2009 
Total amount in 
% 
2010 
% Change 
Drugs 52.6 59.5 12.3 
Source: General Budget Department of the MOH Kuwait, (2005-2010)   
 
 As is apparent, from the above two tables, the Ministry of Health budget 
has doubled and the medicine cost, that represents half of the MOH budget, 
has increased further, therefore employing some kind of control over the 
medicine budget will have a direct impact the general health budget, the table 
demonstrates that in the financial year 2008/2009, the MOH budget increased 
tremendously to over billion Kuwaiti Dinar that will be close to over 3.7 billion 
Dollar, this kind of figure could be considered as the total country Budget of 
some countries, there is another point needs to be considered when looking at 
these figures and budget costs is the fact that Kuwait population is little over 3 
million only, and the MOH and Medicines budget is very high to this population 
size.    
 This kind of increase requires an immediate attention to control it, 
otherwise it reaches unrealistic and unaffordable figures, for this reason starting 
a protocol or a suitable policy to avoid reaching a stage when medicine 
becomes inaccessible, even in a high-income country like Kuwait. 
2.2.5 EML in Relation to Standard Treatments Guidelines (STG) 
 Standard Treatment Guidelines can be defined from its name, but the 
precise definition can be quoted from Ghana STG 2010, which has been 
reported as being ‘STG are systematically developed statements that assist 
prescribers in deciding on appropriate treatments for specific clinical problems. 
They usually reflect the consensus on the optimal treatment options within a 
health system and aim at beneficially influencing prescribing behaviour at all 
levels of care’ (Ghana STG 2010). 
33 
 
 The purpose of a STG is to provide recommendations on the most 
constructive method of treatment for a particular disease, however it aims in no 
way to restrict prescribers or hinder their decision making. The overall aim of a 
STG is to assist prescribers in the choice of treatment, it helps with the training 
of new health professionals, gives patients a direction of how the treatment 
progresses which will improve patient/doctor relationships (NICE, 2013).     
 The relationship between, STG and EML should be fused together. 
Medicines on the Essential List should not be chosen without having evidence-
based treatment guidelines to follow and knowing what kind of medicines are 
being prescribed to patients. Standard Treatment Guidelines need to be placed 
in accordance with the quality of the medicines and benefits/cost-effectiveness 
principle. Therefore, a successful, well thought-through, and functioning 
Essential Medicine List should be combined with a functioning and health 
situation profile related STG.   
The STG and the EML are continuous processes and once the decision 
is made, and the guidelines and lists are published, the work should not stop at 
this point. There should be, regular monitoring, reviewing and follow-ups. In 
addition there should be continuous staff education to ensure an adequate 
knowledge of the STG and Essential Medicine List components (WHO 2002).  
Achieving this process can be done by employing a Standing Committee to 
include members from different health fields.  For instance, the WHO 
recommends that members of the Committee should include doctors, nurses, a 
pharmacologist, pharmacist, public health workers, consumer affairs and health 
workers at the grass-roots level (WHO, 2002).   
Another point which should to be considered when choosing the 
medicine is the strength of the evidence, for example ‘the result of a systemic 
review of clinical trials can carry more weight than the results of an 
observational study without controls, and should be much more than personal 
experience of individual experts’ (WHO. 2002).    
The decision of medicine selection is complex, it’s not very clear and the 
guidelines that are set by the WHO are not straightforward. But this is 
understandable due to the fact that the concept of cost-effectiveness is relative, 
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and some expensive medicines might be considered as being an Essential 
Medicines due to the need character and the importance of a particular 
medicine to the general health and because of the lack of a more affordable 
alternative, this can be explained better in terms of antiretroviral medicines, 
although they are an expensive medicines but they are essential and its 
proposed to be important to have them in a functioning healthcare system 
(Hans V Hogerzeil. 2004).  
2.2.6 EML Timeline 
 In 1977, the World Health Assembly endorsed a new strategy to promote 
all nations health, it’s titled ‘Health for All by the Year 2000’ (F. Antezana & X. 
Seuba, 2008) the main objective of the strategy, is to find ways to enhance 
health; the choice of tools need to be suitable to the country concerned. The 
reaction to this resolution was the development of the WHO Model List of 
Essential Medicine, the development process started in 1975 but the first list 
was published in 1977. The programme was never be finalised that year, it kept 
being monitored, reconsidered, and improved (WHO. 2016).   
 1975 until 1982 is considered the establishing stage of the programme, it 
included launching the EML then getting adopted by the Alma Ata in 1978, until 
later the concept was modified in 1982 where the word Drugs in the title was 
replaced by Medicines, it’s understandable when starting a new policy to have a 
stage where the system is more experimental and awaiting amendment, it’s not 
totally accurate that any new policy when started was faultless and didn’t 
requires modifications at a later stage.   
 In 1999, the medicine selection method changed the medicines from the 
selection based on the Expert committee members own professional and 
scientific experiences, into the available scientific and real life evidences. This 
needed to happen due to the large amount of research on post market efficacy 
of medicines and the pharmacovigilance programme that had been expanding 
worldwide and was adopted by many countries. This new approach for 
medicine selection didn’t get picked up until 2002 (R. Laing et al, 2003).  
 The second phase of the EML programme is related to consolidating the 
programme and the concept as a whole; this is from the 1992 until 1987, there 
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were uncertainty to nature of the programme, it wasn’t clearly defined at that 
time as whether it’s a new unit, a very typical WHO programme or a policy, this 
was sorted and the EML is considered linked with the national Medicine policy 
(WHO, 2004), then the programme get implemented in Tanzania and adopted 
by UNICEF, in 1985 the Nairobi conference agreed that EML policy needs to be 
developed as a tactic to promote rational drug use (F. Antezana& X. Seuba, 
2008).       
 The third phase was from 1988- 1994 and it was related to redefining, at 
this stage the duties of the EML committee moved to being advisory upon 
request by other countries, which limited the members at some level, but it had 
a positive impact which lead establishing education programmes.  
 The fourth phase was from 1995 until 2007, this stage can be considered 
as being very important at Economic, Technological and Social levels.  
 The following flowchart summarises the changes that the WHO Model 
EML went through over the years.  
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Figure 2.2: WHO Model EML timeline from 1977-2008 
Source:  created by author based on data from WHO website. 
37 
 
2.2.7 Challenges of developing an EML 
 As with any new concept that is introduced, concerns will arise when 
introducing the list and a careful well thought through process should be 
adopted to introduce the EML to the entire population and make it acceptable; it 
is a very delicate process and extreme care needs to be employed. It is 
proposed that all issues are required to be addressed and if possible nothing 
should go unresolved. In addition to the structure and operation of an EML, 
there is a need to establish an education programme to the entire population at 
different levels of details, in order that all of the population has the opportunity 
to become familiar with the EML.  
 There are several concerns that might come up if the EML concept been 
introduces, these concerns might be expected by both health care providers 
and healthcare recipients.   
 The Prescribers may see it as a way of hindering and restricting them 
from freedom of prescribing, where Pharmacists may see it as a way of 
reducing financial benefits, but the main concern might be expressed by the 
Manufacturers that fear that their market might become tough and competitive, 
on the other hand patients might think that they are getting lower quality 
medicines of a second class type, and this may lead to loss of confidence in the 
medicine and lower levels of compliance (WHO, 1988).   
 Overall, it’s worthwhile to get the concept explained clearly and makes it 
clear to all that the EML is not a list of cheap medicines; it’s rather a list of more 
quality and affordable medicines and a list that contains some medicines that 
are expensive but very important to the general health.  
2.2.8 Essential Medicines Selection Criteria 
 The WHO has proposed a set of selection criteria which could be 
considered when designing National EML, but the proposals are only made as a 
guidance and it is clear that it is the responsibility of each country to set its own 
selection criteria that will benefit the wellbeing of the population and suites its 
needs. 
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 The Model List of Essential Medicines is therefore provided by the WHO, 
as a guide to support countries in designing their own List that can be unique to 
their specific country and comply with the country’s health needs and budget.  
 The WHO have in place an Expert Committee, which works towards 
revising and adjusting their list every two years and at the same time proposing 
guidelines as to why a medicine has been updated on their List, as an aid to 
countries who may want to use the List or parts of it. It is proposed that the 
revision and update is required for several reasons, which includes; the 
continuous advances in science and research, which are occurring on a regular 
basis. In addition, there are new discoveries in medicines and pharmaceuticals 
together with the availability and accessibility of post market evidence of quality 
and efficacy. All these developments might cause an alteration to the decision 
of medicines selection, some newer medicines might be better choices and 
some previously selected medicines might require deletion based on new 
evidence of quality level or lack of the required level of efficiency.  
 Another aspect of the adjustments to the EML produced by the WHO is 
the reformation with time of developments in Standard Treatment Guidelines 
(STG) for medicines that have been shown to be clinically valid and these 
aspects can be closely related to the selection process of the Essential 
Medicines on the WHO List. However, when a country proposes to introduce or 
continues to use medicines on the list they would normally do so after careful 
deliberation and study of this selection as the drug/medicines from the list 
should be appropriate for the needs of the population in that country.  In order to 
assist a Ministry of Health to make this decision, the WHO can provide advice 
and help to the member countries in terms of their decision to select particular 
medicines.  Furthermore the medicine selection processes is required to comply 
with the national official STG in the country, by following this step it will verify to 
the prescribers that their decision making is not impaired and been withdrawn 
from them, because they are following the national STG in their prescribing 
practice, the last statement demonstrate that since the STG are different from 
one country to another, and comply with the unique disease pattern to each 
country, the national essential medicines are selected in a similar manor and 
adopting the WHO Model EML is an unsuccessful practice.   
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 Therefore, the value of the work by the WHO Expert Advisory Committee 
is in providing knowledge and evidence which can assist a Country’s Ministry of 
Health by proposing procedures which could be followed in selecting, updating 
and eliminating medicines from a countries list.  
 In respect of the terminology used in the early definitions by the WHO 
Expert Committee it was decided that they would use the term Essential 
Medicines rather than Essential Drugs, in order to include a broader range of 
pharmaceutical preparations.  In addition to these points in carrying through the 
selection of medicines for regular use in a country it was proposed by the 
Expert Committee that a country should consider adopting a systemic approach 
when introducing or deleting a medicine from the list.   
 These individual medicines are however part of an overall Policy and it is 
considered important in the general discussions surrounding setting up an EML 
or Health Policy in a country that there should be openness and transparency 
practiced. This is suggested to particularly be recommended when making a 
selection of medicines on a general list and in the medicine selection. For 
instance, the background and the medicines list could be accessible to all and 
should be discussed relatively openly.  It is suggested, with these proposals, 
that they should be discussed, through a country’s own Expert 
Panel/Committee and where possible a country should assemble a group of 
experts with a relatively wide range of background knowledge from various 
pharmaceutical and medical backgrounds. 
 It’s been proposed by the WHO expert Committee to launch an Essential 
Medicine Library at an international level to help in accessing medical 
information to all healthcare providers (WHO. 2001). Currently the WHO has 
launched a wed-based information service and provides access to the WHO 
Model EML, it provides disease information and suggested treatment line, and it 
includes the WHO Model formulary.  
 Jordan is an example of a country which in 2006 considered its 
development of an EML, by using some of the procedures suggested by the 
WHO. It is also a country which has many similarities with Kuwait, and shares a 
similar health profile with minor differences and as will be seen later in the 
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discussion of the research programme, it was used as a comparator to aid the 
basis for the EML selection criteria for Kuwait. Jordan has, had an established 
EML, since 2006 and bears a close similarity to Kuwait. Its Essential 
Medicine Department is part of the Jordanian MOH and as indicated above it 
has developed the selection of Essential Medicines by taking note of the WHO 
guidelines.   
 The Jordanian Essential Medicine List (2006) (Jordan Rational Drug List 
V1, 2006) quotes that the Medicine Selection Process is based on the published 
disease patterns, and that the efficacy and safety of the selected Essential 
Medicines should be based on objective results from adequate pharmacological 
studies, and they should meet satisfactory quality control standards, including 
pharmaceutical stability and when necessary, bioavailability. 
 The overall patient cost of medicines is an important issue together with 
the total cost of the treatment regimen and that can include cost of combination 
of drugs necessary to accomplish the treatment regimen versus unit cost of 
each drug (Jordan Rational Drug List V1, 2006). This criterion is the difference 
between Jordan and Kuwait and this is the case because the income level in 
Kuwait is higher and the level of affordability is different between Jordan and 
Kuwait.  
 It is also reported that the Jordanian MOH Medicine Selection Committee 
(Jordanian MSC) considered during the selection process the capabilities of the 
healthcare providers to use, prescribe, administer, and monitor the safety and 
adverse effects of a single drug or group of drugs in a therapeutic category.  In 
addition, Jordan also considered during the selection process, the influence of 
the concomitant, locally prevalent diseases or conditions, and the medicines 
pharmacokinetic and pharmacodynamics parameters, that might lead to a 
modification in the therapeutic response, e.g., malnutrition, liver disease. 
 The Jordanian Medicine Selection Committee (Jordanian MSC) 
reportedly made specific considerations to evaluate the benefit/risk ratio of the 
medicine undergoing selection, in their deliberations however the committee put 
forward for discussion several comparable drugs/medicines which had similar 
claimed therapeutic indication.  After further discussion and gathering of data, it 
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was necessary to select the one that provided the most favourable benefit/risk 
ratio. These deliberations were able to assist the Committee in coming to a 
decision on which drug/medicine was the more appropriate (Jordan Rational 
Drug List V1, 2006). 
 The WHO recommend  that, It is important to have preferential factors for 
evaluating therapeutically equivalent drugs: when two or more drugs are 
therapeutically equivalent, preference should be given to the drug that is 
thoroughly investigated, and therefore, best understood with respect to these 
properties and limitations, and as a result, it was advisable through the 
Jordanian selection committee to choose the drug that is clinically appropriate 
for more than one disease, this will contribute in further cost reduction, it is 
always wise to choose a medicine that has favourable pharmacokinetic 
properties and an easily produced dosage form. It is proposed by the WHO and 
the Jordanian Selection Committee agrees that such practice will improve 
compliance, and minimize risk (Jordan Rational Drug List V1, 2006). 
  Another important measure in choosing a medicine to be used on a 
countries list is the chemical/ biochemical stability to a range of climatic 
conditions. Taking note of this aspect is likely to improve risk minimisation of 
short and long term stability of certain medicines towards weather conditions 
and if the medicine requires special storage and handling facilities, this could 
result in an added cost if special management was required and in these cases 
the committee may give preference to medicines with a reliable local 
manufacturing and storage facilities (Jordan Rational Drug List V1, 2006). 
 Choosing a particular medicine formulation is important and the 
Jordanian MSC has addressed this aspect in their recommendations. In this 
respect the Jordanian MSC following the WHO Essential Medicines selection 
guidelines has regularly recommend the use of single compound medicines, but 
in some cases fixed-ratio combinations are proposed where the clinical value of 
simultaneous use of more than one drug is documented, and therefore the 
therapeutic benefit of the combination can be greater than the sum of each of 
the individual components. In many cases the cost of the combination product 
can be less than or equal to the total cost of the individual products.  In addition, 
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it has been shown that combinations can improve compliance, and if this fixed-
ratio combination is available in sufficient quantities to meet the needs of the 
majority of the population and the quantities can be maintained through the 
purchasing process. (Jordan Rational Drug List V1, 2006).    
 The Jordanian MSC also recommends Periodic Review of the Essential 
Medicine List: in this case, annually or whenever necessary to incorporate 
significant new therapeutic advances and information.  The committee generally 
recommends that new drugs should be introduced only if they offer distinct 
advantages over previously selected drugs, and medicines can be deleted from 
the List, on the basis of the presence of new information, or where drugs 
already on the list are found to no longer possess a favourable benefit/risk ratio, 
typically this effects drugs with a higher benefit/risk ratio.  One other aspect 
which is proposed in the guidelines of the Jordanian MSC is the 
recommendation to use International non-proprietary names: generic names 
where appropriate in naming drugs/medicines. 
 The Jordanian MSC made The Jordanian Food and Drug Administration 
(JFDA) registration a major requirement for any medicines to be included in the 
Essential Medicine List (Jordan Rational Drug List V1, 2006). 
 Overall the medicine selection process adopted by the Jordanian MSC is 
similar process to the WHO recommendations, one area of the WHO guidelines 
which has been considered in Jordan is the philosophy as set out in a section of 
the publication by the WHO 2003, “How to develop and implement a national 
drug policy” (WHO, 2003), which states that the selection process is a two-step 
process. The first step is the market approval of the drug, which is granted after 
the medicine, undergoes rigorous testing and quality testing, this step is logical 
and pre-requirement of any medicines before being marketed in any country.  
The second step is the comparison of the drug with other similar drugs and 
compares its cost alongside its benefit. 
 The Jordanian MSC has generally focused on medicine quality, a cost-
effectiveness criteria, medicines pharmacokinetic properties, the availability of 
storage facilities that ensure the maintenance of medicine quality. All of these 
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factors should be important when developing an EML in Kuwait and are similar 
in both the WHO Expert committee recommendations and the Jordanian MSC  
 The Ministry of Health regulators in many developed countries and the 
WHO Expert Committee also suggests that a fixed-ratio drug is better choice 
rather than a combination, but it is suggested that combination products could 
be chosen if there is a proven their advantage, and this again is an approach 
followed by the Jordanian MSC. Generally, the countries which have a 
successful medicines supply chain across the world and the WHO Expert 
Committee suggest a country should operate on the basis that the selection of 
drugs/ medicines should be evidence based on post market evidence of efficacy 
rather than just a method of selection based only on science based 
experiments.  However, in a developing country it is not possible to carry out 
suitable robust clinical studies and therefore the WHO Committee advised one 
answer to address the suitability of regularly used medicines is to follow texts 
such as the Essential Medicine library to gain quality information to the limited 
list. In addition, the WHO and other major Medicines Regulatory Groups 
encouraged the use of the large Pharmacovigilance Data Programmes and for 
countries to launch their own pharmacovigilance programmes in countries to 
monitor medicines safety and to ‘feed’ this information into the 
Pharmacovigilance Databases. However, when examining the use of this 
aspect in Jordan, it is clear that the use of Pharmacovigilance programmes has 
still to be introduced in that country (Jordan MOH, 2006). 
 Overall, the proposed WHO selection criterion has evolved through the 
last 20 years.  One such movement is towards the development of small 
differences between countries who have initially introduced a list similar to that 
proposed by the WHO, but have adjusted their list of medicines with time and 
as a result the criterion used and the medicines considered have become more 
suited to countries’ own health profiles and situation.  
 2.2.9 Essential Medicine List General Outline   
 An Essential Medicine List as proposed by the WHO is divided into 
sections; the first section proposed could include the Master EML, the Core 
Medicines, and Complementary Medicines.  
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The WHO describes the Core List as being the list of minimum medicine 
needs for a basic healthcare system, and the list includes the most efficacious, 
safe and cost-effective medicines for priority conditions (WHO Model EM, 
2013). 
 The Complementary List is described by the WHO as being essential 
medicines for priority diseases, for which specialised diagnostic or monitoring 
facilities and/or specialist medical care and/or specialist training are needed. In 
case of doubt medicines may also be listed as complementary on the basis of 
consistent higher costs or less attractive cost‐effectiveness in a variety of 
settings (WHO Model EM, 2013). 
 The actual Essential Medicine List document presented in a similar way 
in most countries, few variances are presented and the variances are country-
specific and relate to each country’s health profile, mainly each EML document 
will include a front page, Explanatory Notes, explaining symbols included in the 
list, List of Essential Medicines, medicines divided in accordance with their 
therapeutic effects, Medicines with special considerations, such as age or 
weight restrictions, Explanation of dosage forms and an Index. 
Basically, this type of sectioning and styling of the EML document is a common 
practice in any documents; it’s a way of making it user friendly and 
understandable by the readers.  
2.2.10 Summary  
The Concept of EML is based on having a limited number of carefully 
selected Essential Medicines, the concept focuses on improving the health 
services from various angles, it provides better drug usage and control, and if 
utilised efficiently it will lead to cost reduction. 
The WHO define EML as ‘those that satisfies the priority health care 
needs of the population’’ (WHO. 2016) therefore, disease burdens need to be 
identified clearly, the quality of medicines needs to be rigorously assured, 
otherwise the EML fails to accomplish its objectives and it would be a useless 
attempt to enhance the health of the population and a big waste of funds, staff 
time and efforts. 
45 
 
The following step is the actual content of the List, it’s important to follow 
a very transparent approach to medicine selection and the medicines on the list 
should to comply with the local Standard Treatment Guidelines, otherwise it 
might be useless and doesn’t really fit with the local health needs.  
 The medicine selections would be more efficient if it considered the 
safety of the medicines, the efficacy and evidently the cost-effectiveness. At this 
point, an important consideration might be useful to fully acknowledge that just 
because a medicine is cheap doesn’t necessary make it suitable for a certain 
setting; it might be wiser to consider other factors, such as the total cost of the 
treatment duration, the level of patient compliances factor towards less frequent 
dosing medicines, and the total cost of a medicine if it requires a special 
healthcare facility or expert to administer it.  
 Once the list is designed and published, it doesn’t get operational 
spontaneously, appropriate regulations might help in enforcing adherence; 
procurement should be based on the EML. Continuity and sustainability very 
important factors and would be advantageous to arrange regular revisions and 
updates at suitable intervals, the WHO suggest revision every two years, but 
that is just a suggestion and each country can use own methods and figure out 
what is the most suitable interval for updates, providing it doesn’t takes too long.   
 The list lasted close to 40 years, it’s been adopted by a large number of 
countries with various levels of income. Many international none-profitable 
organisations base their selection of medicines, for donations and in case of 
disasters, on the WHO Model list of Essential medicines, such organisations 
are; World Bank, GFATM, Unicef, and UNFPA. All the previous demonstrate a 
level of success to the EML, but being selected by international organisation 
might be due to the fact that this list is the only list of medicines that is available 
and it would be easier to adopt the WHO Model List of Essential Medicines 
rather than making a huge efforts and come up with their own List of medicines.  
 Once a healthcare setting adopts the list in its typical form, and adapts it 
to the local health needs and practice transparency in the selection of 
medicines, the EML might have a positive impact on the quality of services, 
budget and fund control.  
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The Medicines Sans Frontiers, stated that the ‘the first List of Essential 
medicines was a major breakthrough in the history of medicines, pharmacy and 
public health’. The reason behind this statement were unclear and no evidence 
to support it, but the EML as a general concept could be beneficial and might 
help in providing fund control and improve quality of Healthcare, and if that 
happened it might be considered as a breakthrough in the history of medicines.  
2.3.0 Relationship with the proposed WHO Outline and the Problems & 
Context for Kuwait: 
  The Ministry of Health (MOH) at the State of Kuwait has a problem of 
escalating costs in its health budget and should deal with problems associated 
with re-organising the issues relating to the budget The Medicine budget 
represents a major part of the MOH general budget (Kuwait MOH Budget, 
2013). The medicine List in Kuwait public sector is massive and includes over 
4500 medicines (Kuwait CMS. 2015), such intensive list makes it difficult for the 
healthcare professionals to prescribe efficiently and might make it challenging to 
correctly follow up the patients. As a result, the general health will suffer and the 
budget will keep increasing.  
 Attempts were made to control the situation, several reregulation and 
restructuring of the pharmaceutical sector were attempted (Kuwait FDFA, 
2013), some were moderately successful and many failed to proceed and 
produce its objective, despite all the attempts the budget is still inflating and 
serious measures are required. The concept of Essential Medicines is none-
existing, and because of this there are no focus on a group of medicines during 
procurement, and that is another issue that requires deliberation.  
 Consequently, the focus of this research project is to measure the 
suitability of the concept of EML to Kuwait; the research will attempt to examine 
the barriers to developing and implementing an evidence-based EML. In this 
respect the research study intends to make recommendations for the 
implementation of such a policy in Kuwait.   
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2.4.0 The State of Kuwait Health Profile and Health Economic Indicators 
 Kuwait occupies the north-western corner of the Persian Gulf. It has a 
boundary in the East with the Gulf and in the southwest by Saudi Arabia and in 
the north and the east Republic of Iraq, with a total land area of 17818 square 
kilometres. The climate is intensely hot in summer with short cool winters (WHO 
EMRO, 2006). 
 
2.4.1 Demographic Profile 
 
 In mid-year of 2010, the population of Kuwait reached 3.6 million 
however, of these only 31.8% was Kuwaiti (Kuwait Health, 2010). 
 The population of Kuwait is distributed into 6 governorates. The highest 
density is seen in Farwaniya governorate with a population close to a million, 
but they are mostly non-Kuwaitis. On the other hand Kuwaitis presented in the 
highest concentration in Al-Ahmadi Governorate (Kuwait Health, 2010). 
 
2.4.2 Kuwait Economy 
 
 Kuwait has a geographically small but wealthy, relatively open economy 
with crude oil reserves of about 102 billion barrels – about 7% of world 
reserves. Petroleum accounts for nearly half of GDP, 95% of export revenues 
and 95% of government income (CIA, 2013), these figures indicates that Kuwait 
solely counts on the Oil revenue as a source of income and such situation could 
be risky, it’s always important to diversify the economy, this is apparent now 
with the current crisis of Oil prices dropping, but Kuwait acknowledges its 
dependence over oil as its main income, for this reason they have tried to move 
towards other resources and explore more investment options. As a result, in 
2010, Kuwait agreed on a 5 year plan costing 130 billion dollars to diversify the 
economy away from oil (CIA, 2013).  
 What Kuwait did following the Invasion of Kuwait by Iraq, is to starts 
international investments opportunities to help in the future, if similar situation 
might occur, Kuwait currently owns several important investments worldwide, 
and with the current Oil crises these investments has been helping but the 
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recession is near and this is evident by the current rise in the domestic vehicle 
petrol rise in Kuwait, the prices of petrol at the local market has risen by almost 
80%, this caused a lot of anger and dispute in the local community and still until 
this current time being debated officially to try to come up with a solution 
(Zainab Calcuttawala. 2016).  
 What comes in mind at this point that the drop in oil prices internationally 
has its effects on Kuwait financial capabilities, the results is a form of a decline 
in Kuwait economy, this decline not only affected the local petrol cost but it is 
affecting several aspects of Kuwait life and particularly the health services, this 
is seen in the form of the department of treatment abroad at Kuwait MOH, this 
department used to send patients that requires treatment not available in Kuwait 
to renowned health treatment centres abroad, due to the current economic 
decline in Kuwait, this department had made a very strict rules to reduce the 
number of patients, looking at this approach it can be viewed in a positive 
manor, this used to be considered as a source of draining to health recourses, 
its believed that by applying restrictions this can save on budget, and only 
patients that requires serious treatment that is not available in Kuwait can utilise 
this service, from this information it can be established that Kuwait is in search 
of means to reduces expenses, at this stage of financial restrictions, it might be 
useful to look at other countries that is suffering from similar financial crisis and 
adopted a suitable measures used by them to control the financial worries.   
 
2.4.3 Kuwait Healthcare Services   
 
 Kuwait healthcare services technologies are comparative to average 
European standards (EMBRO, 2006). This has resulted from the excellent 
government spending on healthcare developments since the independence in 
1961. But there is no physical evidence of the actual efficient utilisation of the 
medical technologies and no data published to support the level of health 
among Kuwait population.  
 The history of healthcare services is reported to date back as early as 
1910 in a form of American missionaries, establishing what is known as the 
American Hospital. But it is also reported that the healthcare services are even 
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older than this, and actually started in the beginning of the twentieth century, 
when doctors from the Dutch Reformed Church were invited by the late Amir of 
Kuwait to establish a clinic (WHO, EMBRO, 2006).  The establishment of the 
Ministry of Health then followed in 1936.  
 
 The year 1949 marked the start of the current healthcare system, by the 
launching of the first hospital in Kuwait. The Amiri Hospital was then followed by 
the Kuwait Oil Company Hospital in 1950. This period relates to the start of a 
full health service which has been free of charge until current date. This 
comprehensive free service ranked the health service in Kuwait as third in terms 
of budget after public works and education (WHO. 2006). 
 
 The Health Service in Kuwait is divided into two main sectors, the public 
sector and the private sector, both overseen by regulations and monitoring from 
the Kuwait Ministry of Health. The following diagram represents the distribution 
of healthcare facilities.  
 
 
Figure 2.3: Kuwait Health Care structure 
Source: made by author based on information from Kuwait MOH public relation 
department 
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 According to Regional Health Systems Observatory (EMRO), 80% of the 
health service is provided by the public service, and includes the KOC Hospital 
and Ministry of Defence Hospital. The services are provided at three levels; the 
primary healthcare is presented as general and specialised poly-clinics, 
followed by secondary healthcare services in the form of general hospitals, then 
the tertiary healthcare facility in the form of highly specialised hospitals.  
2.4.4 Challenges, Issues and Constraints 
 Kuwait’s health system is praiseworthy in relation to the availabilities of 
modern and up-to-date medical technologies to help in diseases diagnosis and 
treatments, but it still faces challenges. It is suggested that these challenges 
could lead to serious concerns if it is not controlled appropriately in the not too 
distant future.  
 One of the main issues of concern is public expectations; for instance, 
the educated patient expects a very high quality service, meaning that when 
some new technologies is available somewhere in the world, patients expect it 
to be available in Kuwait and they require access to it.  Another expectation by 
patients is medicines availabilities, similarly to any new technologies, patients 
requires all new medicines to be accessible and available the minute this new 
medicine hit the market, without any regards to its post market evidence of its 
efficiency or cost-effectiveness value. Such requirement is far from being 
realistic; no healthcare system can provide unlimited medical technologies and 
new medicines to its recipients at all times with no solid and scientific proof of its 
benefits.  Another healthcare recipients concern is related to the fact that 
patients have low confidence in the efficacy of generic medicines. Some 
patients look at generics as being second-class medicines, and some other 
patients term generics as not original medicines.  This situation is important and 
requires measures to resolve it, as the generic medicines can be considered as 
a useful method to control the healthcare budget and provide a good health 
outcome. But patients view on generics requires a good public education 
campaign to explain the concept of generic medicines and its value and to 
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explain the difference between generic medicines and counterfeit medicines, 
these two types are seen by patients as being one.  
 The second challenge is the demographics, as it is predicted that number 
of people over the age of 60 will increase considerably in the next decade, as 
the life expectancy age is increasing, which is linked into better healthcare and 
appropriate medication. This in turn is leading to patients on medication for 
serious and chronic illnesses such as, cancer, coronary heart diseases and 
mental disorders for a number of years. Another major issue with the health 
system is the tendency towards curative services rather than preventive 
services; and it is predicted worldwide that this is likely to cause a large 
increase in cost in the future. It is also proposed by health officials across 
countries that the best approach to improve a health service is to attempt to 
reduce the prevalence of disease through appropriate public education and it is 
expected that Kuwait should adopt this stance.   
2.4.5 Pharmaceuticals 
 The 1987 Ministry Decree no 1987/212 announced the official 
establishment of the Pharmaceutical Services in the State of Kuwait. 
At that time the percentage of purchase from the local and regional (gulf area) 
companies against the total purchase costs of medicines was 9.3%.  Whereas 
the percentage of purchase from foreign companies to the total purchase price 
of medicine was 90.7% (Kuwait MOH web). 
 
 Policies were introduced which led to an alliance with the Central Medical 
Stores and aimed to resolve any issues and help to improve patient care. 
 
 During this time the pharmaceutical services realized the importance of 
maintaining highly qualified employees within the Department as a result, it now 
provides continuous training to enhance the performance of all staff. 
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2.4.6 Central Medical Stores (CMS)  
This Store ensures the supply of all health-related requirements, in 
accordance with the laws set out by the State of Kuwait. The CMS was officially 
launched in 1984 on a plot of land of area of 75500 square meters with storage 
capacity of 44000 cubic meters. The area is divided into 60000 extendable 
storage locations, which are of different types catering for different storage 
requirements.  In these units, the storage temperatures can vary from 15 
degrees below zero up to 21 degrees above zero, such massive store indicates 
that the medicines requirements in Kuwait are high, and the number of 
medicines is very high, therefore it requires very big storage facilities to cover it. 
This another form of budget strain, if the medicines list is minimized and the 
number of medicines is reduced to the medicines related to local health 
conditions, there will not be a massive need for a big storage facilities and large 
workforce to manage it.  
 As a unit, the CMS caters for all needs of the MOH.  In addition, it also 
caters for the needs of other specific healthcare centres including the Kuwait Oil 
company hospital, Ministry of Defence hospital, National Guard hospital, and 
Ministry of Social Affairs. The CMS operates as four divisions; the first one is 
Medicine Control division, the Medical Supplies Control division, Laboratory 
Materials Control division and Import & Export Affairs control. 
2.4.7 International Standardisation 
 The MOH regulations for all aspects of Healthcare have been 
continuously reviewed and altered, however some of the regulations are dated 
and relate back to the early days of establishing the government health sectors, 
and other regulations generally result from the continuous changes in the MOH.  
Some of which have come from, minor political instability resulting in multiple 
changes from within the Ministry of Health (Kuwait MOH, 2010). The changes 
mainly relate to the frequent changes in the Minister of Health, and such 
frequent change could carry with it a sort of instabilities in the decision-making 
process and might halt any new innovations. In reality, the MOH attempts to 
innovates start on a strong note, then pauses once a new Minister of Health get 
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appointed, some of the innovative ideas get redirected in a different course 
other times they stop completely and the funds and efforts that have been 
employed to support the innovative process get wasted, this is another form of 
budget strain and wastage.   
 For these reasons the MOH decided in 2010, to follow the international 
guideline, and employ a team of experts who would look at standardising of the 
healthcare services. As part of this development in August 2010, the Kuwait 
MOH commissioned ‘Accreditation Canada’ a private consultancy company to 
provide technical advice, with the aim of proposing a model for health services 
accreditation activities. This was another innovative step that been suggested 
by a higher authority but unfortunately the process came to stop for two years, 
and the reason was the same as mentioned earlier, is because of the ministerial 
changes and the new Minister did not want to follow the footsteps of the 
previous Minister. In 2013 the Canadian Standardisation Team became active 
again, and that’s happened because the removed Minister came back again to 
authorities and relaunched his previous idea.   
However, after I had a look at the work of the accreditation programme, 
it’s been clearly noted that the pharmaceutical services were not a priority and 
little attention were given to the out-dated pharmaceutical regulations. The 
Canadian Team spent more time in other healthcare departments and spent 
very little time at any given Pharmacy at Kuwait MOH, and looking at the 
Canadian Team Mission Statement, the clinical services that has been 
supported by them doesn’t include any pharmaceutical services, which could 
explain the little time the team spend in any of the MOH pharmacies. 
The main reason the senior healthcare officials sought out the help of the 
Canadian team was to try to practice some type of control over the health 
services, to try to strengthen some parts of healthcare services and try to come 
up with solutions as to why the MOH budget inflation is high.  With that in mind 
and the fact that the medicine budget is a big part of the MOH budget, it would 
have been wiser to try to perform a type of updating to the pharmaceutical and 
medicines services.  
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Unfortunately, until the end of this research the Canadian Team has not 
fully reviewed the system and the intended work is not fully accomplished, what 
has been attempted by the Canadian team was to pass out several posters to 
each Department at the MOH with the suggested Standard Operation 
Procedures related to that particular Department, it’s a good step and might 
help in time managements but might not have a big impact on the budget 
inflation and did not organise any Department in relation to prescribing, patients 
care, counselling, quality of service, referral processes and there was no clear 
innovative policies in place.  
Overall, this attempt to reorganise the healthcare services in Kuwait might have 
missed its target, and the MOH budget inflation still a problem, and the 
medicines budget still account of a large portion of the MOH budget and no 
practical action been adopted to control this case.  
It would be wiser if the MOH senior officials target the source of inflation 
and try to come up with solutions to this particular problem, having a massive 
list of medicines that keeps expanding with little thought to medicine cost could 
make the budget increases even further, and such a massive list of medicines 
that is currently present at Kuwait MOH could be difficult to handle, manage and 
store, and that’s again another fund drainage.  
It might be useful at this point to discuss the health economics and try to 
understand the health budget and what could be the source of drainage and try 
to come up with suggestions on how to resolve the situation.         
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2.5.0 GCC Countries and the State of Kuwait Health Profile and Health 
Economics 
 The Gulf Cooperation Council (GCC) – includes the Kingdom of Bahrain, 
Kuwait, the Sultanate of Oman, Qatar, the Kingdom of Saudi Arabia (KSA) and 
the United Arab Emirates – and was founded in Abu Dhabi in 1981(Deutsch 
Federal Foreign Office, 2012).  In addition, Jordan and Morocco were recently 
invited to join the Council (AL Sharif, Asma, 2011). The GCC seeks to foster 
peace and security in the region, as well as economic integration among 
member states. It also aims to unify regulation among member countries, keep 
up with the advances in Technology and Science, form joint military forces by 
forming the Peninsula Shield Forces and to strengthen bonds among all 
members’ citizens (A B Sturm, et al, June 2005) (Abed, George T. 2003). 
2.5.1 Geographical Location of GCC: 
 
 The GCC states are located in the Arabian Peninsula Southwest of Asia 
between the latitudes of 15 and 35 north of Equator and longitudes of 35 and 60 
east of Greenwich, bordered by Iraq and Jordan in the North, Republic of 
Yemen and the Arabian Sea in the South, Arabian Gulf in the East, and Red 
Sea in the West (GCC Facts sheet, 2010). 
 
2.5.2 GCC Population 
 The surface area of the GCC countries is distributed unequally and as a 
result the population is variable, a large surface area country such as the 
Kingdom of Saudi Arabia, has a big population of 25.3 Million with a large 
number of rural Areas, where a small country like the Kingdom of Bahrain has a 
population of one million only and everything is at close proximity. Such 
variances could result in different health related issues, for example having a 
number of rural cities will give rise to an efficient transport system for medicines 
and health related services, such situation might have an effect on the health 
budget, the variation in the population will evidently requires suitable allocated 
budget, a large population could require a bigger budget to cover its health 
needs.     
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The following table adapted from the GCC library represents the 
population distribution among GCC countries in (2007/09).  
Table 2.5: GCC countries population variation from 2007-2009 
Country 
2009 
(in Million) 
2008 
(in Million) 
2007 
(in Million) 
% change in 
3 years 
U.A.E 4,8 4,8 4,5 6.2 
Bahrain 1,1 1,1 1,0 6.5 
K.S.A 25,4 24,8 24,2 4.7 
Oman 3,2 2,9 2,7 15.7 
Qatar 1,6 1,4 1,2 25 
Kuwait 2,6 2,5 2,4 7.6 
Total 38,7 37,5 36,0 6.8 
Source from GCC; a Statistical Glance; Vol II, Information Centre- Statistical Dept., 
Dec 2010. 
 
 The table above demonstrate an increase in the GCC countries 
population, there is a big increase in Oman and Qatar, such changes could 
have some sort of an impact on the health services, this increase in the 
population in Qatar can be explained due to the rapid economic growth Qatar 
recently faced. This has happened due to the discovery of Natural Gas, that 
required more of a workforce to build Qatar energy infrastructure, therefore, 
there is an increase in the population, mainly western immigration (Leah 
Hyslop. 2010).  Similarly in Oman, expatriates represents 45% of the 
population, but they are mainly Indian and Bangladesh (Gulf News. 2016), who 
were all needed to build the country’s infrastructure, this situation of a rapid 
increase and sudden increase in the population might have an impact on the 
health services, and it will require more medicines access for the larger 
population.  Since the increase is rapid and unplanned it might cause a type of 
a problem in healthcare and medicines. Another important health constrain that 
might appear due to this sudden migration, is the diversity of the population 
ethnicities that requires different method of health adaptation, such a problem is 
apparent in the Kuwait population, where 69% of the population is expatriate 
and mainly Indian and Bangladeshi (Kuwait Public Authority for Civil 
Information. 2014). In a situation like this the healthcare might need to cover a 
wider ethnicities and diseases profile and health requirements might differ, not 
accounting for the population diversity might lead to inefficient healthcare, and 
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might consequently cause the population to suffer and loose its confidence in 
the health system.   
A more recent increase in the population of Bahrain also been registered, 
and this has been the case because Bahrain has allowed the Syrian refugees to 
remain in Bahrain until the resolution of the crisis in Syria (Arthur Miller. 2016), 
such approach might bring with it new health-related conditions. For instance, 
some refugees might require psychological counselling to help them overcome 
what they have gone through and help them to accept the new way of living. 
Some have war related injuries that requires serious intervention and might 
need invasive medical procedures to help them recover, but all this requires 
further expenditure and will cause further health budget inflation.  
 Overall, the GCC states share a similar geographical structure; 
furthermore, they are similar in the socio-economic environments, parallel 
encounters, strains and the standard of living are relatively alike, the large 
percentage of expatriates in the GCC countries can be related mainly to the 
economic growth that the GCC countries went through, since the discovery of 
the oil and gas. This discovery left the GCC with the requirement of a large work 
force to deal with the recently discovered wealth, and because such fortune 
brought with it an attractive level of living and excellent financial rewards, the 
GCC countries became more desirable for the foreign workforce, and such a 
situation could have an impact on the health requirements and makes them 
unpredictable and could eventually inflate the health budget.     
 The following figure represents a comparison between all the GCC Health 
Expenditure, Public (% of Total Health Expenditure), the percentage has been 
measured with three decimal points due to the proximity of the values. It clear that the 
GCC countries share similar spending trends in healthcare, and the healthcare is a 
priority in the overall government budget. There is variation in the allocated budget and 
this is due to the variation of Oil revenue, since all the GCC countries depends on oil 
production as the main source of income.       
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Figure 2.4: Comparison of the GCC health Expenditure, created by the author, 
sourced from the World Bank stat. 
 
 
Another measure used internationally to estimate the health of any given 
population is Morbidity and Mortality rate. 
Infant mortality rate is the number of infants dying before reaching one 
year of age, per 1,000 live births in a given year. Reductions in infant mortality 
are possible in any stage of a country's development (Bishai, 2007). Rate 
reductions are evidence that a country is advancing in human knowledge, 
social institutions and physical capital. Governments can reduce the mortality 
rates by addressing the combined need for education (such as universal 
primary education), nutrition, and access to basic maternal and infant health 
services.  
The following figure represent the Infant mortality rate in the GCC since 
the year 200 until 2014. 
1996 1998 2000 2002 2004 2006 2008 2010 2012 2014
Kuwait 79.449 78.996 76.012 79.833 79.748 81.084 78.275 84.593 85.039 85.934
Bahrain 68.149 66.755 67.325 66.364 67.374 69.074 73.002 71.293 63.278 63.253
SA 55.142 58.739 72.541 72.162 71.48 74.412 65.829 64.85 71.239 74.524
UAE 79.251 71.058 70.465 63.07 59.137 59.454 65.618 72.126 74 72.343
Oman 83.919 81.557 81.752 83.47 81.914 80.689 78.834 82.714 82.431 89.766
Qatar 62.637 66.522 72.301 75.076 84.209 84.078 83.97 77.45 84.944 85.749
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Figure 2.5: GCC Mortality Rate, created by the author, sourced from the World 
Bank. 
 
The overall finding is that the Mortality rate is declining and the GCC 
countries have similar mortality rate except of Saudi Arabia, which is slightly 
higher and that could be because Saudi Arabia is a large country and has a 
large number of rural areas, and comprehensive health services might not be 
available to all.  
In regards to the Morbidity rate at the GCC countries, which can refer to 
either the incidence rate, or the prevalence of a disease or medical condition. 
This measure of sickness is contrasted with the mortality rate of a condition, 
which is the proportion of people dying during a given time interval. 
It would be useful to consider the expenditure on medicine in Kuwait , by 
age and gender, and compare it with the GCC countries but Such data is not 
available.  
As indicated previously Jordan was not one of the original GCC 
countries, but has recently been invited to join the other countries and brings 
with it a level of organisation not generally seen in the other countries. Short 
2003 2004 2006 2008 2010 2012 2014 2015
Saudi Arabia 17.6 17.2 16.4 15.5 14.7 13.8 12.9 12.5
Oman 11.9 11.4 10.6 10.2 10 10 10 9.9
Kuwait 10.4 10.3 10.6 9.7 9.2 8.5 7.7 7.3
Qatar 9.5 9.2 8.6 8.1 7.7 7.3 7 6.8
UAE 8.9 8.7 8.2 7.8 7.3 6.7 6.1 5.9
Bahrain 9.9 9.2 9 8.1 7.1 6.3 5.6 5.3
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descriptive backgrounds to the health position of these GCC countries are given 
below, starting with Jordan. The reason for choosing Jordan as an example to 
describe its health system, is because Jordan is the only GCC country with 
limited financial resources, and for this reason they have adopted many policies 
to control the inflation of healthcare cost. Furthermore, Jordan shares a number 
of similarities with Kuwait in terms of health profile and disease burdens, where 
the three main causes of death in Jordan are Cardiac problems, Road Traffic 
Accidents and Cancer (WHO. 2014). These health conditions are similar to 
Kuwait, and by looking closely at the Jordanian experience it might give an 
indication on how the State of Kuwait might gain an experience and could utilise 
it to reorganise the healthcare services at the State of Kuwait, or could use the 
gained experience to predict problems and prearrange a method of overcoming 
such problems.  
2.5.3 Hashemite Kingdom of Jordan 
 Jordan is a relatively small country with a total area of 89,342 square 
kilometres and an estimated population of 5.6 million (Department of Statistics. 
Jordan in Figures, 2006). It is bordered with K.S.A in the north resulting in a 
similar climate and social behaviours. The countries’ economic position is 
however different than that seen in the other GCC countries, and according to 
the National Poverty Strategy (2002), in Jordan there are up to one third of 
Jordanians living below the poverty line (CIA fact-book, 2013). On the other 
hand, the rest of the GCC countries, do not have any published figures to the 
percentage of the population living under the poverty line, therefore, the 
comparison between Jordan and the GCC countries in relation to the level of 
poverty is not possible. However, such comparison would have been useful to 
help in understanding the level of healthcare affordability by the whole 
population at several levels of incomes and out-of-pocket cost.  
2.5.3.1 Population of Jordan 
The first population survey was in 1961 and the latest survey results 
indicate that the population in 2010 was close to 6 million. Over the years, the 
average growth has fluctuated, due to a number of reasons, and in particular 
because of the many political interruptions. The population growth was highest 
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between 1979 and 1994 due to influx of immigrants from the West Bank and 
Gaza, because of conflict in these areas. Also, population growth occurred, 
following the Gulf Crisis in 1990 when it was estimated up to 300,000 
Jordanians returned from the Gulf States and also in 2003 when tens of 
thousands of Jordanians who lived in Iraq returned to Jordan following the 
second Gulf war.  Added to these numbers, at the same time, a very large 
number of Iraqi immigrants relocated to Jordan, and in recent years and since 
the start of the Syrian revolution there is another influx of migration from Syria, 
with people escaping the war and trying to seek refuge in a safer environment. 
Such a situation caused huge financial loads, and it required more healthcare to 
help the refugees get over all war related health conditions.   
According to the Jordanian Department of Statistics, this inflow of 
immigrants and the return of Jordanians to the country resulted in several 
problems of provision of infrastructure support which included putting a strain on 
government services, particularly the health services and education. This is 
however true in any sudden disruption in any given population.   
2.5.3.2 Jordan Health Care System Organisation 
The Ministry of Health as the major healthcare provider, is responsible 
for all health matters in the country, and is responsible for health promotion, for 
monitoring all aspects of health facilities in both the public and private sector 
and providing health education programmes and training. In addition, the 
Jordanian Food and Drug Administration are in charge of quality control for 
locally manufactured and imported medicine, medical supplies, drug 
registration, licensing and pricing.  The MOH also introduced a programme 
known as the Civil Insurance Programme (CIP), for the Public Sector (WHO, 
2013).  
To clarify the position further, the WHO has published the following table 
in 2013 in its periodical, Country Cooperation Strategy for WHO and Jordan, 
2008-2013, which summarises the different types of healthcare sectors 
available in Jordan, and who is responsible for funding the sector. 
  
62 
 
2.5.3.3 Jordan Healthcare Finances 
The WHO has also stated that Jordan’s total expenditure on health is 
among the highest in the region, at 9.8% of GDP, which could be partly 
explained by the constant changes in the population and the refugee crisis that 
requires serious funds to resolve any war related health conditions.  
However, the government share of 51% of the total health expenditure, 
has since been reduced by 10% between 1998 - 2005 (Jordan MOH, 2006), the 
figures suggest that there has been a growth in the private sector by 59% 
(Jordan MOH, 2006). This could be explained in two ways, the first thing might 
be that patients have more confidence in the private sector rather than the 
government sector, and it is suggested that this situation requires exploration 
and evaluation to reach the reason behind such approach. The second 
explanation could be because the public sector is not efficient enough and the 
healthcare services is not up to speed with the modern advances in the medical 
technologies, another point which needs to be considered is the cost of 
pharmaceuticals in the Jordan public sector account for one third of the total 
health budget, which places Jordan among the highest spenders on medicines 
(WHO, 2013).  
Jordan has similarities to the state of Kuwait in terms of the availabilities 
and access to health-related data, but unfortunately there is a lack of research 
within health authorities in Jordan; and although there are many ideas on what 
to research, but the main problem is lack of information (Ibrahim Al-Abbadi, 
2007).  
The different sectors of healthcare and its eligible beneficiaries are 
demonstrated in Table 2.6. 
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Table 2.6: Providers of Health care and eligible/beneficiaries in Jordan 
Sector Authority Eligible/Beneficiary 
Public MOH Civil Insurance 
Any citizen, resident or visitor 
Other insurance – MOU 
Royal Medical Services 
(RMS) 
Military insurance 
Private customers (including 
visitors) 
Other insurance - MOU 
University hospitals and 
specialized centres 
Jordan University 
Hospital 
Own 
constituency 
King Abdullah I 
Hospital (JUST) 
Other 
insurance 
King Hussein 
Cancer Centre 
Private 
customers 
Private Clinic Private insurance 
Hospital Private customers 
Treatment abroad Visitors, other insurance 
International UNRWA Registered Palestinian refugees 
Non-governmental 
organizations 
National Red Crescent Society 
International Clinics and hospitals 
Source: Country Cooperation Strategy for WHO and Jordan 
 
The health sectors in Jordan is slightly different from that available in 
Kuwait, but the similarities is in the fact that Jordan and Kuwait both have Public 
and Private sectors, but Jordan receives further aid from international 
organizations and non-governmental organizations, this is the case in Jordan 
because the Palestinians and the more recent Syrians refugees crises, and 
because of the fact that one third of the Jordanian population lives below the 
poverty line. Such a scenario is not present in Kuwait, the reason could be 
because Kuwait doesn’t receive any donations but on the contrary Kuwait is 
ranked the highest donators in the world.  
2.5.3.4 Pharmaceuticals 
25% of medicine needs in Jordan are manufactured in the country, the 
rest are imported. Although local production of medicines in Jordan is not 
enough to cover the country’s needs, the Jordanian pharmaceutical industries 
manages to sell medicines to other surrounding countries (Jordan Ministry of 
Finance, 2004).  One operational matter which has been organised in Jordan is 
the National Medicine Policy and part of the policy is the Essential Medicine 
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List, which was established in collaboration with the WHO and the World Bank.  
By introducing this Policy, Jordan MOH believes that it has been possible to 
move towards better control of the inflation related to the cost medicine.  
In Kuwait, there is one medicines and pharmaceutical factory, called the 
Kuwait Saudi Pharmaceutical Industries Company, KSC. It was established as 
a Kuwaiti company in the early eighties then after the invasion of Iraq to Kuwait 
the company was relaunched in co-operation with Saudi Arabia, the factory 
manufactures 86 generic types of medicines, but this covers a very small 
percentage of the medicines requirements at the state of Kuwait, Kuwait 
depends mainly on import for its medicines requirements and this situation is 
similar to Jordan with one difference, is the fact that Jordan makes 25% of its 
medicines needs. 
In additions to the discussions above the second country to be discussed 
is the Kingdom of Bahrain, because it’s the one of the two GCC with an 
operational EML, and Bahrain health profile is similar to Kuwait. 
2.5.4.0 The Kingdom of Bahrain 
Bahrain is officially the Kingdom of Bahrain and is a small island country 
situated near the western shores of the Arabian Gulf. It is an archipelago of 33 
islands, the largest being Bahrain Island, at 55km long by 18km wide. 
2.5.4.1 Population 
In 2013 the population was suggested by the World Bank to be 1.3 
million as compared to 561,872 in 1994 (Health statistics, Ministry of Health 
2003–2004).     
The following table, was adopted from the Bahrain Health Statistics, 
(MOH 2003-04), and appears to best describe the population distribution in 
Bahrain.  The table again represents a high percentage of non-Bahrainis and 
this can again relate to migration from the western world and from Indian for 
better pay, and the Syrian refugees escaping war.  
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Table 2.7: Demographic and socioeconomic indicators (2004) 
Total population 707 106 
Bahraini (%) 62 
Non-Bahraini (%) 38 
Population below 15 years (%) 24.5 
Population 15–64 years (%) 73.3 
Population 65+ years (%) 2.2 
GDP per capital (US$) (%) 15 572 
Unemployment 15+ years (%) 5.5 (2001) 
Source: Health statistics, Ministry of Health 2003–2004 
             Country Cooperation Strategy for WHO and Bahrain 2005–2010 
 
2.5.4.2 Healthcare System 
 In 1903 the first hospital was opened by the American Mission, with a 
bed capacity of 21. Following this another Victorian Memorial hospital opened 
with a 12-bed capacity. In 1936 a small hospital was established for the Bahrain 
Police Forces.  
 As the population grew there was a need for another well-equipped 
hospital, and in 1957 the Salmaniya Hospital was constructed. 
This healthcare system is very similar to Kuwait, and the method of funding is 
closely related to Kuwait.  
2.5.4.3 Bahrain Health System Financing 
 In 2004 the total healthcare expenditure including the Bahrain Defence 
Forces, Private Sector and Ministry of Health, was $282 million US dollar (CCS 
for WHO and Bahrain, 2010). In the following table is the percentage of the total 
health cost taken from the national budget from 2000 until 2010 (World Bank 
Report 2012). From these figures, it’s clear that there has been a rise of 1.5% 
over the 10 year period. 
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Figure 2.6 and the table indicates the rise in Bahrain health expenditure, 
with an increase by 1.5% over the ten years which is not a great increase and is 
very predictable due to the general inflation that is taking place worldwide. The 
EML of Bahrain were first started in 2009, which was an attempt by Bahrain 
Healthcare services to control future unexpected inflation.  
Bahrain, Oman, and Jordan are the only three GCC countries with an 
operational EML, other GCC countries like the Kingdom of Saudi Arabia, has a 
form of EML but not operational and not published yet, for the purpose of this 
research it is important to view their experience with the list and try to identify 
what point’s need to be considered when planning the EML for the State of 
Kuwait.    
 From the information mentioned earlier, Kuwait Oman Jordan and 
Bahrain have frequent population changes, to be more accurate all the GCC 
countries suffers from a high percentage of immigration, some political others 
financial. Such diversity on the population could change the health requirements 
and the results might be a bigger strain on the health budget, not being able to 
predict the actual health needs of a certain community due to the continuous 
changes of the community which might cause a failure to the health system in 
general and might cause an inefficient medicine supply system, all at the end 
might have a negative effects on the health budget. 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Column2 10.23 10.26 9.47 9.64 9.43 10.04 9.49 9.82 10.85 11.41 11.41
9
9.5
10
10.5
11
11.5
12
%
Figure 2.6: Health Expenditure; Public (% of Government 
Expenditure) in Bahrain
Source: The world Bank 2012  
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 However Oman, Jordan and Bahrain have all made several attempts to 
control these changes, and the approach that been conducted by these three 
countries to control the situation was to plan a medicine policy that includes an 
important medicines in relation to the health requirements of these countries 
diverse population and try to maintain a reasonable level of medicine supply.  
The three countries adopted the concept of the EML as an attempt to exert a 
type of control over the medicine budget, unfortunately, there are no hard 
evidence data to support the success of this application, this is a recurrent 
situation in the GCC countries in regards to the availabilities of health studies in 
general and medicine related studies in particular.  
At this point the Health System at the State of Kuwait will be discussed; 
which might help in understanding what are the issues and allocate the 
drainage of the Kuwait MOH budget.   
2.6.0 GCC Health Profile and Health Economic Indicators 
2.6.1 GCC Health Economics 
 In 2012 the GCC produced a collective document, Statistics at Glance 
(GCC; Statistics at Glance. 2012), mentions in the introduction that healthcare 
services have evolved tremendously in parallel with the population and life style 
growth in GCC countries. This is evident in the increased hospital numbers, in 
the number of doctors working at the healthcare facilities and in the number of 
patients per doctors, as shown in Table 7, the figures display that every ten 
years there is a duplication in the number of doctors and as a results the 
number of patients per doctor has reduced. This development in the services 
could be beneficial to the patients, and might help in providing better patient 
care, but again this type of approach might put some type of strain on the health 
budget, and if such duplication is continuous, the GCC countries might find 
themselves with a large number in the work force. With such large workforce it 
might be difficult to have an efficient follow-up to the doctors performance, and 
there may be no clear indication as to whether the workforce is fulfilling patient 
needs and is providing the appropriate care required, and with a large workforce 
the MOH of each GCC country might increase its health budget to cover the 
cost of doctors.   
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Table 2.8: Evolution of GCC healthcare 
(1990/2011) 
 1990 2000 2011 
Hospitals 345 475 635 
Doctors 23000 50000 100000 
Patients per Doctor 937 - 458 
Hospital beds 44500 60000 87000 
Source: GCC; Statistics at Glance. 2012 
 
Over the years the representatives of the GCC committee have taken 
these figures and converted them to the overall costs, and thus a budget figure.  
However the figures produced have shown that there has been an increase in 
the budget allocated to the MOH in each of the GCC countries. The following 
Table 8 represents the GCC financial resources indicators. 
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Table 2.9:  Financial Resources Indicators 
Country MOH 
allocation 
from 
Government 
budget 
MOH 
expenditure 
as % of 
GDP 
Government 
Expenditure 
as % of total 
Expenditure 
on health 
Annual 
budget of 
MOH (per 
Capital) 
National 
expenditure 
on health 
(per capital) 
% Year % Year % Year $ Year $ Year 
UAE 7.3 08 0.3 08 69.9 07 217 08 1140 07 
Bahrain 10.4 09 2.7 09 70.9 09 417.3 08 657.1 08 
KSA 6.2 09 - - - - 310 09 - - 
Oman 4.9 09 1.29 08 82.50 07 269 09 373 07 
Qatar 5.1 07 9.7 08 70.1 09 2059 09 2935 09 
Kuwait 7.6 10 - - - - 801 10 - - 
UAE: The indicators mentioned above are for the whole union 
Source: Health Indicators for The GCC, 2011. 15th edition. Riyadh. KSA 
 
 From the table above it is clear that the healthcare services are a big part 
of the GCC countries general budget, the highest found in Bahrain and the 
lowest in Oman. In Oman and due to the drop in oil prices and the reduction of 
33% of Oman annual oil and gas revenue (Oman State Budget, 2016), the 
government tried to cut expenditure, and part of this plan is a five year plan to 
privatise several public sectors including healthcare.   
 Due to the discovery of Oil and Gas in the GCC countries, resulting in a 
large revenue, the health services in the GCC countries are much better than 
they were before the Oil and Gas discovery (McKinsey et al, 2012), but the 
demands on healthcare services are escalating due to the population increase 
and the immigration from various Western and Asian countries to the GCC 
countries, in addition the general population are not entirely satisfied with the 
care level provided, as patients expect to have access to all kind of modern 
clinical technologies, with no regards to its cost and benefit. Another issue that 
might require careful deliberation, and could be another form of budget inflation 
is the lack the proper managerial skills at a high level and for a relatively new 
modern healthcare system it might be worthwhile to get international medical 
experts input into the newly developed system, but unfortunately the cash 
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motivations are often not enough, alone, to attract medical specialists, who are 
increasingly required by the Health Services,  
 The GCC Health Statistics suggests that chronic diseases are rising, 
such as diabetes and hypertension and that the healthcare facilities are not fully 
appropriate to deal with such an increase, this is the case due to the harsh 
weather conditions that makes it impossible to practice any kind of outdoor 
physical activities, because of the high rate of smokers and bad food habits, 
that all requires cures and it is proposed that it would be wiser if the GCC 
countries moved towards preventive care and patient education to reduces such 
prevalence’s.     
 Overall over the last 40 years the GCC countries have been faced with 
main areas of healthcare concerns, which have led to increases in demand on 
their healthcare services and consequently have led to increased cost. These 
are population growth, increased life expectancy and health risk factors.  
 In the first case it is expected that the size of the population of GCC 
countries is likely to double by the year 2025 (McKinsey et al, 2012), one of the 
main reasons is due to an increase in life expectancy in the GCC region and a 
reduction in the infant mortality rate. As a result there will be a more aging 
population that subsequently requires more healthcare support and this has 
lead to extra cost. It is estimated, from the study conducted by McKinsey et al 
2012, that over the next 20 years the treatment demand in the GCC will 
increase in the region of 240%. In addition the number of hospital beds will 
probably need to be doubled to deal with the demands, and it is estimated that 
the healthcare cost is expected to increase by around five times the present 
levels. 
2.6.2 The State of Kuwait Health Budget 
 In Kuwait the majority of the Public Healthcare expenditure is linked 
through the Government Departments, and as an example it was 78.1% and 
75.1% in 2000 and 2002 respectively. In contrast only a small percentage is 
related to the supply of Healthcare support through the private sector and 
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expenditure linked to the government out of pocket accounts (Kuwait Health 
Sector report, 2012). 
 When looking at the yearly figures for Kuwait, overall, the Government is 
estimated to spend a large amount of money on health services in general and 
a large proportion of it is spent on the supply of medicines. The following Table 
(obtained from the Kuwait Government Budget Department, at Kuwait MOH) 
shows a comparison of the total budget of the MOH and the percentage of the 
cost of medicines from the total. 
Table 2.10:  MOH budget and Medicine budget 2006 until 2010 in Kuwaiti Dinar 
year MOH Budget 
(Million) 
Medicine Budget 
Agreed (million) 
KMB 
Changes 
Agreed after 
changes 
% 
2006/2007 555,0 84 4,2 88,2 16 
2007/2008 638,6 89 1,3 90,2 14 
2008/2009 1,019,3 121 0 121,3 12 
2009/2010 876,8 140 10,1 150,4 17 
2010/2011 1,082,0 144,4 14 158,5 15 
2011/2012 1,197,2 217 0 217 18 
Agreed and changes of Kuwait medicine budget (KMB) in comparison to the total MOH budget 
(MOH.B) 
Source: Kuwait MOH Budget and expenditure department, 2013 
1KD = 3.51  US$ 
 
 From the data in the Table it is clear that the overall budget of the Kuwait 
MOH has increased considerably in the past 6 years alongside increases in the 
medicine budget.  It is suggested in the Kuwait Ministry of finance reports that 
this growth requires consideration and deliberation, and it is presently being 
reviewed (Kuwait Ministry of Finance. 2015).  
 During the early part of this study in 2013, the Assistant Undersecretary 
of the Ministry of Health for Planning and Quality Affairs (Dr Waleed Al-Falah), 
was interviewed by the major Arab Times News Paper and it was mentioned 
that the MOH budget rose to almost double in the last five years from around 
KD 620 million in 2007 to KD 1.197 billion in 2013, that is 2.05 Billion to 3.97 
billion US Dollar. In the interview, he added that although the figures have 
increased considerably, it does not seem to be the case that the health 
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outcomes are reflected in aspects of efficiency and quality of the Country’s 
Health Services. Dr Alfalah added that he believed that ‘improving the health 
services can only be conducted if there is better handling of the economic tools 
including auditing, financing, and statistics’. (Arab Times, 2013, p 4).  Dr AL-
Falah further explained in an interview with myself in February 2014 where the 
main points of the his statement for the Arab Times Newspaper were discussed, 
that Kuwait’s Health Services and Healthcare Expenditure however requires 
careful monitoring and deliberations to control the inflation and to assist in this 
the health indicators need to be examined carefully and attention should be 
given to each section. Therefore, there is a need to give special attention to the 
medicine budget and try to investigate areas in which the medicine budget can 
be controlled.  From Dr Alfalah statement to the Newspaper, its evident that the 
Kuwait government acknowledge the fact that the medicine budget is rather 
high and might require some type of reorganising, the statement also indicates 
that a system or a policy that focuses the number of medicines to a list of 
medicines that is closely related to the general health needs of Kuwait could be 
adopted and such system might help in practicing a type of control over the 
budget inflation.  
The following chart demonstrate a comparison of the GCC countries 
Consumer Price Index for Medical Care in 2011, in the chart, Figure 8 Kuwait 
has the highest CPI for Health Care, meaning that patients in Kuwait pays 
higher retail prices for medical goods, including medicines than any other GCC 
countries.  This finding insinuates that patients have higher out of pockets 
expenses than any other GCC country and might indicate that Kuwaiti patients 
are moving towards the private sector for treatment and healthcare, and such a 
situation might require further deliberation to come to decision on the reason 
behind it.   
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 Figure 2.7: sourced from the GCC Library 
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Chapter 3 
Methodology 
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3.1 Introduction 
 Research according to Johnson (1994) can be described as being ‘A 
focused and systematic enquiry that goes beyond generally available 
knowledge to acquire specialised and detailed information, providing a basis for 
analysis and elucidatory comment on the topic of enquiry’ (white, 2005). Based 
on this definition or description of the research work, it needs to be 
concentrated, logical and follow rational steps to be able to answer the research 
questions.   
 This chapter describes the methods which were used and the rationale 
behind choosing each method and how appropriate they are for delivering the 
required information. This chapter will cover all aspects of the research and 
data collection process as well as the location of the field work.  
It will also define the different types of research philosophy and will 
demonstrate the best philosophical description for this particular research work.    
 In the early stage of this research work, it was aimed to investigate and 
review the current medicine situation in terms of availability, cost and quality at 
the State of Kuwait MOH healthcare facilities. The methods focus on trying to 
explore, analyse and discuss the present situation. By doing so it was proposed 
that the actual concerns could be raised and highlighted.  Once this is achieved, 
it is proposed that some solutions or suggestions for the future of the medicine 
situation could be generated.  Once this was completed, it was proposed to 
tackle the main area of this study, which is to discuss and suggest whether it 
would be appropriate to introduce an EML programme into Kuwait. If one was to 
be introduced, it would be suggested whether it will enhance the general 
medicine situation of the country and increase its efficiency (Collins & Hussey, 
2003). 
 Later as the research progresses, it moves towards the attempt to extract 
knowledge and try to identify the processes, which other countries used to 
develop and established their EML; this part of the research work will attempt to 
identify the difficulties they faced during and after the implementation of the 
concept. It was proposed to focus on gathering data from the key actors in the 
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medicine supply system. This project does purposefully not include healthcare 
recipients in the data gathering process, because such stakeholders are 
unlikely to have sufficient knowledge or practical experience of the system to 
provide any meaningful data. 
 Later, in the research work, it was intended to make a comparison 
between previously published and already operational Essential Medicine List’s 
in several countries with various geographical locations and different standards 
of living.  
 At the final part of the research there will be a close investigation to the 
WHO Model List of Essential Medicines, and a close inspection to Kuwait List of 
Medicines that is available at the Central Medical Stores.  Overall it is proposed 
that by doing this study, it will be possible to formulate the most appropriate 
recommendations to illustrate how the Essential Medicine List of Kuwait might 
be presented. Because it aimed in this part of the study to obtain a general 
understanding of a Kuwait EML, but not the actual list.    
3.2 Research Type: 
 It is proposed that the research can be considered, at the early stage, as 
being exploratory, because it was found that there are few or no previous 
studies in this field, which relate specifically to the medicine system in Kuwait. 
The research methodology was designed from the origin and didn’t follow any 
previous work, simply, because such work does not exist. This finding was 
established following a very intensive and time consuming literature review that 
revealed this statement.  
3.3 Research Approaches 
 The research is considered to be a deductive approach, the research 
aims to deduct the appropriate interpretations to the suitability of the Essential 
Medicine List to Kuwait. This approach is believed to be the most suitable to this 
particular study because it should test the major research questions which are, 
“What are the contextual factors in Kuwait which would assist or hinder effective 
implementation of EML?” 
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These particular research questions are the reason behind starting the 
whole research study. 
 To explain the approach more, we can quote Beiske (2007), by 
explaining that ‘The deductive approach follows the path of logic most closely. 
The reasoning starts with a theory and leads to a new hypothesis. This 
hypothesis is put to the test by confronting it with observations that either lead 
to a confirmation or a rejection of the hypothesis’ (Snieder and Larner, 2009, 
p.16). 
 The deductive approach tends to test theories, phenomenon or concepts, 
and in this type of work, the concept of EML will be tested. The outcome will be 
verified and depending on this finding, the concept can be rejected or carried 
forward.  
 To do this type of research approach, two types of research methodology 
have been used, Qualitative Research Methodology and Quantitative Research 
Methodology, the following explain each.  
3.3.1 Quantitative research:  
 Quantitative research is defined by Bryman and Bell (2007, p. 154) as 
‘entailing the collection of numerical data and exhibiting the view of relationship 
between theory and research as deductive, a predilection for natural science 
approach, and as having an objectivist conception of social reality.’ 
 The most popular research methods from this category are closed-ended 
questionnaires, experiments, correlation and regression analysis methods, and 
others. 
 For the purpose of this research two questionnaires were designed and 
the numerical data collected was analysed quantitatively using SPSS. The 
questionnaires aimed to reflect participant attitude and establish the level of 
satisfaction with the current medicine situation in Kuwait. The second 
questionnaire would focus on figuring out the availability of medicines 
Standards Treatment Guidelines in Kuwait public healthcare facilities. The 
questionnaires were conducted to gather a large amount of data in a relatively 
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short time; questionnaires, as a method of data collection, are considered 
preferable due to the confidentiality of the method, this will encourage 
participation and increase the level of reliability in the responses. 
3.3.2 Qualitative Research: 
 The second method to be used for the purpose of this research is 
qualitative research, ‘qualitative methods are often regarded as providing rich 
data about real life people and situations and being more able to make sense of 
behaviour and to understand behaviour within its wider context. However, 
qualitative research is often criticized for lacking generalizability, being too 
reliant on the subjective interpretations of researchers and being incapable of 
replication by subsequent researchers’ (Vaus, 2002, p.5). 
 The qualitative methods vary and come in many tools; for the purpose of 
this research, the methods used are interviews, document analysis and cross-
comparison analysis. 
The following will describe each qualitative method used. 
3.3.2.1 Interviews 
 The second part of the research study is conducted by way of interviews; 
where the aim is to explore the attitudes towards the current medicine situation, 
and the perception of the senior healthcare managers towards an EML concept. 
 In the early studies the work is considered to be a baseline study or basic 
research, to improve the knowledge and get a feel of the current situation, 
without any particular purpose in mind. 
3.3.2.2 Cross-Comparison 
 One of the objectives of the research is to gain experience from previous 
Essential Medicine List implementation procedures. For this reason a qualitative 
cross-comparison method is used to compare the procedures of various 
countries in their trip towards the implementation of the Essential Medicine List 
concept.    
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 The comparative qualitative methodology was carried out between 5 
international countries with different levels of income. The reason for this was to 
test the implementation processes from different perspectives and observe the 
transnational differences that these countries faced while launching their own 
interpretations of the Essential Medicine List. In order not to miss the finer 
details, that the research methodology might reveal, when countries with similar 
geographical and ethnical profiles were chosen, another comparison was 
carried out between all the Arab countries with an established or announced 
Essential Medicine List. This type of qualitative methodology was carried out 
because the Arab countries share similar ethnicity with the State of Kuwait; they 
have similar climate, some of them are very similar in terms of standards of 
living. By conducting this type of qualitative research, it’s assumed that it might 
give an indication on what needs to be done in Kuwait once the Essential 
Medicine List has been adopted and implemented. 
 It was believed that this approach is a type of method that employs a 
multiple discipline in one study and that is what makes it flexible, but there are 
limitations to the technique which will be discussed later in the Methods 
Limitations section.  
3.3.2.3 Visits 
 Several field visits have been conducted to two countries, one is Kuwait 
and the other country is the Kingdom of Saudi Arabia.  
 The reason for the visits is mainly because of the lack of resources and 
publications in regards to the Kuwait Health sector and lack of access to any 
literature to give a clear understanding of the health situation at a GCC level 
and at a more local Kuwaiti level.    
3.4 Mixed Method Approach  
 The mixed method of data collection was necessary to enhance and 
validate the data and because the research question required this kind of 
approach. Conducting a mixed method approach will help in answering the 
research questions from various perspectives, it will help in ensuring the 
information gaps are minimised. The first parts of the research questions aimed 
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to investigate the health and medicine situation in Kuwait. In order to answer 
this question it was necessary to conduct a questionnaire and gain the views of 
the health professionals who are in close relation to medicine procurement. 
When moving to collect data on the health budget and Medicine budget in 
Kuwait, the only tool available was direct interviews. 
 The later part of the research questions were related to the EML 
implementation and what is likely to be expected when it’s carried forward and 
becomes fully implemented in Kuwait. For this type of research question is 
suggested to be the best way to look at local, Arabic and International written 
and published material and documentations. This comparison has then been 
applied and aims to differentiate the hindrances that need to be accounted for 
when implementing an EML in Kuwait, and it helps to gain experience from 
other countries strategies and which will enable Kuwait to develop their own 
methods of implementation.   
3.5 Methods Limitations 
 The qualitative research is challenging when it comes down to making 
prophecies and interpretations, it’s time consuming and requires a very large 
number of resources to get to the information required. Very careful care needs 
to be practiced in order not to influence the results with personal biases and 
idiosyncrasies.  
 A major limitation was found when conducting the visits, as seen 
especially within The Kingdom of Saudi Arabia; the local culture and the 
limitation of women, made access to various departments and thereby the data 
collection process very difficult and challenging.  
  Another common limitation found when conducting the qualitative 
methodology, was that the data extracted from different countries did not use 
similar terminology and even more research and time was spent extracting the 
required data.  
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3.6 Organisation Studied 
 The research was approached at three different levels; the first level was 
the international level, to help in understanding the concept of the essential 
medicines list internationally. By exploring the concept internationally it’s 
proposed that it will help in gaining experience from these countries methods in 
the implementation of the Essential Medicine list. In having awareness to the 
various processes used by different countries.  It also may give an idea on what 
is the most suitable method in implementing the Essential Medicine concept in 
the State of Kuwait.  It’s proposed that if the international health organisation 
techniques were studied, it might assist in extracting interpretations to the 
difficulties they have undergone, and their methods of overcoming such issues. 
It’s proposed that by studying the Essential Medicine List concept 
internationally, it will give some direction as to the best possible way to 
approach the process of introducing the Essential Medicine concept. It will 
provide knowledge to carry it forward and convey a perception of what might 
rise as an obstacle; it’s proposed that it might give an indication on the best plan 
to introduce the concept of Essential Medicine.       
 The second level of the study was carried out to investigate the Arabic 
countries’ Lists of Essential Medicines; this part has taken place due to the fact 
that the Arab countries share similar health profiles and ethnicity, they are 
similar in terms of climate, but they differ in the level and standards of living. For 
this reason all the Arab countries that have a list of Essential Medicine were 
included, the idea behind such an approach is to view all levels of income 
experiences with the list; how they managed to make it operational, how they 
overcome the various issues with stakeholders, that are usually resistant to any 
changes that might have an effect over their interests.  
 Finally, fieldwork studies were carried out in Kuwait in person, and a 
large number of Healthcare facilities and organisations have been visited, this 
was the case because in Kuwait, very few to almost none, of the information 
and figures are accessible online. Generally all data is available in the form of 
hardcopies and the process of obtaining approval to gain access was quite 
lengthy and the bureaucracy was exhausting. This part of the research was 
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carried out to gain awareness of; the current medicine situation at the state of 
Kuwait, the health needs of Kuwait, disease profiles, the available guidelines 
and regulations, current health policies, the process of introducing new policies, 
Kuwait Ministry of Health general budget and the public sector medicine budget, 
medicine catalogue, medicine consumption rate, procurement cycle, references 
available to the healthcare professionals, Quality Assurance and Quality Control 
process, medicine registration process, withdrawal of medicines, 
pharmacovigilance availability, health transparency and medicine corruption.  
 The research work in Kuwait was carried out at various levels, it started 
at a high ministerial level, this is important to gain clearance to proceed and get 
the required information from different departments. Various Undersecretaries 
(the term for the highest operating managers) have been engaged in personal 
meetings, such as; Dr Waleed Alfalah, Undersecretary of Development and 
Quality at the Kuwait Ministry of Health and Dr Omar Alsayed Omar, 
Undersecretary of Medicines and Medical Appliances.  
 At a more academic level, a meeting was held with Dr Mohammad 
Wahede, Associate Dean at the Faculty of Pharmacy, at Kuwait University. The 
reason for this meeting was to gain the academic view of the general situation 
of medicine in Kuwait and because the Faculty of Pharmacy is the only source 
of a pharmacist training centre in Kuwait. It was considered important to get the 
Faculty of Pharmacy involved in the concept as early as possible, because 
when the Essential Medicine Concept becomes a reality, it will be explained and 
taught at the Faculty of Pharmacy to pharmacy students. 
 At a lower level, various managers were met with and documentation 
was obtained to be included in the research and clearance to work in other 
departments was granted, through these managers. These managers included 
the following; Pharmacist Essam Alsultan, Head of Pharmaceutical Department 
at the Psychological Hospital (Secondary Healthcare hospital) and pharmacist 
Asma Al-Mutairi, Pharmacist in-charge of Ashbelia Polyclinic pharmacy (primary 
healthcare Centre), both are directly involved with the medicine procurement. 
 Chief Pharmacist Fahad Al-Qatan, Special Medicines Department 
Manager at the CMS, and at Kuwait FDA, the head of the New Medicine 
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Registration and Listing Department Dr Dina Bustaki, and the Head of Quality 
Control and Quality Assurance and Laboratory Dr Sarah Maqseed, were both 
interviewed to provide information in regards to their departments. At a lower 
level at the FDA, Pharmacist Izhar Al-Ostath, pharmacist in-charge of New 
Medicine Registration was interviewed. Pharmacist Joseph of the Reviewing of 
New Medicine Department and the staff of the Pharmacovigilance Department 
were also included in the interviews.  
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The following Figure 3.1, summarise all levels.   
 
 
 
 
 
Figure 3.1: The Organisation levels that been studied
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3.7 The Philosophical Paradigm of this Study  
 Guba and Lincoln (1994), divide research philosophies into four 
paradigms, which are Positivism, Postpositivism, Critical Theory and 
Constructivism (Interpretivism).  Guba and Lincoln state that these paradigms 
have been challenged, until recent years. This is true for qualitative research, in 
order to gain its position as being the paradigm of choice, for reporting, 
informing and guiding as well. Paradigms have been described by Guba and 
Lincoln ‘as a set of A paradigm may be viewed as a set of basic beliefs (or 
metaphysics) that deals with ultimate’s or first principles. It represents a 
worldview that defines, for its holder, the nature of the "world," the individual's 
place in it, and the range of possible relationships to that world and its part.’ 
 Guba and Lincoln (1994), state that each paradigm has three elements, 
the first element is the ontology which is the ‘’truth’’ that is being investigated 
and researched. The second element is the epistemology, which is described 
by Guba and Lincoln (1994) as the relationship between the truth or reality and 
the researcher. The final element is the methodology, this can only be 
described as the procedure that is being used to investigate the reality.   
 The following will give a brief description of each paradigm, and will 
indicate the best research paradigm that can describe this particular research. 
3.7.1 Positivism 
 Positivism assumes that phenomena can be accurately defined and 
measured (normally quantitatively). It provides a single, and unbiased view of 
reality (Carson et al., 2001). It can be defined as being the philosophy of 
knowing. In this type of philosophy, the researcher role is basically data 
collection and interpretation of the findings. Usually in such models the findings 
are visible and measureable.  
 Some researchers assume that positivism is not a suitable method to 
measure human responses and life experiences. (Healy & Perry. 1997). It’s a 
suitable paradigm in science, if that particular method of science can be 
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measured qualitatively. It is considered not to be a suitable means of measuring 
reality in a social sciences situation (Guba and Lincoln, 1994, p. 110). 
 From this definition of the positivism paradigm, and since the study 
focuses on researching healthcare professionals’ attitudes towards the 
medicine situation and researching the policy makers and senior health 
managers’ behaviours towards the introduction of new policy, this type of 
paradigm is not a suitable paradigm to this particular study, simply because 
there is no expected response reality of the interviewee and the participant’s 
reaction cannot be anticipated or predefined.  
3.7.2 Postpositivism 
 Postpositivism believe that a reality exists, like positivists do, though they 
hold that it can be known only imperfectly and probabilistically (Robson, Colin. 
2002). Postpositivism came, in a way, to criticise positivism, because no 
phenomena are 100% rock-solid, it can be described as being an amendment 
of positivism. In another way it’s a more flexible paradigm than positivism. 
Postpositivism still fails to address human attitude and behaviours, for this 
reason it fails as a paradigm to explore the research questions of this study.  
3.7.3 Critical Theory  
 Critical Theory is a type of paradigm that focuses on criticism and trying 
to alter society. It’s been developed by the Frankfurt School, which is not an 
actual school, it’s more a group of scholar’s thoughts (Heal and Perry, 2000). 
 For the purpose of this research, this type of paradigm is not suitable and 
doesn’t tackle the research questions because this research study doesn’t 
intend to alter any society and doesn’t criticise any particular society.  
3.7.4 Constructivism (Interpretivism) 
 Guba and Lincoln (1994), define Constructivism as a paradigm that 
refers to a particular belief-system, and is held in a particular context. Some 
researchers, in the field of research philosophy, refer to Constructivism as 
Interpretivism; it is a method of multiple realities as explained by Lincoln and 
Guba (1998). This paradigm integrates human interest into the study, 
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Interpretivism was explained by Collins, (2010, p. 38) as being ‘associated with 
the philosophical position of idealism, and is used to group together diverse 
approaches, including social constructionism, phenomenology and 
hermeneutics; approaches that reject the objectivist view that meaning resides 
within the world independently of consciousness.’ 
 Hudson and Ozanne (1988) state ‘that the researcher inter the study with 
a prior insight of the research context but assumes that this is insufficient in 
developing a fixed research design due to complex, multiple and unpredictable 
nature of what is perceived as reality’ (Hudson and Ozanne, 1988). 
 Carson (2001) explains Interpretivism as being personal and can be 
adopted to form a more flexible research structure, and avoid rigid structural 
framework that is found in positivist research.  
 In summary, the interpretivism research paradigm is a form of philosophy 
that is able to understand and get interpretation of the meaning of human 
behaviours’, without focus and no prediction of the causes and effects 
(Neuman, 2000; Hudson and Ozanne, 1988). 
 The philosophy of this research is considered, interpretivism philosophy, 
where interpretivists believe that the reality is relative and multiple. According to 
this tradition there can be more than one reality and more than a single 
structured way of accessing such realities (Lincoln and Guba, 1985).  In order to 
carry out this exploratory work which is often based on field work, observation, 
the methodology used is surveys and/or interviews which are cross-sectional 
(Livesey, 2006). 
3.8 Strategies and Research Design 
 The following section will explain the process of data collection, the pilot 
stage, the rationale behind using this type of data collection and methodology 
and sample selection and the justification of sample selection.  
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3.9 Research phases  
3.9.1 Pilot Study 
 A pilot study was carried out at the very early stage of the research, the 
two questionnaires were both piloted with a small group of participants to 
confirm the efficiency of the instrument being used and to help in modifying any 
confusing or imprecise questions. It aims to observe where the data gathering 
method is reliable and accurate or need improvements and modifications.  
 By conducting a pilot study, it was hoped that it would reveal any faults or 
weakness with the study design. It is also intended to approximately predict the 
time scale required to complete the questionnaire. It helped in predicting the 
best method to introduce the questionnaire to maximise participation and 
responses.  
 Overall, the pilot study is a justification of the methods and tests its 
reliability. 
3.9.1.2 Pilot Study Limitations 
 Although the pilot study helps to identify the parameters mentioned 
earlier, it also has major limitations, as it can successfully hide issues that may 
arise in a large scale study. Such issues are the number of personal required to 
work on the study to cover the required large number of participants, and most 
importantly it will not address the issue of the handling, organising and 
analysing of the large data collection that will be generated from the main study.  
3.9.1.3 Pilot Study Sample Size 
 Connelly (2008) suggests that the sample size should be 10% of the 
population of the larger study. Where Isaac and Michael (1995), suggest 10-30 
participants, this is agreed by most researchers in the field, such as Julious 
(2005), Treece and Treece (1982). 
 The first pilot study was conducted with a group of 10 Pharmacists, to 
test the validity of the first questionnaire ‘the Current Medicine situation at the 
State of Kuwait’; the responses were not included in the actual data collection of 
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the project. With regards to the second questionnaire ‘the presence of standard 
treatment guidelines at Kuwait MOH healthcare facilities’ another 5 pharmacists 
and 5 doctors where approached and took part in the pilot study, the responses 
were again not included in the final data collection and were not analysed.   
 The reason for choosing a smaller number of participants for the pilot 
study, is because Kuwait is a small country with a population of 1.3 million, the 
number of pharmacists in the public sector is very small, around 400 
pharmacists, and the medical staff that is involved in the procurement of 
medicines is also small. 
3.9.1.4 Pilot Study Outcome  
 The outcomes of the participants’ views were considered and changes 
were made to the process of gaining access to the willing participant. It became 
clear that the best way to find a willing participant was if they were in a group, 
and during a break, this was the reason for approaching participants who were 
on a short break, between workshops or medical lectures. It was discovered 
that if one candidate agreed to participate the rest of the group would agree to 
take part.   
 It was also found that it is often best for more than one person to 
approach the participant, this is evident by the fact that more responses were 
gained when each person approached different groups and it also saved time.    
 3.9.2 Data Collection and Analysis Methods 
 All the data collection processes were carried out in Kuwait and one visit 
to Saudi Arabia, it was collected in the form of two questionnaires and several 
interviews with Under-secretaries and Senior Health and Budget Managers. The 
second part of the data collection was aimed to perform a cross-analysis 
between different existing EML’s, at an Arabic level and International level.  
 The data was generally collected in person, all the interviews were 
carried out by the researcher of this study. In order to speed up the process and 
gain more data, the questionnaire part, required help from two other colleagues 
in the Ministry of Health in Kuwait.  
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 The interview participants were contacted in several ways, some were 
contacted by email, phone, through the social media-WhatsApp application and 
through arranged appointments with their secretaries in person. All interviews 
were recorded for later referral and analysing. The questionnaires were handed 
to the participants in person and returned inside a sealed envelope to enhance 
confidentiality. 
 The cross-comparison table information were gathered from various 
resources, some from governmental official web pages, WHO library, GCC 
official Library, online publications and previous studies.    
3.9.2.1 Analysing tool 
3.9.2.1.1 Questionnaires Analysing Tool 
 SPSS was used for both questionnaires; it’s an abbreviation for 
‘Statistical Package for the Social Sciences.’ This package was selected based 
on the familiarity with the statistical data analysing package, the practicality of 
manually entering the data, and the ability to edit data easily and from various 
sources.  
 Another practical reason for choosing SPSS is because it doesn’t require 
definition of variables manually. It also offers a great range of graphs and 
charts, and the output and results are stored in a separate file from the data 
itself.     
 The limitation of the SPSS method of analysing the data, was mainly 
found in the lack of evaluation of how well the data is represented.  Another 
limitation was not being able to use it in any computer; it can only be uploaded 
to one computer and used on that one.  
3.9.2.1.2 Interviews Analysing Tool 
 The primary reason for using interviews is because they will provide 
more in-depth information than surveys, because the population of the 
interviewee were mainly senior managers and under-secretaries, it was the 
most appropriate method for such situations and more suitable to their status. It 
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permitted asking further questions spontaneously and gave the participants the 
chance to express their views freely.  
3.9.2.1.3 Qualitative Coding & Analysis  
 This type of analysing tool is ideal to analyse interview transcripts, codes 
can be based on themes, topics, ideas, concepts, terms, or phrases.  It 
transfers information and prepares it into a form of understandable data using 
computer software.  
 Iain Hay (2005), outlines a two-step process beginning with basic coding 
in order to distinguish overall themes, followed by a more in-depth, interpretive 
code in which more specific trends and patterns can be interpreted.  
 This process can be done with several computer software, such as 
Atlas.ti, QDA Miner and Nvivo, but it can also be done manually. This is 
possible by highlighting the concept with different colours and analysing them 
further.  
 Interview data can be coded in three ways, Open Coding, Axial Coding 
or Selective Coding. The following explains each coding; 
- Open Coding 
 Open coding focusses on the text and categories it into primary level and 
secondary level. The primary heading or level in this research is the EML and 
the subheading would be its value to the medicine situation in Kuwait.  
In other words, the data obtained will be divided into segments then inspected 
for common theme, keywords or phrases. The way this data is obtained is by 
asking questions, making comparisons and looking for common ground 
between responses.   
- Axil Coding 
 Axil coding differs from open coding in the way the responses are 
interpreted, it’s more related to using your own concept and categories to 
analyse and read the results rather than allowing the data to reveal its own 
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theme. This coding might be suitable to different types of research but it’s not 
suitable to this particular study because this study when conducted did not have 
any prior expectations or opinions on the matter.  
- Selective coding 
 The third type of coding, is selective coding, which selects a main 
category then relates it to the other categories. It’s suitable is generally for 
making a type of storyline to describe an occurrence. For this reason, it was not 
used in this research.   
In addition the Limitation is that the method is considered time consuming and 
labour intensive.  
3.9.2.1.4 Comparative Research Method Analysing Tool  
 The comparative approach was used because it can best, to clearly 
identify the differences and similarities between nations. It’s defined by 
D.E.Sanga (2004) as ‘a research methodology in the social sciences that aims 
to make comparisons across different countries or cultures.’  
 For the first comparative study, 5 countries where selected, from different 
continents with different levels of income and different levels of development 
and access to resources. The reason for this is because Kuwait is a wealthy 
country, similar to Norway, with high access to various international resources 
and technologies similar to the developed countries such as Australia. At the 
same time Kuwait suffers from bureaucracy and resistance to change, which is 
found in the less developed countries such as India, Sri-Lanka and Bangladesh.  
 In the second comparative study the choice was based on geographical 
location and ethnicity, all the countries in this study are Arab countries with 
similar ethnicity and relatively similar health issues, but they all have various 
income levels.  
 The analysing tool of choice was a comparative tables that demonstrates 
the required data simply and clearly; this was put together following intensive 
document review.  
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3.9.2.2 The General Sampling Process  
 The sampling methods vary depending on the type of research being 
carried out, and the method used. For example a survey that contains a large 
population has a different form of sampling than interviews that have fewer 
numbers of participants. The choice of the sample population will differ in 
accordance to the method being followed and the purpose of the study. The 
following explains each sampling method used in this research. 
- Questionnaire Sample Selection 
 Sample selection is the principle used to target the most appropriate 
population to take part in responding to the questionnaires. When conducting 
the sampling process a few points need to be considered, these are the size of 
the sample, which needs to be manageable, the target population, which needs 
to be able to provide insightful and meaningful data and the participants need to 
be involved directly with the topic being researched. For these reasons, when 
selecting the population, for the first questionnaire, only health professionals, 
who are directly involved with medicine procurements, were included. The 
reason behind this, is that they can provide a very realistic and honest opinion 
to the actual medicine supply system in Kuwait. The participants were all from 
Kuwait, simply because the research aims to implement the EML in Kuwait.  
 The sampling method can be divided into two methods, Probability 
Sampling Methods and Non-Probability Sampling Methods. The basis of these 
methods is explained below. 
- Probability Sampling Methods (PSM) 
 In this type of sampling, participants have exactly the same chance of 
taking part; it has a subdivision of simple PSM, stratified systematic PSM, 
Multistage PSM and Cluster sampling.  
- Non-Probability Sampling Methods (nPSM) 
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 In this type of sampling methods, not every member of the population will 
take part, but they are selected in a non-random manner based on judgment, 
quota, convenience and extensive sampling. 
 For the purpose of this study, the sampling choice was clearly the Non-
Probability sampling methods, simply because not all of the pharmaceutical 
staff and medical doctors were involved in the questionnaire. It was a type of 
Judgement Sampling because the participants were chosen in relation to their 
direct involvement with the medicine supply cycle.  
- Interview Sample Size and Selection Purpose 
 The interviews were carried out with two purposes in mind, the first to 
gain the general response towards the EML implementation and the second, to 
explore the medicine situation at Kuwait MOH. The first aim was carried out with 
Dr Waleed Alfalah, Undersecretary of Development and Quality at Kuwait 
Ministry of Health and Dr Omar Alsayed Omar, Undersecretary of Medicines 
and Medical Appliances, and at a more academic level, Dr Mohammad 
Wahede, Associate Dean at the Faculty of Pharmacy, at Kuwait University. The 
staff of the Ministry of Health, which have a more direct interaction with 
medicines handling and procurement, were also involved. Three interviews 
were carried out with, Pharmacist Essam Alsultan, Head of Pharmaceutical 
Department at the Psychological Hospital (secondary Healthcare hospital), 
Pharmacist Asma Al-Mutairi, Pharmacist in-charge of Ashbelia Polyclinic 
pharmacy (primary healthcare Centre) and Chief Pharmacist Fahad Al-Qatan, 
Special Medicines Department Manager at the CMS. 
 The second part of the interviews, were aimed at exploring the medicine 
situation in Kuwait public health sector. For this reason, staff from different 
departments were met with, in order that they could explain each experience of 
the medicine situation at the state of Kuwait, each in accordance with his/her 
expertise. The samples selected have various pharmaceutical background, 
which will help in exploring the medicine situation as a whole and from different 
perspectives. The candidates were the head of the New Medicine Registration 
and Listing Department, Dr Dina Bustaki and the Head of Quality Control and 
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Quality Assurance Laboratory Dr Sarah Maqseed. At a less high level, at the 
FDA, Pharmacist Izhar Al-Ostath, Pharmacist in charge of new medicine 
registration was interviewed. Pharmacist Joseph of the Reviewing of New 
Medicine Department and the staff of the Pharmacovigilance Department were 
also included in the interviews.  
3.10 Ethics, Reliability, Validity, Generalisability and Limitations 
 The following section describes the strength of the research methods 
used to answer the research questions. 
3.10.1 Ethics 
 Ethics approval has been granted by the Chair of the Biomedical, Natural 
and Physical Research Ethics Panel at the University of Bradford on 18th June 
2014. The data obtained was treated with strict confidentiality and no 
participants were identified when doing the survey. In relation to the interviews 
all participants were asked if they would like their names to be included in the 
research, they all gave consent, this was all recorded on a mobile and they 
were all fully aware of the situation. All the required clearance was obtained in 
Kuwait to get the required information.  
With regards to the data obtained in Kuwait, all the required official procedures 
were followed and all the information release forms were granted.  
3.10.2 Research Study Challenges 
 The study was challenging, to be able to obtain the required 
documentation and records, the researcher needed to be fully involved in 
Kuwait Health system. The researcher needed to have the right acquaintances 
to be able to speed-up the process of obtaining data. The interviews conducted 
with the Undersecretaries were very difficult to arrange and required being in a 
close affiliation with the Undersecretary or being able to get access to arrange 
an appointment; this was similar with the rest of the Senior Managers. For 
another researcher to do similar work, that researcher needs to be certain of his 
or her network, otherwise it will take an extremely long time to get access to the 
correct person.  
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3.10.3 Reliability and Validity of the Study Methods  
 The method needs to demonstrate validity and reliability, this is 
considered by the researcher as the fundamental of any research; otherwise the 
methods are not dependable. What is meant by reliability is that the results 
obtained are reproducible and not a onetime finding. In other words, if some 
other research was going to follow the same research methodology, it should be 
able to reproduce similar results. Validity refers to the strength of the test 
measures (Martyn Shuttleworth. 2008).  
 Validity has several types, the first type is the external validity and it’s 
related to the generalization of the process used, which can be subdivided into 
population validity and ecological validity (Martyn Shuttleworth. 2009). The 
second type of validity is the internal validity; this ensures that the design of the 
experiment is related to the cause and effect of the research (Martyn 
Shuttleworth. 2009). There are other subtypes, such as; test validity, criterion 
validity, content validity, construct validity, and face validity (Martyn 
Shuttleworth. 2009).   
 To ensure the validity of this particular research, the goals and objectives 
are well defined and close care has been taken not to divert from them. The 
assessments methods used are being selected to demonstrate the aims and 
objectives.    
 It’s important to mention that this study is designed to test the Kuwait 
Medicine situation. It is aimed at finding out the available guidelines and 
policies, and trying to figure out an appropriate recommendation on how to 
launch and implement the Essential medicine list. The study also observed the 
established Essential Medicine Lists at an Arabic and international level. The 
information gained from this study can be applied to future comparative works 
but not the exact application of the study design. If the work is carried out in 
Kuwait, for this research to be considered reliable, the results need to be 
reproducible. 
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3.10.4 Reliability of the Research Methods 
 'The Free Dictionary', defines reliability as “Yielding the same or 
compatible results in different clinical experiments or statistical trials." It’s a very 
important measure and researchers need to be fully aware of it. Reliability at a 
scientific setting are expected to reproduce similar results with slight variations, 
on the other hand in social sciences that is not the case. The reason is because 
in social sciences setting, there are uncontrollable variables and some factors 
are random (Martyn Shuttleworth, 2009). Testing reliability can be achieved 
using the Test-Retest Method; this is done by conducting the same measure at 
a later time.  
 Another way we can measure reliability is by using the Internal 
Consistency Test; this is achieved by comparing two different methods to test 
the same concept. Because Reliability is very important, pre-tests are always 
involved and that is another reason for pilot studies.  
3.10.5 Generalisability of the Methods 
 The results obtained are related to the Kuwait medicine situation but the 
testing methods can be used for other countries. This study totally focused on 
the medicine situation in the public sector of Kuwait, the findings are only true to 
Kuwait, but if, another researcher used the method to examine other countries 
medicine situation it would be appropriate, with adjustment. The reason being is 
that the Kuwait medicine situation is unique to Kuwait, it’s a wealthy country 
with great access to great resources, but there are a lot of bureaucracy that 
causes obstacles. This was established from the literature review carried out in 
relation to Kuwait, it’s been found out that there are a lot of dated regulations 
and at the same time they are very strict, and need to be followed to introduce 
any policy. For this reason the method is relatively general to be used by other 
countries to measure their health situation and to try to introduce an Essential 
Medicine List, but modification is still required.       
3.10.6 Limitations of the Methods 
 The study was limited to Kuwait only, but data from other countries was 
also used to gain experience and knowledge of the previously implemented 
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Essential Medicine Lists. The study purposely focused on healthcare 
professionals and excluded healthcare recipients. The reason for this, being 
because Healthcare recipients lack knowledge of such concepts and lack the 
appropriate information in regards to the survey questions, because they are 
not involved in the procurement and purchasing of medicines and not aware of 
the process of quality control and quality assurance of medicines which need to 
be the major focus when procuring medicines. 
3.11 General Research methods  
 In general, the research methods are summarised by the following flow 
chart.    
 The survey carried out, in this case, involves selecting unbiased samples 
of participants closely involved in the medicine supply chain in the state of 
Kuwait. 
 The method of collecting data composes of two parts, the first part was 
two questionnaires handed to the participants directly, and the second part was 
through direct interviews with senior healthcare managers. 
 The study is considered cross-sectional because it involves participants 
from different medical backgrounds, different work experience and different 
organisations.    
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Figure 3.2: General Research methods 
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3.12 Fieldwork Report 
 The fieldwork of the whole study was carried out over a period of three 
years (June 2013 until September 2015), this was the case because the 
research required different methods. In the first year it was exploratory work, to 
view the current medicine situation in Kuwait public health facilities and to 
explore the availability of Standard Treatment Guidelines, which is vital 
component for any EML. Later, it moved towards viewing the policy making 
process and how it’s possible to implement this concept with well-informed 
background information on what to expect as concerns or gains. The work then 
focused on the Arabic countries’ experience with the EML concept and how 
these countries managed to present a suitable EML.    
3.13 Questionnaires Design  
 When designing the questionnaires several points needed to be 
considered and many steps were attempted to design significant 
questionnaires. The first point is to decide on the information required clearly 
and specifically, in this case it was the medicine situation in Kuwait and the 
availability of Standard Treatment Guidelines.  
 Following this step, the target respondents were decided; both 
questionnaires needed to include healthcare providers that are in direct contact 
and involvement with the medicine supply in order to give a valuable response 
that is closely related to the actual situation. The healthcare recipients were 
deliberately excluded due to their lack of knowledge to the aims of the 
questionnaires, hence they will not provide any meaningful data.   
 The method of choice to reach the target audience was decided and 
explained earlier, by approaching them in person and directly, the reason being 
that when emails were sent, there was no response/reply.   
 When designing the questionnaires, the question choices were carefully 
selected, they were clear, direct and relate fully to the research questions. The 
length of the questionnaires and number of questions in each questionnaire 
were not many, this was done to enhance response rate and encourage 
participation.  
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 The questions were all multiple choice type; it having been found out that 
participants prefer these type of questions because it takes less time to 
complete. But there was also, an open question to allow the participants to 
express their opinion if they felt the need to.  
3.13.1 The Current Medicine Situation at the State of Kuwait Questionnaire 
 The questionnaire was limited to 8 questions to increase the response 
rate. The questions were purposely brief and direct. The questions were all 
multiple choices except of 2 questions that gave the participants the chance to 
explain their own concerns with a section at the end to give the participant the 
chance of adding views to the topic being discussed. The following table 
represents the questions, choices and the focus of each question. 
Table 3.1: Questionnaire 1; Assessments of the Current Medicine Supply 
System in the state of Kuwait, and the medicines regulatory system. 
healthcare provider’s views on the concept of Essential Medicines List 
Question Question Focus 
How long have you been working as a 
healthcare provider 
Focus on work experience, to 
compare old school with new 
generation views.  
Speciality To find out if speciality variation has 
different opinions. 
Are you satisfied with the current 
medicine supply system 
Examine the level of satisfaction. 
Do you think the medicine supply 
system is well regulated 
Focus on the dated regulation and 
see if the participants think new laws 
need to be in place. 
In your own words, how do you think 
the medicine supply system can be 
improved 
Open question to allow expression of 
own thoughts.  
If a generic drug has proven to have 
good quality and efficacy, to what 
extent would you prescribe it 
How well generics are accepted.  
What are your views on the 
establishment of 'Essential Medicine 
List’ program at the state of Kuwait 
This will allow a preview of what might 
come up as objections or acceptance 
to the concept in the future, and there 
was a space to allow further 
explaining of thoughts. 
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3.13.2 Standard Treatment Guidelines Questionnaire 
 The second questionnaire aimed to investigate the presence of Standard 
Treatment Guidelines at Kuwait MOH healthcare facilities. The questionnaire 
included 6 questions only. 
 The questions focused on the type of healthcare facility, participant work 
experiences, participant STG currently followed, the reason behind using such 
STG, and are they aware of their colleagues STG.  The questionnaire 
population were all medical doctors. The STG was investigated at all healthcare 
levels, at the primary healthcare facilities, secondary healthcare facilities and 
tertiary healthcare facilities.  The participants were contacted directly, at their 
work place and a small group were contacted by phone, their responses were 
completed from their comments. 
The following table represents the question choices and the focus of each 
question. 
Table 3.2: Questionnaire 2; Assessment of the availability of Standard 
Treatment Guidelines in Kuwait Healthcare Facilities. 
Question Question Focus 
The Healthcare facility type involved. To find out which level of healthcare is 
more up to date. 
Duration of work experience at the 
current healthcare facility. 
Focus on how the experience of the 
healthcare provider effects their STG.  
Are you aware of the Standard 
Medical Treatments Guidelines (STG) 
of your Healthcare facility? 
Focus on the efforts to make STG, 
and how well they would be followed if 
they existed.  
What type of STG do you use? Open question, allow to demonstrate 
the type of STG used.  
Are you using the same STG as your 
colleagues? 
Measure the level of awareness and 
involvement in the work place. 
Why using this specific type of STG? To understand the variety of STG 
available. 
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3.13.3 Time Frame 
 It took 12 weeks, excluding Fridays and Saturdays, public holidays of 
Kuwait, to complete the questionnaires.  
3.13.4 Confidentiality and Consent  
 The questionnaires, although handed in directly to the participants were 
later returned in a sealed envelope to ensure confidentiality, a consent form was 
handed in to the participant to explain their rights and the right to withdraw from 
taking part at any time. The consent form is in appendix I.  
3.13.5 Location of the Questionnaires 
 The questionnaires were all carried out in Kuwait, simply because the 
study is related to Kuwait and investigates the medicine situation in Kuwait 
public healthcare facilities.  
 The questionnaires were conducted in primary, secondary and tertiary 
healthcare facilities; this was the case to ensure the required information was 
gained from all the healthcare levels available in Kuwait Public Health Sector.  
The following is a list of the healthcare facilities involved in the questionnaire. 
• Ashbelia Poly-clinic (primary healthcare) 
• Dasman Poly-clinic (primary healthcare) 
• Mubarak Alkaber University teaching Hospital (secondary healthcare) 
• Ibn-Sina neurological hospital (tertiary healthcare) 
• Al-babtain Burn and correction surgeries (tertiary healthcare) 
• Al-bahar Ophthalmology Hospital (tertiary healthcare) 
• Zain ENT Hospital (tertiary healthcare) 
• Psychology Hospital (tertiary healthcare) 
• Kuwait Cancer Research Centre (tertiary healthcare)  
 
 The questionnaires were later tested and two pilot studies were 
conducted, the following explains each study. 
 
104 
 
3.13.6 Pilot Questionnaires  
 Once the questionnaires were fully completed, both questionnaires went 
through a pilot study to examine their suitability and practicality and to amend 
any questions that might be confusing or unclear. It involved testing each 
questionnaire with 10 participants. The pilot study revealed the need to adjust a 
question and delete another.  
3.13.7 Data Collection – Questionnaires 
 At the initial stage of the questionnaires, it was attempted to email the 
required participants, it took a long time to get the required emails, about 50 
emails were sent and unfortunately no responses were received. Upon enquiry 
about the lack of replies, it’s been found out that almost most the people 
contacted by email don’t check emails regularly, and some of the emails are 
closed because they are not being used and not checked regularly. It might 
seem unlikely in any developed country that educated people are not checking 
their emails regularly but it is common in Kuwait where people prefer to use 
smart phone applications to communicate even at a professional level; if there 
is a need to communicate officially, emails are not acceptable and only official 
letters and hard copy memos are accepted. For this reason, the participants 
were contacted in person and the help of two other colleagues were sought to 
speed up the process of data collection.    
3.13.8 Questionnaires Participants  
 The target groups were physicians, because it was expected that they 
would be affected by the list greatly and their patients are concerned with any 
changes to the supply chain.  
 The second group were academic staff at Kuwait University, because 
they are involved in teaching the student the concepts and their views do 
matter. 
 The next group were Central Medical Store staff, and their involvement 
would obviously be in procuring the medicines and they are dealing with the 
majority of the medicine supply cycle.  
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 The fourth group were public sector pharmacists, they were included 
because they are the last people before the public that deals with the supply of 
medicines and public complaint or appraisal.  
3.14 Interviews  
 Kvale, 1996, define interviews in Qualitative research as a tool to 
‘describe central themes and the meanings of it in the life world of the subjects. 
The main task in interviewing is to understand the meaning of what the 
interviewees say.’ (Kvale,1996). 
 McNamara, 1999, states that ‘Interviews are particularly useful for getting 
the story behind a participant’s experiences. The interviewer can pursue in-
depth information around the topic. Interviews may be useful as follow-up to 
certain respondents to questionnaires, e.g., to further investigate their 
responses.’ (McNamara,1999). 
 It’s generally known that interviews are more personal than 
questionnaires, it provides direct interaction with the interviewee, it helps in 
further investigating the researched topic; on the other hand they are time 
consuming and require a certain level of skill.  
Interviews can be conducted in several ways; the following is a short description 
of each; 
• Informal or conversational interview, (No pre-set questions). 
• General interview guide approach, (there is a guide approach with a 
degree of freedom). 
• Standardised, open-ended interview (set of open-ended questions 
asked for all).  
• Closed, fixed-response interview. (Pre-set question with multiple 
replies to choose from). 
 
 For these particular research interviews, there were two sets of 
interviews; the first set was the standard interviews with pre-set questions. This 
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was chosen to ensure adherence to the objectives of the research questions, 
appendix IV. 
 The second set of interviews that were conducted to gain information 
used the general interview guide approach. This is intended to extract the 
knowledge from the participants in specific areas and allows them to express 
and share as much information as possible; this method was useful due to the 
fact that there was a lack of published information in regards to Kuwait health 
and medicine budget statistics, health policies availability and quality assurance 
techniques.   
3.14.1 Development of the Interview Protocol 
 There were two interview protocols to ensure coverage of the research 
questions, the first interviews aimed to explore the following research question,  
 What are the contextual factors in Kuwait which would assist or 
hinder effective implementation of EML? 
 The interview protocol contained open-ended questions to allow the 
interviewee to express his/her opinion fully.  
 
 Several meetings and interviews were conducted with senior managers 
at the MOH and Kuwait University, Faculty of Pharmacy. The meetings and 
interviews were carried out with the following;  
Dr Omar Alsayed Omar, Undersecretary of Medicines and Medical 
Appliances. His long experience with the medicine supply chain and all the 
issues with the pharmaceutical services both in terms of private sector and 
government sector would be beneficial to the work being carried out. 
Dr Waleed Alfalah, Undersecretary of Development and Quality at 
Kuwait Ministry of Health. His area of expertise aims to improve the healthcare 
services at the state of Kuwait. 
Dr Mohammad Wahede, Associate Dean at the Faculty of Pharmacy, 
Kuwait University. University of Kuwait resources are of great value to the 
research. Many unavailable online. 
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Chief Pharmacist Fahad AlQatan, Special Medicines Department 
manager at the CMS. He is directly involved with the majority of the 
procurement of medicines and supplies all levels of MOH healthcare facilities, 
Ministry of Defense Hospital, the National Guard Hospital and the ministry of 
social affairs centres. The medicine list and the consumption rate of medicines 
are very important for the purpose of this research. Dr Al-Qatan was kind 
enough to provide the data related to handling and procurement of the 
medicines at the CMS. 
Pharmacist Essam Alsultan, Head of Pharmaceutical Department at the 
Psychological Hospital (secondary Healthcare hospital). And Pharmacist Asma 
Al-Mutairi, Pharmacist in-charge of Ashbelia Polyclinic pharmacy (primary 
healthcare Centre). Both are directly involved with the medicine procurement. 
Ministry of finance, national budget division. The aim of the visit was to 
obtain the proposed MOH budget and the actual MOH budget. 
MOH Budget analyst, the contact aimed to obtain what percentage 
medicines represent in comparison with the total MOH budget. 
 Several approaches were followed to contact the persons taking part, but 
mainly they were spoken to over the phone and arrangements were made for a 
suitable time to meet with them. On a few occasions when the persons’ number 
was not available, a meeting was arranged through their office, by going 
personally to the secretary and asking for a meeting.  
 The second part of the research adopted a casual, informal and more 
conversational interview, this was important to describe the following; 
• The policies that are being established in Kuwait,  
• The type of protocol being followed,  
• What are the end results?  
• Are they operational?  
 
 These interviews were conducted at Kuwait FDA, it was carried out at the 
new medicines registration department, the laboratory and quality assurance 
department and the newly established pharmacovigilance section.  
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3.14.2 Management of Interviews 
 The interviews were all conducted in Arabic and then translated into 
English.  A transcript was later sent to the interviewees to verify the content, but 
no response was received. Later visits were therefore, made in person, to 
confirm the content of the transcripts, and it was read to the interviewees and 
consent was given.   
 The later part of the research was focused on gaining background 
information on the Kuwait health situation and the Gulf Co-operation Council 
countries, the information was not available online and not published thereby 
requiring personal presence to access the hard-copies of the required data. For 
this reasons several visits were made to gain the required information.  
3.14.3 Interviews Preparations 
 The location of the interview needs to be selected carefully to ensure 
continuation and no distraction; the purpose of the interview was fully explained 
to each participant. The confidentiality terms were discussed and consent was 
given, the interview format was explained fully and questions and queries were 
encouraged, all interviews were recorded after taking permission from the 
participants.    
3.15 Visits 
 Visits were carried out for the purpose of this research, few were local in 
Kuwait and one was to Riyadh in the Kingdom of Saudi Arabia. 
 These visits included the Arab Planning Institute-Kuwait, where there is a 
large library with several Arab health economy references, the majority in Arabic 
language. 
 Visits were conducted to Kuwait Ministry of Finance to obtain the 
proposed and Actual Ministry of Health date. 
 Visits to Kuwait M.O.H to the budget Department and finance, to the 
CMS, and to the FDA. 
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 The second major visit was to the GCC council in Riyadh, which was 
faced with hindrances due to the local laws of the region, as a result I was not 
allowed admission to the GGC headquarters, but Professor Tawfik A M Khoja, 
Director General Executive Board, Health Ministers Council for Cooperation 
Council was kind enough to communicate with me and provided the related 
health data for the GCC countries  
3.15.1 Limitation of the Visits 
 The visits conducted in Kuwait faced a number of changes through 
rescheduling and delays, but were achieved after several attempts.  
 The visit to the Kingdom of Saudi Arabia was very challenging, and I was 
refused admittance to the GCC building because I’m a woman and the building 
was men only. At a later time Professor Khoja was kind enough to meet at 
another location which is King Saud University to provide me with the required 
data.  
3.16 EML Cross-Comparison Methods 
 The third type of methodology was the cross-comparison qualitative 
research, which was conducted to answer the following research questions; 
 What is an Essential Medicine List and why do countries need it? 
 What are the characteristics of an effective EML Programme? 
 To what extent have other countries succeeded in their 
implementation of an EML? 
 The information was extracted from several publications, some were 
official government resources and others were published online at the WHO 
library and other reputable scientific journals. 
3.16.1 Countries Investigated 
 The choices for the first part of the comparison were conducted at an 
international level, to gain an international perspective and be able to compare 
the implementation of EML in a variable international setting.  
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The countries chosen were different in their geographical location and different 
standards of living.   
3.17 Language of the Data  
 The data presented in the official resources was in several languages, 
the main language was English but some countries used French and others 
used Arabic. 
 Translations were required, google translate was used to translate 
French into English. The Arabic references were translated by the author, 
because it’s the researcher’s mother language.  
3.18 Summary  
 The Methodology Chapter has drafted the research work conducted in 
this study, the Chapter started with a brief introduction to describe the work in 
the Chapter. It discussed the philosophy of the research methodology, the 
paradigm used, and the type of methods and all the required justification for 
approaching the research questions with this type of mixed method approach. 
The use of the mixed method was argued and it was found that due to the 
nature of this research work, using a mixed method approach is the best choice 
in order not to miss out on data.  
 Methodology aspects such as confidentiality, ethics, validity, 
reproducibility, sampling, data analysing techniques, etc. were all described and 
discussed in detail. The limitations and the challenges faced in this study were 
all mentioned and discussed fully.  
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Chapter four  
Findings and Analysis 
112 
 
4.1 Introduction 
 This chapter presents the outcome of the research. The sole purpose of 
carrying out the research work was to be able to answer the research 
questions, and since the framework of the research was divided into four stages 
the findings were also divided into four, each section is equivalent to a specific 
stage of the conceptual framework.  
 The first section of this chapter is related to the World Health 
Organization Model List of Essential Medicine. It will explore the concept and 
the objective of the list and it will try to find out if the WHO EML succeeded in 
fulfilling its purpose or not.  
 The EML will be examined in terms of the evolvement of the definition 
from the beginning until its current form. There is a description of the timeline of 
the WHO EML, then all the related statistics, and an attempt to provide 
evidence as to whether the list would be suitable for wealthy countries.  
 The second part is concerned with the 5 international countries EML 
study, it will give a description of each countries’ journey in the process of 
implementing EML, all the attempts the countries tried to reach the current form 
of the EML and the difficulties each country faced during that process. 
At the third stage, there is a comparison between 12 Arabic national EML; this 
might help in giving an idea on how Kuwait EML can be presented.  
The final section of this chapter is related to Kuwait and the health situation in 
the State of Kuwait Public Sector. In this part it will be demonstrating the output 
of the questionnaires and the interviews conducted. It will include the charts 
created with SPSS to analyze the questionnaires and the interviews findings. 
4.1.1 The World Health Organisation Model List of Essential Medicines  
The World Health Organization is a specialized agency of the United 
Nations that is concerned with international public health. It was established on 
7th April 1948, headquartered in Geneva, Switzerland.  
 WHO has been in pursuit, of good health, and trying to invent and 
implement programmes and policies to help the world to a better health.  
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 One major concern, for the less fortunate countries is access to medicine 
and the quality assurance of the available medicines.  
 Many countries with the support of the WHO, attempted several efforts 
and policies to enhance medicine access nationally, this started in Sri Lanka as 
early as 1959 (J. D. Quick et al, 2002), Peru had another, sort of, what is known 
as the Basic List of Medicines. In 1960, all the efforts of having a suitable 
restricted list of medicines which is suitable to the country’s health needs were 
unsuccessful, the reason being that it lacked the appropriate support and the 
relevant regulations to enforce it.   
 The concept of the WHO Essential Drug List as it was named then, 
started in 1977, and has evolved since that time. Initially the list incorporated 
almost 208 essential medicines. There was a specialised Expert Committee that 
revised the list every two years. Until current time, the 19th List of Essential 
medicines been released in April 2015. The need for an update is very 
understandable because disease patterns change, health profile varies over the 
years and medicine technology is growing and resulting in new treatment 
options all the time. When the list initially started it was targeted at countries 
with poor sanitation and limited resources, therefore the focus of the list was to 
treat tropical diseases, but the current lists have evolved to include priority 
conditions such as; Malaria, HIV/AIDS, Tuberculosis, reproductive health and, 
the new life style conditions and the increasing chronic diseases such as 
Cancer and diabetes (WHO, 2015).   
 The fact that the concept lasted until current times is a great testament to 
its validity and effectiveness. The progress of the list will be discussed later but 
first, the definition of Essential Medicine List development needs to be 
mentioned. The Essential Medicine List can be defined as ‘those that satisfy the 
priority of healthcare needs of the population’ (WHO 2016). The concept of the 
List is based on a limited number of carefully selected Essential Medicines 
which lead to better healthcare, better drug management and lower cost. When 
the WHO adopted the EML, it did not aim to make it a mandatory form to be 
applied in the exact contents and shape, the aim was to give a model list on 
which the countries could design their national EML basing their choices on 
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diseases profile, and standards of living. The WHO Model List of Essential 
Medicines is only a guide not mandatory.  
 The concept might seem simple but to be able to produce a well-thought 
list of medicines and consider them ‘Essential’ is a very delicate process and 
great deal of experience is required (Hans V Hogerzeil, 2004).   
4.1.1.1 Essential Medicine List Adaptation 
The WHO continually endorsed equitable access to basic Health 
services (H V Hogerzeil, 2006). Shortly after the first Model List of Essential 
Medicines was published in 1977, the 1978 Alma Ata declaration on health for 
all, endorsed the list and considered it one of the WHO’s most vital and 
significant public health accomplishments (H V Hogerzeil, 2006).  Over thirty 
years later the concept still standing and remains a major achievement in 
medicine access in relation to the WHO work in this field.  
Many countries have adopted the concept and more than 156 countries 
have a form of national EML (USA Department of Health, 2008). Primarily the 
EML was aimed to resources-constrained countries, but currently it’s been seen 
as a practical economical tool to middle and high income countries (WHO, 
2016).  
 The EML not only focuses on enhancing medicine access but over the 
years it also demonstrated further advantages, it can aid in medicine 
procurement and provide a better control over the process, especially when the 
number of medicines needed to be procured is reasonably limited and the cost 
is already established. Over time, the EML has demonstrated that having a well-
documented list of medicines, with known quality, will help the prescriber to 
better practice which will enhance patients’ trust and compliances. Rational 
drug use is another benefit to having an EML, the reason being that having a list 
of medicines that is based on a well-documented Standard Treatment Guideline 
will contribute to better knowledge of prescribing and the follow-up of patient 
treatments would be satisfactory and organised.    
The list has been adopted by many international organisations and they 
base their supply on the WHO Model EML, such organisations include, Doctors 
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without Borders (Médecins Sans Frontières), as well as NGOs, UNCEF, 
UNHCR, and UNFPA (H. V. Hogerzeil. 2004). 
By 2002, it has been estimated that 4 out of 5 countries, of the WHO 
member countries, have EML, some even took it further and came up with more 
regional Lists that have fewer medicines suitable to each region’s health needs 
(J. Quick et al, 2002).  
In 2007, the world health sector, in general, and the WHO in particular, 
had noticed that children are more sensitive to some types of medications and 
require specific attention, for this reason the WHO published the first WHO 
Model EML for Children (EMLc) (WHO EMLc, 2007).  
4.1.1.2 The Essential Medicines Concept utilisation by Middle to High 
income countries 
Middle to high income countries face new challenges as life progresses 
and more advanced pharmaceuticals are being produced. Costs of medicine 
are escalating and need careful deliberation otherwise countries will be faced 
with a very serious uncontrollable medicine situation. from the literature review it 
has been established by Hans V Hogerzeil (2006), that the reason behind such 
inflation in medicine, is due to the current advances in pharmaceutical 
technologies that resulted in a reduced child mortality number, a larger aging 
population, and the new, less active life, resulted in the appearance of more 
chronic diseases such as diabetes and cardiac problems. All the previously 
mentioned, would result in an increased demand for medicines and 
subsequently it will intensify the medicine budget. Hogerzeil further explains that 
in the USA the Pharmaceutical budget increased by 18% in 1999, 16% in 2000, 
and 17% in 2001. Another major problem facing the higher income countries is 
the high cost of new medicines that lacked the suitable scientific background to 
support its quality and efficacy (H V Hogerzeil, 2004). 
  The following table summarises the number of medicines added or 
deleted each time the EML gets reviewed. The process of adding and deleting 
medicines follows very careful deliberation and careful decision making by 
qualified experts.   
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 The changes can happen for many reasons; the addition of new 
medicine could happen simply because there is more data available for its 
quality and efficacy, at the time of the EML Expert Committee, the added 
medicine safety profile is better documented and better proven. Another reason 
could be the availability of better evidence of the cost-effectiveness ratio 
(Murray Aitken, 2015). On the other hand and according to Murray Aitken 
(2015), the deletion of medicines from the list can occur due to lack of its 
essentiality, because there are better choices available at the time of making 
the decision. Medicines get deleted due to post market evidence of their side 
effects and adverse drug reactions; a major medicine deletion is due to the 
availability of a safer and more cost-effective medicine.  
The WHO Model List of Essential Medicines is divided into Core Medicines and 
Complementary medicines. The WHO defines the Core Medicines as 
‘efficacious, safe, and cost-effective medicines for priority conditions’ (WHO, 
2013). 
Core medicines can be further explained as the minimum number of 
medicines that can relatively cover the health needs of a population. On the 
other hand the complementary medicines are medicines that treat a priority of 
diseases but require specific health technology to be given or administered. 
Such technologies could be specialised diagnostic or monitoring facilities and/or 
specialist medical care and/or specialist training may be needed; 
complementary medicines can be classified as such because of their cost 
(WHO, 2013).    
Table 4.1: The additions and deletions of Essential Medicines on EML from 1979 until 
2011 
 1979 1983 1985 1988 1990 2000 2003 2004 2006 2007 2009 2011 
Master 
EML 
(core & 
Comp.) 
235 243 263 280 293 322 331 319 
(2005) 
 
---- 337 352 
 
358 
Addition 45 20 21 21 15 14 12 4 9 22 16 27 
Deletion 17 13 8 13 11 6 12 (2005) 
17 
(2005) 
17 
3 4 21 
Table source: WHO Essential Medicine List 
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  The concept of an EML is trying to keep up with the medical advances 
and the WHO is always trying to come up with various options to enhance 
health and medicine access all over the world, but that is not enough when the 
concepts are not being followed accurately. Some countries adopt the EML, but 
never base their prescribing and procurements on it, this can lead to total failure 
to the concept. Other countries didn’t update the list for over 5 years, in such 
cases the list is dated and fails in fulfilling its objectives. The WHO states that 
95% of developing countries has a form of EML, but only 86% has been 
updated in the past 5 years (WHO. 2008). The other issue with having an EML 
is the availability of the essential medicines, a survey conducted by the WHO in 
2008 including 27 developing countries, states that only 34.9% of the essential 
medicines were available at the public sector (WHO, 2009). 
 This is another mismanagement of the concept, because its main 
objective is to enhance medicine access, and since only almost 35% of 
Essential Medicines are available then the concept is not performing efficiently 
or it is not the correct method to improve medicine availability.  
 The WHO suggested the reason for this situation is the lack of funds, 
which is a long standing problem, other reasons could be more technical; the 
personal in-charge not managing the resources efficiently, inaccurate and bad 
procurement practice, failed distribution practice. The results, according to the 
study that is conducted by the WHO, is that the patient will resort to the private 
sector for medicine supply and pay out of their own pocket, these funds might 
not be available to some patients.   
4.1.1.3 Summary  
 The Concept of an EML is based on having a limited number of carefully 
selected Essential Medicines, the concept focuses on improving the health 
services from various angles, it provides better drug usage and control, and it is 
proposed that if the EML concept utilised efficiently it will lead to cost reduction. 
 The WHO define the EML as ‘those that satisfies the priority health care 
needs of the population’’ (WHO. 2016) therefore, disease burdens need to be 
identified clearly, the quality of medicines needs to be rigorously assured, 
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otherwise the EML fails to accomplish its objectives and it would be a useless 
attempt to enhance the health of the population and a big waste of funds, staff 
time and efforts. 
 It is considered important to follow a very transparent approach to 
medicine selection and the medicines on the list should comply with the local 
Standard Treatment Guidelines, otherwise it would not generally be possible to 
choose medicines which will fit with the local health needs. In making the 
medicines selection there should be a consideration of the safety aspects 
associated with the medicines which were chosen, together with the efficacy 
and evidence supporting the cost-effectiveness. At this point it needs to be fully 
acknowledged that just because a medicine is inexpensive it doesn’t necessary 
make it suitable for a certain application and any other factors should be, also 
considered.  
 Once the list is chosen and published, it is normally not introduced   
spontaneously, as suitable regulations are required to be put in place to enforce 
adherence.  However, procurement of the medicine is likely to be more effective 
if it were found in an EML. Continuity and sustainability are also important 
factors which can be maintained if there are requirement and it’s proposed that 
they might be ensured by regular revisions and updates at suitable intervals, the 
WHO suggest revision every two years, but this is not an obligatory.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
 The concept of a list has lasted close to 40 years, it’s been adopted by a 
large number of countries with various levels of income. Many international 
none-profitable organisations base their selection of medicines, for donations 
and in case of disasters, on the WHO Model list of Essential medicines, such 
organisations are; World Bank, GFATM, Unicef, and UNFPA. All the previous 
can be considered as a demonstration of the success of the list in its objectives 
at some level. 
 Once a healthcare setting adopts the list in its typical form, and adapts it 
to the local health needs and practice transparency in the selection of 
medicines, the EML might have a type of improvement to the quality of services, 
and might have a positive effect on budget and fund control. A testament by the 
Medicines Sans Frontiers, stated that the ‘the first List of Essential medicines 
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was a major breakthrough in the history of medicines, pharmacy and public 
health’. This can be right if the list adopted in a suitable manner and altered 
appropriately to fit a certain country healthcare situation.  
4.2 EML – International Case Studies: what has worked and what has not 
worked? 
 A comparative and evaluation case study was conducted on the process 
of implementing and establishing National Medicine Policy (NMP) and National 
Essential Medicine Lists in 5 countries with different levels of income and 
wealth.  
 Comparative research methods were used to identify, analyse and 
explain similarities and differences across the countries’ health situation. The 
comparative approach has always been used by researchers ‘to explain and to 
develop a classification of social phenomena and to establish whether a shared 
phenomenon can be explained by the same causes’ (Linda Hantrais 1995).  
 For the purpose of this study, an attempt has been made to compare 5 
countries’ NMP and EML, in terms of its timeline to implement it, the aims and 
objectives each country set when setting up the policy and the outcome of such 
a journey. Cross-country comparison of healthcare systems and policies is not a 
distinct method in the social sciences, but a diverse field that faces a distinctive 
set of challenges because it focuses on comparing ‘large macro-social units’ 
(Ragin 1987; 5).  
 This type of study has some concerns; several factors are required to be 
considered when conducting the comparison, such as; cultural factors, income 
level, political stabilities, and demography.  
 Another important point was required to be considered and carefully 
monitored and was the fact that awareness needs to be present at all times, in 
interpreting the outcome, it is important not to allow a country own cultural 
interferences to be included and to avoid bias when discussing the results (L. 
Hantrais.1995).  
 The study were conducted for 5 countries with operational National 
Essential Medicine Lists, it aimed to gather information about the countries 
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included in the study, in terms of demography, political situation, income level, 
health situation and past and present health policies. The study attempts to 
identify the process of implementing national EML carried out by each country 
included in the study, it is believed that by conducting this research it might help 
in categorising the obstacles faced by each country when the EML concept was 
launched, and once these issues are clearly identified it might be useful to 
detect the approaches used by each country to overcome all hindrances and 
challenges.   
 The comparative study was based on the information published by each 
country and by the work of previous researchers. In order to gain an insight to 
this, a literature review was conducted to cover all aspects of this study.  
 Going through the available literature, it became clear that there are a 
number of challenges faced by the countries undergoing the study. In order not 
to drift away from the topic, the research was directed towards health policy and 
National EML matters only when away from the different political challenges 
and economic problems many countries had confronted or still in the process of 
dealing with it, such political and economic challenges might have a direct or 
indirect impact on other aspects of these countries’ stabilities, the research 
gathered data from as early as the forties.  
 Safety, affordability and the effectiveness of medicines might seem like 
common sense, but in reality that is not the case. It is the goal and main 
concern of all health services of all countries but the process of ensuring this 
goal is not easily attainable.  
 Many factors hinder the process of health innovation that ensures 
rational drug use and proper excess of quality assured medicines. One of the 
main difficulties is that the main decision makers, in health services, support 
their own interest rather than the interest of the majority of the population (P K 
Sarkar, 2004). For this reason many countries have not reached a suitable drug 
policy and a functioning national EML that satisfies all and ensures adequate, 
quality medicine access (S. Nordberg et al 1995).  
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 Despite government efforts to ensure a suitable level of medicines 
access, the problem remained an issue, many suggestions have been 
presented by governments to overcome the problems, but not all are very 
successful and many have not reached the light of day and are never executed 
(Hoebert et al. 2013). There are several factors influencing medicine access, 
according to Hoebert et al (2013), Morbidity patterns have changed, medicine 
from private sectors became the new source of medicine access, changes in 
healthcare policies, different health insurance regulations, in addition to all the 
mentioned previously.  There is also, another major influencer in medicines 
access which is the new trends and the several diverse international and 
national trade arrangements, the trade agreement would direct the local 
production of medicines to export rather than utilising it nationally and enhance 
medicines access (Ictsd.org. 2016). All these factors might be present 
independently or in combination, but the result would affect the medicine 
situation in each country and might obstruct patients’ access to it.  
 The WHO’s main mission is ‘to help save lives and improve health by 
closing the huge gap between the potential that essential drugs have to offer 
and the reality that for millions of people-particularly the poor and 
disadvantaged- medicines are unavailable, unaffordable, unsafely used’ and 
this is the foundation of the mission of the National Medicines Policy and 
Essential Medicines List.  
 The major components for any NMP includes National Essential 
Medicines List, National Drug Formularies and Clinical Guidelines, together they 
are the foundation for fulfilling the national health target in any country, a 
national medicine policy wouldn’t be considered as such without the three major 
components (WHO, 2016).   
 According to the WHO works, it’s been established that having a National 
Medicine Policy (NMP) based on Essential Medicine List helps to pave the road 
to better health; NMP/EML identify the footsteps that need to be followed in 
order for the NHP objectives to take place. The WHO estimates that a time 
frame for NMP to be effective and operational is a 10-year period (WHO. 2003)  
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 Since 1970, experience and time have shown that having a well-
established and monitored medicine policy is very advantageous. Based on the 
strong health position and the work of the WHO, it’s only natural that WHO 
takes the leading role in the process of implementing and setting the guidelines 
for health policies. This is the case in the majority of the countries that started 
medicine policies to improve services and general health (S. Nordberg et al 
1995). The WHO however only merely set guidelines for countries to refer to 
when implementing their own policy; the health policy and the choices of 
medicines on the National Essential Medicine List, differ in accordance with 
each country’s situation, and many factors needs to be considered when 
planning the list.  
 When setting the framework of any policy, it’s important to consider 
cultural and historical factors; the country’s ability to reregulate and enhance 
quality assurance, the country’s financial capabilities, the pharmaceutical 
situation and the strength of government enforcement of regulations; since 
these factors tend to change with time, updates and reviews should be carried 
out at reasonable time intervals (Hogerzeil, 2004). 
 Currently and since the seventies, a vast literature has become available 
to countries to carry own policy that would enhance medicine excess and 
improve medicine quality. Unfortunately not many countries have taken up this 
facility and the ones who did, have been faced with a number of challenges that 
requires a close inspection and deliberation to gain an understanding of other 
countries’ experiences with medicine policies (S. Nordberg, 1995:1).  
 The following figure demonstrates countries with an NMP divided 
according to income level. The figure is sourced from WHO level 1 survey, as 
appeared in the World Medicine Situation Report 2004 and the global overview 
of pharmaceutical sector country profiles (2011).  
 The bar-chart demonstrates that low income countries have more 
NMP/EML in place than high income countries and the percentage has 
increased over the years. It makes sense in a way that low income countries 
are always trying to find means to reduce expenditure and reduce strains on 
budgets.    
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Figure 4.1: Trends in the formulation of national medicines policies (NMP/EML), by 
countries’ level of income, 1999, 2003, 2007 and 2011. 
 Source: WHO level 1 survey (as appeared in the World Medicines Situation Report 
2004), and the global overview of pharmaceutical sector country profiles (2011). 
Percentages are based on number of countries surveyed by WHO. 
  
 Laing et al, suggests that low and mid income countries adopted 
Essential Medicines with the aim to improve all aspects of the pharmaceutical 
sector, such as; selection, procurement, distribution and rational drug use 
(Laing et al, 2001). It’s an understandable to believe that having a small number 
of well documented and assured quality medicines can contribute in cost 
reduction during procurement and provide a type of a more focused medicines 
management.    
 Walley suggests that high income countries do not have a set and unified 
NMP/EML (Wally et al, 2000). That being said, most high income countries 
have policies directed at pricing or purchasing (Rietveld, Haaijer-Ruskamp. 
2002). 
 The following map demonstrates the distribution of NMP/EML around the 
world. The figures were collected in 1999; it shows that 44% of the world have 
published NMP/EML within the past 10 years, where only 3% had NMP/EML 
older than 10 years. It also shows that almost 24% have a draft of NMP/EML 
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but it is not fully operational yet and around 29% have no official documents 
(WHO, 2004). 
 
Figure 4.2: Formulation of national medicines policies worldwide, 1999 
Source: WHO Website, accessible through 
http://apps.who.int/medicinedocs/en/d/Js6160e/8.html 
 
Table 4.2: cross comparing the existence of NMP/EML with the level of incomes 
Years of NMP/EML No of Countries 
NMP/EML within 10 years 67 
Official NMP/EML more than 10 years 5 
Draft NMP/EML 36 
No NMP/EML 44 
No response to survey 40 
Source: the data adopted from the WHO website, World Drug Situation Survey (1999), 
accessible through http://apps.who.int/medicinedocs/en/d/Js6160e/8.html 
 When cross comparing the existence of NMP/EML with the level of 
incomes in countries, there were clear indications that countries with less 
income try to adopt means to control medicine budget in the form of having n 
EML. The following table shows this outcome, the source of this table is WHO, 
World Drug Situation Survey (1999). 
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Table 4.3: Formulation of national medicines policies in low-, middle- and high-income countries 
in 1999. 
Status of 
NMP/EML 
document 
Low-income Middle-income High-Income Total 
 No of 
Countries 
% No of 
Countries 
No of 
Countries 
% No of 
Countries 
No of 
Countries 
% No of 
Countries 
 
Official 
document 
within 10 
years 
35 56 29 41 3 17 67 
Official 
document > 
10 years 
4 6 1 1 0 0 5 
Draft 
document 
18 29 17 24 1 6 36 
No 
document 
6 9 24 34 14 77 44 
Total 63 100 71 100 18 100 152 
Source: the data adopted from the WHO website, World Drug Situation Survey (1999), 
accessible through http://apps.who.int/medicinedocs/en/d/Js6160e/8.html 
 
 The work of the WHO states that, only in recent years, have high income 
countries turned towards having published official NMP/EML documents, but 
many high-income countries have a very well-regulated pharmaceutical system 
without the written document (WHO: The World Medicine Situation. 2004).  
 The following figure demonstrates how the trend of having NMP/EML 
grew over the years in all levels of incomes, but there is greater growth in the 
recent years in high income countries. 
 
Figure 4.3: Trends in the formulation of national medicines policies, by countries’ level 
of income, 1985-1999. Source: World Drug Situation Survey (1999) 
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 The NMP/EML setting is however country-specific and cannot copy other 
countries’ process, but it’s important to gain experience from past lessons. The 
WHO made commendable efforts in setting guidelines on National Medicine 
Policies; they are clearly presented in publications outlining the process of 
starting an individual policy. The guideline is not specific to each country and 
requires adjustments in accordance with each country situation. The WHO 
suggests that it’s very difficult to ensure a NMP/EML is effective if the country is 
going through strains such as; financial and economical, it’s particularly tough in 
countries where the majority of the pharmaceutical market is private. The result 
of such situations is that the prices are very difficult to regulate and control 
(WHO, 2004).  
   
 Countries described later, are chosen for several factors, but mainly 
there was focus on chosen countries with different levels of wealth. It’s only fair 
to research and carefully study different countries from diverse levels of living 
and different demography. For this reason 5 countries have been chosen; 
Norway was chosen because it’s an example of a high income country with an 
almost impeccable Health System, they are considered a pioneer in health 
system planning (Ian McAuley, 2014). Sri Lanka and Bangladesh are low 
income countries with a large percentage of their health budget based on 
donations (Ananda Jayasinghe, 2004). Australia is a country with a very diverse 
population due to immigration; it might be worthwhile to view their experience in 
dealing with very different authenticities (Australian Government, 2011). India, 
considered one of the early third world countries, tried to implement and adopt a 
National Medicine Policy, since 1970s the attempt has been made but that 
doesn’t indicate in anyway if the efforts were successful  (Bidwai P. 1995). 
4.2.1 Norway’s Experience with National Medicine Policy and EML  
 The Health Services in Norway are free to anyone under the age of 16 
and free for pregnant ladies (My Little Norway. 2009). Hospitals are funded by 
the public by taxes, but adults get an exemption card to allow them free 
visitations to the Norwegian public hospitals, this exemption card is paid for 
yearly (Norway Ministry of Finance, 2012). 
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 Norway has the highest expenditure in health in the world (Britnell, Mark. 
2015). With that thought Norwegians are still required to pay for extra 
specialised care, such as; physiotherapy, any extra materials and medical 
equipment (My Little Norway. 2009). 
In Norway, almost all the major pharmaceutical companies and manufacturers 
are presented, but only a few of them are in production and of manufacturing 
status (Norwegian Medicine Agency. 2016).  
 In terms of a medicine list, Norway always had the need for a specific 
medicine clause. The result was an almost constant list of medicine for the past 
20 years; Norway health authorities believe that it is important to prevent 
individuals from unnecessary medicines. 
Table 4.4: shows the trends in which the medicine in Norway has changed since 1974 
until 1992 
Year 1974 1977 1985 1992 
Number of 
Medicines  
1,903 1,889 2,080 2,244 
Source: created by author based on data from Norwegian Medicine Agency. 2016 
 
 The above table shows the trends in which the medicine in Norway has 
changed since 1974 until 1992. (Marit Andrew et al. 1995) it’s important to note 
at this stage that Norway has the highest standard of living in the world; a health 
policy came into action from 1994-1997 to ensure access and quality of 
medicine and other health services. The introduction of the policy was 
welcomed and well received by all political parties the debate was in the form of 
the process of implementing it and how realistic is this approach (Marit Andrew 
et al. 1995). 
 In the early eighties, Norway realised the importance of preventive 
medicine rather than curative and focused their efforts to establish a more 
preventive strategy (Siem, H. 1986). 
 When Norway developed the National Drug Policy, they had areas that 
needed to have special consideration and focus; the main area was to evaluate 
the health situation in general, together with a specific consideration to the 
healthcare system. Another area of concern is the health professional level of 
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education and experiences; they focused on health insurance and social 
security; Norway has always thought that maintaining high standards in health 
research is very important. The drug industry is very important and requires 
careful monitoring; the process of drug distribution has to be efficient and 
appropriate. Another two areas that were considered were the control over the 
medicines available and assurance of rational drug use and good attention must 
be paid to the international drug policies.  
 When the Norwegian Healthcare Services planned their Medicine List, 
they aimed to include and select medicines with high safety margins and 
medicines with established efficacy. Medicine accessibility was an important 
consideration together with promoting rational drug use. The chosen medicines 
should comply with the national health burdens, diseases profile and country 
needs.  
 Norway made early attempts in enhancing medicine quality, years before 
the modern forms of international ethical regulations. The first act of Drugs and 
Poisons came as early as 1928, medicine had to be approved, and 
advertisements need to comply with government regulations. It is a positive step 
towards quality assurance, but during that period the available data was very 
limited and the quality of medicines couldn’t be assured fully.  
 The concept of Essential Medicines has been strong in Norway and been 
enforced by the national health services in Norway; the focus of the Essential 
Medicines was not for cost reduction only, but also to illuminate irrational drug 
use. The following explains how the director of Health Services in Norway was 
considered the initiator in EML concept foundation. 
4.2.1.1 Essential Medicine Concept in Norway 
 The Director of Health Services in Norway from 1938 until 1972, had 
clear insight to the issue of irrational drug use, he even wrote a book to explain 
its concept and view. His successor, Torbjorn Mark, agreed and continued in 
the same path, he was one of the main players in the foundation and 
introduction of WHO’s Action Program on Essential Drugs (DAP). He was an 
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actual builder of the initial Essential Medicine List and Pharmaceutical Policy 
and was the director of the Pharmaceutical Services from 1965 until 1991. 
 In 1977, Professor Lunde, Head of Dept. of Pharmaceutics, drafted the 
first Essential Drug List.  
Like many, industrialised and wealthy countries, Norway did not have in place 
an actual document of a National Health Policy nor an actual written form of an 
Essential Medicine List. In 1987, but a paper was introduced to the parliament 
with a section related to developments in the pharmaceutical sector. Included in 
the document is the expectation from the pharmaceutical sector in terms of 
providing safe and effective accessible medicines to all Norwegian 
communities. The section ensured; rational drug use, and health professional 
education. The focus of the proposed policy is the foundation of a 
pharmaceutical regulation body, and to control all aspects related to health and 
medicine use. 
 In 1930, the Quality Control Department was launched, then in 1948 drug 
standardisation was introduced and in 1974, the Norwegian Medicine Control 
Authority (NMCA) was set up. The NMCA had a medicine selection criteria, it 
was closely similar to that which had been suggested by the WHO; the following 
are the main requirements for any drug to be included in the List of Medicines in 
Norway;  
 The Norwegian Health services based medicine selection on the 
medicines list and on sound scientific research and strong scientific 
evidence. 
 Important consideration is given to the efficacy/toxicity ratio against 
disease severity and how effective a drug is in the healing process.  
 Norwegian Pharmaceutical services preferred to select new medicines 
that are supported with solid scientific evidence of quality. 
 It’s common practice in most health services to avoid fixed-drug 
combination unless it is proven to be superior to each combination 
individually taken. 
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 The clause related to the need, must be considered every time a choice 
is to be made. 
 There should only be a specific and limited number of medicines. 
 All medicines are reviewed after a 5 year approval period. 
 There are specific restriction as to who can use a medicine and who can 
prescribe it, such as Hospitals and prescribers.  
 In 1994, Norway was concerned that the number of medicines on the list 
might increase, therefore they introduced a directive that the medicines should 
not only be scientifically justified, but they should be needed. It’s common sense 
to include only relevant medicines to the health needs of the nation, otherwise, 
there is a waste of resources and the reasons for that choice are not critically 
chosen. 
 A positive point found in the process of registering new medicines was 
that the choice is not indefinite and requires regular updating and review.  In 
addition, leading medical experts are routinely consulted. Involving 
professionals from different clinical backgrounds which has helped to gain 
support for the pharmaceutical and health policy. 
 On the other hand, the challenge was to preserve the concept of 
Essential Medicines against the pressure of free trade, as with any new policy, 
and in this case, it relates to medicines, the industry in Norway accused the 
regulators who set up the list of being restricted.  However at the same time the 
regulators were warning of the dangers of deregulating the NDP.  
 The Norwegian experience with medicine selection and health policy is 
however commendable, although Norway has a very high income, that did not 
mean that the medicine list should go uncontrolled. They focused tremendously 
on the clause related to need, which indicated, a medicine would only be 
included if it is really needed and supported by evidence of safety and efficacy. 
 In comparison moving to a country with limited resources and a less 
developed health programme, Sri-Lanka, which has suffered from various 
political conflicts, financial and social challenges. The next segments will 
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demonstrate how this been handled and how Sri-Lanka tried to make use of the 
limited resources they have. 
4.2.2 Sri-Lanka National Drug Policy and Essential Medicine List 
Experience  
 Sri-Lanka became independent in 1948; they tried to provide free access 
to education and healthcare to all the population. Although an NMP/EML was 
not in place at that time, there were a number of laws, reports and 
recommendations to control the healthcare position of the country.  
 In 1962, the National Formulary Committee was launched as a result of 
the work of Professor Senaka Bibile. The committee was able to reduce the 
number of medicines to 2100 medicines, but unfortunately many conflict and 
political events occurred resulting in an ending of Professor Bibile’s work and 
the developments to control of pharmaceuticals were lost. However in the last 5 
years the work started by Prof Bibile has started again and is close to being 
completed today.  The reasons for this were; the powerful external 
pharmaceutical industry and the vast number of generics instead of brand 
names which were being imported, particularly from India. Later in the eighties 
and nineties a stronger government was established and imposed a more 
powerful control over the generic industry and a health reform took place. 
Examples of this reform were seen as a more restricted medicine registration 
procedure, introduction of the concept of the need for the medicine and strong 
proof and unbiased medicine information. Over the next 15 year there were a 
large number of   reforms and regulation changes in Sri-Lanka. 
 The following timeline demonstrates this, starting in the fifties, where the 
government, due to lack of proper experienced health decision makers, adopted 
specific international pharmacopoeias as a reference to approve medicines 
without any regards to how suitable the medicine was to the needs of Sri Lanka, 
at the time However although the decision was justified, it gave the local 
healthcare system no choice over what is suitable and what is not. As a result, 
in 1957, concerns arose over the loss of control and as a result a Formulary 
Committee was launched to set out further guidelines and provide a means of 
control over the stocking of medicines. The list of medicines on the formulary 
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were only related to the public sector, as the private sector continued  to  import 
all kinds of medicines that are not included in the public sector lists (K. 
Weerasuriya 1995). 
 In the sixties, the economic situation of Sri Lanka wasn’t in a great 
position, and for this reason, the government needed to demonstrate and 
enforce control over medicines to control the budget. For this reason the 
Ministry of Health introduced   the National Formulary Committee (NFC) to act 
as a regulatory body and review the 4000 available medicines and over 6000 
pharmaceutical dosage forms and reduced them to 2100 and 3000 dosage 
form. The government also gave the NFC the power to approve medicines 
before they were brought into the country.  However this kind of practice was 
not common in countries at the time. The two major criterion Sri Lanka focused 
on when importing a medicine was affordability and usefulness.  
 In 1977 however a new government came into power, which had the 
approach of encouraging again the private sector and free trade in 
pharmaceuticals, (Lall, S., and Bibile, S., 1977). The business people with high 
resources saw this as a chance to redevelop the pharmaceutical market and 
import more expensive drugs.  They however faced resistance from the State 
Pharmaceuticals Corporation (SPC) under the support of the Ministry of 
Industry, and SPC took control of imports in a phased manner, with minimum 
disruption to the supply of pharmaceuticals (Bibile, S. 1977). Further to this 
work the government introduced the Cosmetics, Devices and Drugs Act 
(Gazette of the Democratic Socialist Republic of Sri Lanka. 1985). 
4.2.2.1 Essential Medicine List of Sri Lanka 
 In 1985, the first meeting was held to introduce the Essential List 
concept, attendees of this meeting were officials from the Ministry of Health, a 
few academics and a member of the Medical Association, who was an advocate 
of the pharmaceutical industry. In 1988.  As a result of this meeting the EDL 
was revised (Department of Health. 1988). The pharmaceutical industry 
however tried to oppose the EML but when asked to provide a written statement 
to support the opposition, they failed to do so.  
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 From these meetings both the private and public sectors of health have 
similarities in their prescribing approaches, and the top 10 medicines at that 
time were prescribed from the Sri Lanka EML which had been developed 
(Weerasuriya, 1989). 
 As can be seen from the information above Sri-Lanka Health Services 
have gone through many years of turmoil up to the nineties and they were faced 
with a strong pharmaceutical and political opposition.  But they managed to 
stand against such challenges and the EML was beginning to be used in an 
efficient manner. Although it is suggested that the changes that took place in 
Sri-Lanka, were more economically inspired rather than health or scientific 
based.   
 But the difficulties in Sri Lanka were not fully resolved and a political-
religious issue was developing which was to last about 15 years. This was 
through the Civil War between the Sinhalese – Tamil religious groups.  This led 
to a major disruption in keeping the pharmaceutical developments in place.  
However there has been peace in Sri Lanka in recent years and the 
Pharmaceutical Regulation and the introduction of a National Drug Policy in the 
last year has re-energised the developments. It can be said however that the 
Sri-Lanka experience is country related and may not be appropriate if it were to 
be applied to other countries, but there are some similarities with Kuwait in 
terms of the periods of conflict and movement on an EML.  It is therefore 
considered important to take lessons from their experiences and make use of 
the knowledge gained from the challenges that have been faced and the 
method by which the country overcame them.  
4.2.3 Bangladesh National Medicine Policy Experience and Essential 
Medicine List  
 Bangladesh gained its independence in 1971; it has a poor, undiversified 
economy, with increasing population and lack of infrastructure. The infant 
mortality rate was high; in 1972 it was 140 per 1,000 live births. The health 
facilities were inappropriate, unmaintained, access to Essential Medicine was 
not in place and inefficient quality control system and counterfeit drugs were in 
circulation. The first basic Medicines Act was in place in 1940 and it was not 
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reviewed, and was therefore inadequate. It was not until 1975 when a new 
government came out with a new Act in 1975, that there was major movement 
again, but even with the new act there was no control over medicine quality. 
 In 1982, the Bangladesh Council of Ministers approved the proposals for 
a National Drug Policy, the interesting aspect of the work of the Expert 
Committee was that the work was done promptly and didn’t develop over an 
extended time. The Expert Committee worked out the policy, based on 16 
criteria, in 15 days. Later in the same year it became a law. However the 
opposition, as expected, came from the pharmaceutical industry which was 
however not particularly developed and regulated at that time.  But that did not 
affect the decision and the Policy and Report was introduced.  However there 
has been little progress from the 1980’s and hasn’t changed much in the 
following 13 years. It however had a positive impact on the healthcare in 
general, in terms of dropping prices, adherence to the Essential Medicine List in 
procurement and prescribing, increased quality of production, and health 
professional awareness of the medicines has increased positively (Z. 
Chowdhury 1995). 
 The Committee which discussed and formulated the Report and Policy 
was composed of Academics, Regulators, and Health activists, they were 8 in 
total. The Committee members were chosen from areas to exclude bias, for this 
reason, no members were chosen who had any relation with the pharmaceutical 
industry. The members were knowledgeable of the past experiences of 
neighboring countries such as; India and Sri Lanka; and it was the first and last 
committee in Bangladesh that didn’t include a civil servant or a military 
bureaucracy.  
 The Committee decided to follow the guidelines generally set by the 
WHO, in the selection of medicines. The committee made decisions using the 
scientific literature available at that current time and to only make deletions on 
medicines after a unanimous decision. The report the committee submitted 
included the rationale behind the decisions made and an action plan. The 
decision was also made to make the written document in simple, clear wording, 
avoiding difficult scientific words in order to make it understandable by all 
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readers. Because confidentiality was very vital at this point, no secretary was 
used and all members were vowed to strict secrecy until the report became 
public. The concealment approach proved to be useful, as the work of the 
Committee was achieved. The Committee managed to ban 1,742 medicines 
that they found inappropriate for several reasons. The recommendations for the 
drugs to be in the list were as follow:  
 Establish a basic list of 150 essential drugs and a supplementary list of 
100 specialized drugs. The total number of drugs on the list was to be 
available in all tertiary healthcare facilities; only 12 were available to be 
prescribed for village workers and 45 medicines were available for 
prescribing in primary healthcare facilities.  
 The 45 medicines available for prescribing in primary healthcare needed 
to be addressed by generic names only. 
 National Formulary needed to be prepare and publish a by 1983.  
 Eliminate product patents and limit the use of process patents.  
 Revise the 1940 Drugs Act to include: 
- a registration system for Ayurvedic, Unani and homeopathic 
medicines; 
- enforcement of good manufacturing practices (GMP), including 
adequate quality control; 
- control of labeling and advertising; 
- price control; 
- prescription control of toxic/poisonous and habit-forming drugs; 
- establishment of special drug courts and heavy penalties;- regulation 
of technology transfer and licensing agreements with foreign 
collaborators; 
- Restriction of ownership of retail pharmacies to professional 
pharmacists only.  
 Set up a National Drug Control Laboratory by 1985  
 Prevent TNCs from manufacturing simple products like common 
analgesics, vitamins and antacids. 
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 Establish registered retail pharmacies, under the supervision of qualified 
pharmacists, at every government hospital. 
 Strengthen Drug Administration by training all 5 health administrators to 
act as drug inspectors. 
 The National Drug Policy also came into action to control all aspects of 
manufacturing, procurements, distribution, medicine use and quality control.  
 It is possible at this point to ask the question with respect to the ‘small 
number of medicines’ as there were only 100 medicines on the list which can be 
considered as very limited.  The rationale according to the committee is that, 
they had conducted a study among practitioners and they found that the 
prescribers used only a total of 50 to a maximum of 100 types of medicines 
(WHO. 1979). As a result, almost all the pharmaceutical manufacturing 
companies were affected by the committee decisions; and there were 166 at the 
time.  
 There were also other problems the Committee and the Ministry of 
Health had to face.   These included the fact that Bangladesh depended on the 
donations of several countries, and as a result the NMP/EML was faced with 
rejection by a number of countries.  In the case of the USA their objection in 
supporting the List was because they did not seek their approval on the 
decision-making process as it would conflict with the American interest in the 
country. The German and the British also had similar oppositions to 
Bangladeshi attempts to control the medicine situation in the country and 
Bangladeshi efforts to enhance medicine access to the population (Z. 
Chowdhury, 1995). 
 The opposition did not come only from the Western industrialised 
countries but also from small companies in Bangladesh. With this opposition a 
public hearing was made by officials in the Bangladeshi government and they 
reacted by stating that the oppositions are merely protecting their own financial 
and commercial interests. As a result the Government went ahead with the 
document of NMP/EML and it was made public in 1982. But the NMP/EML, was 
faced with international opposition by other Governments, but against this it was 
also received well by human rights activists. This caused a lot of concerns and 
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antagonism by Transnational Corporations (TNC), fearing the other countries 
would follow the same path and that was true as shortly after, in 1983, India 
followed a similar path.  
 The result of the NMP/EML was evidenced however in the country and 
was demonstrated by increased local production from 30% of essential 
medicines to 80%, and prices were somewhat stabilised. This meant the drugs 
were more accessible to the population.  But these were not the only gains, the 
local production increased with less dependence on import and most 
importantly the quality of medicines increased.  
 The opposition against the Bangladeshi NMP/EML however continued 
throughout the eighties and nineties but the support of the WHO and UNICEF 
gave it strength. But although the struggle to implement the NMP/EML 
continued, part of the policy is still operational.  
4.2.4 Australian Experience 
 In 2010, Australia had a population of 22,3 Million. It is one of the world’s 
most urbanised countries, with around 89% of Australians living in urban areas 
(WHO, 2010).  
 Australia’s healthcare system is a complex combination of public and 
private sectors; 50 years ago, Australian government decided to make reforms 
to ensure that all the population have free access to medicines. They developed 
a comprehensive National Drug Policy, the policy aimed to provide a limited 
number of life-saving medicines to the population free of charge. They included 
a process of ensuring price control over medicines. This yielded a greater 
reduction of medicine prices than anywhere else in the word, costing almost 
60% less than what they cost in the European countries. This was the case in 
the previous decades; the prices are now more due to pharmaceutical 
innovation and developments.  
 Price control and medicine access were not the only two criterions 
considered by the Australian government, another important aspect is that the 
quality of pharmaceuticals had to be high and effective with a high safety profile 
(M. Murray, 1995). Australia has faced a number of challenges when setting up 
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the policy, mainly because of the diversity of the demography, plus other 
challenges such as aging population, changes in disease pattern, advancement 
in medical care and, as in most communities, the high expectations of patients.  
 When the Australian Health Services developed the Australia Health 
Policy and the Essential Medicine List, they aimed to achieve the following ‘to 
meet medication and related service needs, so that both optimal health 
outcomes and economic objectives are achieved’ (National medicines policy 
2000). The policy was designed in a way to achieve four main objectives, the 
objectives are as follows: 
1. Access to suitable medicines related to the Australian health needs in 
good time, with suitable cost.  
2. Medicines with proper quality, safety and efficacy. 
3. Preserving suitable pharmaceutical industry. 
4. Rational Drug Use (National medicines policy 2000). 
 
 The following diagram represents those four objectives best; the source 
of this diagram is the Commonwealth Department of Health and Ageing 2002 
(Commonwealth Department of Health and Ageing. 2002). 
 
Figure 4.4: Medicine Policy major Objectives 
Sourced from the WHO Document, National Medicine Policy, Chapter 4. 
 
 
 The diagram illustrates the major objectives considered when 
implementing the policy, they are very similar and can be related to all 
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countries, the process of ensuring adherence to the objectives and 
guaranteeing its implementation is key.  
 What Australia did was to construct a complete National Drug Policy 
slowly but steadily. The process started 40 years ago and it’s still an on-going 
process (Mary Murray, 1995). According to Murry, all the objectives had been 
addressed except rational drug use which remained a concern, as there was 
evidence of overuse, wastage, underuse and misuse (Mary Murray, 1995). 
Thoughts were then directed towards making a separate policy for rational drug 
use, but that would indicate that the National Drug Policy was not strong 
enough, and the reason behind it according to Murry, was that there was 
tension between health professionals and there were economic reasons. The 
agreed solution was to revise the current NDP/EML and reregulate it to suit the 
issues and challenges faced. This has however taken a very long time to 
develop and demonstrates the conservative nature of Australia.   
 Another major concern that caused Australia to re-evaluate its NMP/EML 
is the fact that the demography keeps changing due to immigration from Asia 
and Europe.  
 The following is a brief description of how Australia dealt with each 
objective. 
4.2.4.1 Access to suitable medicines related to the Australian Health 
needs in good time, with suitable cost 
 Australia came up with The Pharmaceutical Benefits Scheme (PBS), 
systems provide general public subsidy to make frequently used medicines 
more available and affordable (Raftery JP, 2008). The system started in 1950 
with 139 essential medicines prescribed free of charge and now PBS subsidises 
593 medicines in 1,451 formulation. A self-governing legal organisation, the 
Pharmaceutical Benefits Advisory Committee (PBAC), is responsible for 
endorsing which medicines are listed on the scheme (E.E. Roughead, no date). 
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4.2.4.2 Medicines with Proper Quality, Safety and Efficacy 
 This is the role of the Therapeutic Goods Administration, to ensure 
quality of circulating medicines. The Administration launched in 1958 in the form 
of a laboratory. Current premarket surveillances are being carried out and the 
Administration is responsible for drug registration and post market surveillance.   
4.2.4.3 Preserving Suitable Pharmaceutical Industry 
 The pharmaceuticals partnership program (P3), is the current program 
used by the Australian Government to monitor the Pharmaceutical industry 
since 2004, but before that, in 1998, it used to be known as the Pharmaceutical 
Industry Development Program. According to Australian Pharmaceutical 
Manufacturing Association, production and research has evolved since the 
introduction of the program (Productivity Commission, 2003), (Australian 
Pharmaceutical Manufacturing Association, 2000). 
4.2.4.4 Rational Drug Use 
 The WHO defines rational use of medicines as ‘patients receive 
medications appropriate to their clinical needs, in doses that meet their own 
individual requirements, for an adequate period of time, and at the lowest cost 
to them and their community.’ (WHO.2015). Australia detected several 
incidences of irrational drug use. The Australian government established The 
National Policy for Quality Use of Medicines in 1992; it drew a multi-level, multi-
strategic systems method to accomplish rational drug use (Commonwealth 
Department of Health and Ageing, 2002).  
 Policy making needs to be based on realistic approaches and aims, that 
benefit the community and is for the community, it’s a relationship between 
policy-makers, health professionals and the community. If this is not considered 
and consulted the policy fails its target, which is the general well-being of the 
community. Australia understood the concept and realised NMP is partly about 
medicines but is actually more about the overall well-being of the people with all 
the different levels of diversity (Murray, 1995). What Australia did was set up a 
committee for each objective to ensure its properly controlled and managed, 
they came up with regulations that will ensure adherence to the plan in hand, 
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and delayed the process of registering new medicines to not over flood the 
market with new drugs that have little information available to support their 
quality and efficacy claims.  
4.2.5 India NMP/EML Experience 
 Since the seventies, India aimed to have a form of national medicine 
policy and an essential medicine list, it can actually be back dated to the early 
years of India independence, India can be considered as one of the first third 
world countries trying to set up a NMP/EML. Unfortunately the policy failed to 
deliver due to the fact that the objectives were not clearly set out and the aims 
were not very significant to the population (P. Bidwai, 1995).  
 Another reason for NMP/EML failure was because, the concept did not 
focus on Essential Medicines List and the need clause, as most countries 
targeted when planning the policy. A major reason for the failure to deliver is the 
extremely powerful pharmaceutical industry, that made the policy, basically 
diminishes in the eighties. Since the fifties, India’s pharmaceutical industry was 
controlled by transnational corporations (TNCs), no price control was 
achievable and no proper regulation were in place; quality was unregulated, 
irrational drug use was common, especially because of untrained chemists and 
witch doctors (refer to healers, particularly in third world regions, who use 
traditional healing rather than contemporary medicine). India tried to control the 
situation by coming up with regulations to control TNC’s, but TNC’s managed to 
escape them. The Indian government came up with three things to contain the 
situation:  
1. Set up indigenous antibiotic production lines in the government sector. 
2. Intellectual property right changes, this would give chance for domestic 
pharmaceutical producers, it removed patency from food and health-
related products and reduced patency duration for pharmaceuticals. 
3. Create a system to test the quality of drugs through Indian FDA. 
 
 The timeline India went through to set up the final draft of the NMP/EML 
is very intensive. It started in 1946, at the evening of independence, a complete 
NMP/EML was prepared with a description of what the National Health Service 
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should be, it included what needed to be done to enhance the current services 
and called for structural changes (Duggal, 2001). This plan was not adopted 
straight away; instead the Indian government had a series of 5 year plans. The 
fault, which had been seen by Banerji, is that these plans focused on 
eliminating epidemics and not enhancing the health services in general (Banerji, 
1985). Another major fault in these plans is the fact that Indian health services 
depended on international donations for the majority of its health funds. For this 
reason any plan in place was controlled by international experts who saw to 
their own interests and politically controlled these plans resulting in its failure 
(R.Duggal, 2001). 
 In 1959, Mudaliar Committee was setup; it concluded that more than half 
of the population lack access to any appropriate health facilities, trained medical 
staff and Quality Medicines; this need to be addressed (Mudaliar, 1961).  
 In 1961, a third plan was started. The outcome of this plan is that, the 
previous plan failed to deliver its target and the population, especially in the 
rural areas, lack access to basic health needs (R.Duggal, 2001). In 1969, a 
fourth plan started. According to Duggal this was the most poorly written, and 
achieved almost nothing (R.Duggal, 2001).  
 A number of plans followed such as the 5th Plan that came up with the 
Minimum Need Programme (MNP), in a way to try to control the discrimination 
between rural and urban areas.  Then in 1973 Kartar Singh Committee followed 
by the 1977 committee, which focused on the health workers, for this reason 
this committee set up another committee called Community Health Workers 
Committee and in 1975 Shrivastava Committee was launched. And so on it 
went until finally in 1983, India’s first official National Health Policy was 
launched and adopted by the government. The policy was planned and 
prepared based on the principle recommendations of the Indian constitution, 
which clearly state the following ‘universal, comprehensive primary health care 
services which are relevant to the actual needs and priorities of the community 
at a cost which people can afford.’ (MoHFW, 1983, 3-4). 
 In this document, it is the first time Indian Health services are clear on 
the objectives of the Policy and acknowledge the main beneficiary, which are 
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the people. Years after the launch of NHP/EML and in 1992 an analysis was 
carried out to trace the progress of the policy, but the conclusion was 
disappointing, because according to several researchers in 1983 the general 
National Health Policy, which included the Essential Medicine List, was not 
realistic and did not meet the demands of the rural area population, therefore it 
did not meet its objective of being universal and comprehensive  (NSS-1987, 
Duggal&Amin,1989, Kannan et.al.,1991, NCAER,1991, George et.al.,1992). 
 In 1991, India went through economic changes and a new NHP was 
launched, the financial crisis India was going through, left it with external debt 
mounting to US $70 billion. Surely this would delay reforms and improvements 
and obstruct the effective operation of the NMP/EML. 
 It seems, from the above timeline that every time India tries to do 
something, a major crisis or obstacles arises preventing them from achieving 
their goal. The reasons are not as clear as one might think, it is obviously 
financial, but it also has many other factors that require several exhaustive 
studies to point out.   
4.2.6 Summary 
 The attempts of medicine cost-control has been the aim of many 
countries, regardless of the income level, the concept of Essential Medicines 
has been adopted by many countries, the reason is not only to control costs, but 
there are several reasons for it.  
 A major benefit to the EML is the quality assurance objective, it is 
believed by many countries that having a smaller number of quality medicines 
will ensure better control over observing them and reduce wastage. 
 Many other benefits have been paired with the concept of EML, such 
benefits are the rational drug use, enhance of health professional experience 
with the Essential Medicines, which will result in better patient compliances, 
minimisation of wastage, which is yet another form of cost reduction and 
promotion of good procurement practice. 
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 The concept of Essential Medicines is very disturbing to some 
stakeholders, who have a number of losses if the EML gets implemented; this is 
mainly seen in the Pharmaceutical Industry where they strongly oppose the 
implementation of the concept.  
 The less resourceful countries had very early attempts to launch the 
concept of Essential Medicines, even before it was adopted by the WHO and 
launched officially.  
 The opposition was always there and economical and political crises 
have always halted the concept. Currently, it’s more feasible to start the 
concept, because there is much more support from international organisations 
for the concept and the knowledge of medicines is easily available, health 
experts are more knowledgeable, even in a developing country, and more 
developed countries with good resources are adopting the concept.  
 The following section will compare the available Essential Medicine Lists 
for all the Arabic countries, and aims to provide an insight into the structure of 
the List.  The Arabic countries share similar health profiles to Kuwait but they 
differ in their standards of living.      
4.3 Arabic Countries Essential Medicine Lists 
 Over the past few decades, Arabic health has gone through major 
improvements (Kronfol NM. 2012), it’s been found that between 1990 and 2010, 
the mortality rate in the Arab world decreased and the population has aged 
(Malak Makki. 2014).   
Over 30 years ago the concept of an Essential Medicine List was not available, 
few countries had the concept in place and it was not fully organised.  
 The List became popular over the years and proved its benefits, this is 
evident because it’s been adopted by over 100 countries worldwide (WHO. 
2015).  In April 2015, the 19th revised WHO model EML was published and up-
to-date, there are 117 National Essential Medicine Lists available worldwide, in 
the Arabic region, around Kuwait, there are 12 countries with some type of 
national EML.  
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 The following table demonstrates the Arab countries with National 
Essential Medicines list and the level of income for each country. 
 
 
 To help to understand the impact and the process of operating and 
launching the National EML, a comparative analysis study between 12 Arab 
countries’ Essential Medicine Lists and WHO Model List has been conducted. 
The reason behind this comparative analysis is to demonstrate how these Arab 
countries developed and conducted their own list of Essential Medicines, the 
procedures they used to adopt the WHO Model EML to suit their health situation 
and the variations between the National EML and the WHO Model EML. The 
other reason for choosing these Arab countries in which to conduct the 
comparison, is because, these Arab countries share very similar health needs 
to Kuwait and some of them share similar income levels and standards of living. 
By examining each closely, it was proposed that it might give a helpful 
indication on how the Essential Medicine List of Kuwait could be presented.  
  
Table 4.5: Arabic countries Income Level 
Country WHO Region Income level 
(World Bank Ranking) 
Sudan Eastern Mediterranean Lower middle 
Yemen Eastern Mediterranean Low 
Syria Eastern Mediterranean Lower middle 
Egypt Eastern Mediterranean Lower middle 
Jordan Eastern Mediterranean Lower-middle 
Lebanon Eastern Mediterranean Upper-middle 
Tunisia Eastern Mediterranean Lower-middle 
Morocco Eastern Mediterranean Lower-middle 
Bahrain Eastern Mediterranean High 
Oman Eastern Mediterranean High 
Iraq Eastern Mediterranean Upper middle 
Saudi Arabia Eastern Mediterranean High 
Kuwait Eastern Mediterranean High 
Source: Data extracted by author from the World Bank website, 2014. 
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Table 4.6:  Arab Countries Essential Medicine against WHO Model EML Comparison 
Table 
country Operational 
EML 
Year 
Committee 
members No 
First list 
and 
Reviews 
Total M 
with 
dosage 
form 
Sections 
No 
Sudan 2007 N/A 1982 543 28 
Yemen 2007 (4th) Not Available 1986 419 27 
Syria 2008 (7th) N/A 1988 
(1st List) 
1180 33 
Oman 2009 10 1995 1103  
Egypt 2006 (2nd) 45 First 1998 579 (2nd) 
453 (13/14) 
18 
Jordan 2011 (4th) 
(2nd 
operational) 
32 
(various 
committee) 
First 1999 635 17 
Lebanon 2014 7 
( Editorial 
Committee & 
Experts 
Committee) 
2002 
(no reviews 
for 12 yrs) 
310 14 
Tunisia 2008 (2nd) N/A N/A 2310 16 
Morocco 2008 N/A N/A 270  
Bahrain 2009(1st) 15 2009 1045 161 
Iraq 2010(1st) N/A 2010 2300(?) 18 
Saudi 
Arabia 
2012 Multiple 
committee 
( Dr’s, Pharm’s, 
Nurses) 
2011(1st) 183 29 
WHO 
model List 
2015 15 core 
+ 
4 temporary 
1977 410 
 
30 
Source: the information gathered by the author from all the listed countries official 
source for nEML 
 
 The following represents the timeline of the EML in the Arabic countries, 
it’s apparent that at the beginning, only countries with limited financial resources 
adopted the list, but as time went by and the EML proved its efficiency and 
benefit, more and more countries are adopting the concept and in the recent 
years, wealthy Arab countries are implementing the concept as well.  The 
reason behind this can be explained by the time evidence of the effectiveness 
of the EML; it’s not only useful to make medicines accessible but it also helps in 
having better control over medicines, support budget management and provides 
better understanding of medicine quality and adverse effects. 
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Figure 4.5:  EML launch in the Arabic region timeline 
Source: The figure was created by the author based on the information from the official 
listed government nEML documents. 
The comparative table above demonstrates several variances in the way 
the medicines are sectioned, members of the country’s own expert committee 
and the number of medicines on the list. For this reason it’s necessary to look 
closely at each country’s experience and the process adopted by the healthcare 
officials to design the final form of the list. 
 It’s obvious that there are large variances in the number of medicines in 
the list, if we cross-compare the number of medicines against the income level 
of the country the result is demonstrated in the following table. 
Table 4.7: Arabic Countries cross table of Essential Medicines number against Income 
level 
Country Total M with dosage form Income level 
(World Bank Ranking) 
Yemen 419 Low 
Sudan 543 Lower middle 
Syria 1180 Lower middle 
Egypt 579 Lower middle 
Jordan 635 Lower-middle 
Tunisia 2310 Lower-middle 
Morocco 270 Lower-middle 
Iraq 2300(?) Upper middle 
Lebanon 310 Upper-middle 
Bahrain 1045 High 
Oman 1103 High 
Saudi Arabia 183 High 
Kuwait N/A High 
The table was created by the author based on the information from the official listed 
government nEML documents 
 
 It can be stated that there were no significant findings or patterns found 
between income level and the number of Essential Medicines on the list. They 
Sudan 
1982
Yemen 
1986
Syria 
1988
Oman
1995
Egypt
1998
Jordan
1999
Lebano
n
2002
Tunisia
2008
Morocco
2008
Bahrain
2009
Iraq
2010
Saudi 
Arabia
2012
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are all more than the number of medicines on the WHO Model EML with the 
exception of Lebanon and Saudi Arabia. Syria and Oman where the number 
was similar and the same was found in Iraq and Tunisia.  
 From examining each list, one reason was found which can explain the 
large number of medicines in some lists, that in some of the nEML’s, each 
dosage form has been listed as individual medicines, whereas in other lists the 
pharmacological identity of the medicine only is considered as an item.  
 The following is a brief description of each nEML; which briefly includes 
background information, the timeline of when the list was attempted and the 
way the list is divided. Up.  The information was difficult however to obtain, the 
reason behind this is the fact that the information is not well-documented and 
not many publications exist, if any. Another problem that occurred, when 
collecting the nEML information, is that the Moroccan and Tunisian information 
was written in French, as a result Google translate had to be used to explain the 
material, which in translation of pharmaceutical information was not always 
easy to understand.  
 The National Essential Medicine List, described below, is arranged from 
the earliest ones to the most recent. 
4.3.1 Sudan Essential Medicine List 
 Sudan can be described as a lower-middle income country and the 
largest Arabic country in size, there are a large number of rural areas and the 
access of medicines to the many villages can be challenging. 5 years after the 
WHO published the First Model List of Essential Medicines, Sudan launched 
their own National List of Essential Medicines, the information but the process 
of implementing the list is not however clear and not well guided, and therefore, 
the introduction of the list was not operational and no official adaptation took 
place for some time. However later, in 1987, the list was revised by the 
Standing Committee for Drug Products Registration, at that time the Sudanese 
Ministry of Health were more involved and pushed the enforcement, and 
combined the launch of the new list with Ministerial Order No 7 dated 15th 
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October 1987. The list was printed in English, and was distributed to all 
healthcare facilities (Sudan MOH, 2007). 
 There were more revisions following this in 2001 and 2004, the extent of 
how many of the medicines procured depended on the Essential Medicines List 
was not found in the literature.  
The medicines in the list were divided in accordance with the level of usage; 
and the following outline is the way it’s been divided:  
 AA: Medicines used in primary health care units, dressing stations and all 
other health institutions. 
 A: Medicines used in dispensaries and health centres run by medical 
assistants (in addition to AA medicines). 
 B: Medicines used in rural hospitals and health centres run by medical 
officers (in addition to A, AA medicines). 
 C: Medicines used in hospitals with specialist departments (in addition to 
A, AA, B medicines). 
 S. Medicines used in specialized centres or specialized units in some 
designated hospitals (in addition to all other essential medicines).(Sudan 
MOH, 2006) 
 
4.3.2 Yemen Essential Medicine List 
 Yemen adopted the first list of medicines in 1986, making it the second 
Arabic Country to adopt the programme (HV Hogerzeil et al, 1989). 
 The essential list of medicines includes 419 Essential medicines, and is 
divided into 27 sections, and the list is presented in table form and has sections 
for Drug Name, Form, Strength, Unit, level and a code to indicate its priority 
level. The codes are; 
 V, Vital Medicine. 
 E, Essential Medicine. 
 N, Necessary Medicine. 
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 The medicines on the list are either in single dosage form or in fixed 
combination dosage form. There is an extra section to give guidance for 
prescribers on which drug is more favourable or give warnings to its use.  
 A study conducted by Hogerzeil, demonstrated that the adaptation of 
Yemen to the Essential Medicine List had a positive impact and 
enhanced the availability of medicines and rational drug use in peripheral 
health areas in Yemen (Hogerzeil HV et al, 1989). Another literature 
review conducted by Le Grand, demonstrated that doctor’s knowledge of 
medicines had improved and more rational prescribing has taken place 
(le Grand A. 1999).  
4.3.3 Syria Essential Medicine List 
 Syria did take pride in being able to produce 88% of the total medicines 
needed in the country and they were aiming to make it 100%; the medicines 
that are not manufactured in Syria are classified under four classes of 
medicines, the classes are as follows:  
 Insulin. 
 Vaccinations. 
 Blood products and plasma substitutes. 
 Some anticancer medicines (Syrian EML. 2008).   
 
 Syrian Ministry of Health realised the need to have a list of medicines 
that are essential, some time ago and for this reason they published their first 
list in 1988, and at the same time introduced a government law to enforce its 
application. A second revised list came out 4 years later and a third one in 
2001, 8 years later. The Syrian Essential Medicine List and its selection were 
mainly based upon on the WHO model List of Essential Medicines in 
combination with the knowledge and expertise of the local health professionals 
(Syrian EML. 2008).   
 The list is divided into 33 sections in accordance with the 
pharmacological properties but there is no indication of the dosage form. The 
medicines are listed in generic names and no trade names are included. This 
could be due to the fact that most of the medicines on the list are made locally.  
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 It is quite admirable that the Syrian local production of medicines is 
almost self-sufficient but its raises concerns in terms of the quality of such local 
productions and the fact of whether they are good enough for human use, 
stable enough for storage and transportation and hold a reasonable and 
acceptable safety margin.  However, the developments in Syria, before the 
conflict should be taken into account in developing the Kuwait EML, because of 
a number of similarities between the countries.  
 Obviously following the crisis in Syria and the war, all has changed and 
the innovation has halted, and this is understandable in relation to the fact that 
war and conflict destroys hospitals, water and sanitation systems and drives 
health workers away from combat zones, and that has led to totally destroying 
the country’s infrastructure, to include healthcare (Health Alliance International, 
2015).  
4.3.4 Oman Essential Medicine List:  
 The Sultanate of Oman is a high-income country with a population of 4 
million (The World Bank, 2014). According to the Oman Ministry of Health the 
Public Health Sector has advanced intensely in the past 25 to 30 years (Oman 
National Drug Policy, 2000).  From these points it indicates that it has many 
similarities to Kuwait 
 The Oman MOH Approved Drug list contains 500 Chemical Entities and 
over 900 Medicine products. The first list was published in 1995, but a revision 
followed resulting in the reduction of 100 items and a rejection of 150 new 
medicine applications.  A committee named The Central Drug Committee 
(CDC) is responsible for the selection of medicines. The committee is 
composed of ten members, headed by the MOH undersecretary, physicians, 
pharmacists, pharmacologists, the director of Medical Stores and the Director of 
the Pharmaceutical Sector.   
4.3.5 Egypt Essential Medicine List: 
 Egypt has a much larger population than Kuwait and the income levels 
vary considerably across the country at the time of the EML.  But there are 
some lessons to be learned by Kuwait.  The work of the introduction was much 
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earlier than many similar countries and the first list was published in 1998, the 
objective at that time, according to the Ministry of Health and Population 
(MOHP), was to enhance access and availability of good quality medicines that 
are related to the health needs of the population. The MOHP believed by doing 
so and having a smaller list of medicines the cost would be reduced and more 
funds could be available for other health care requirements (Prof. H. E. Gabaly, 
2006). This again could be a consideration that the MOH may find beneficial. 
 The Egyptian National Essential Drug List was divided into three parts; 
the first part contained medicines listed under generic names together with; the 
concentration, the appropriate dosage and the level of the medicine. The 
second part contained the Medicines Monographs. The last part covers the 
medicines written under trade name.  
 Medicine use was organised by assigning each medicine to a level of 
healthcare, and three levels were identified as follows: 
1. For use by all medical professionals. 
2. For use only by medical specialists and consultant physicians. 
3. For use only by consultant physicians. 
 
4.3.6 Jordan Essential Medicine List: 
 Pharmaceuticals takes up a large percentage of Jordan expenditure on 
health, as is the case in Kuwait and it’s estimated that in 1998, 2000 and 2001 
Pharmaceuticals accounted for 30-35% of the total Jordanian Health 
expenditure (Jordan Rational Drug List V1, 2006).  For this reason and with the 
technical help provided by the Partners for Health Reform plus (PHRplus), 
Jordan developed its first EML which was published in 1996.  Then 
amendments were made in 2001 and 2002, but neither was made official. The 
reason, according to the Jordan MOH is that at that time, there was a lack of 
commitment to rational drug use, collaboration problems, being limited by 
normal boundaries and not willing to take decisions outside the usual scope of 
the work which had been undertaken at that time (Jordan Rational Drug List V1, 
2006).   
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 Again the selection criteria, was generally based on the WHO 
recommendations.  
 However the first functioning list was published in 2006 and was divided 
into the following lists:   
 Unrestricted Medicine List. 
 Restricted medicine List. 
 Pre-authorized List. 
 However as a lesson to Kuwait, a large number of committees were 
involved in the selection of medicines in the list, the reason given was that each 
committee was specialised on one section of the therapeutic classes. There 
were also 17 chairpersons for the 17 therapeutic committees to decide on 
Standard Treatment Guidelines and medicine choices. Again this is an issue for 
Kuwait if they decide to follow a similar direction.  It was also reported that there 
were technical committees to decide on medicine selection and there was an 
advisory board to organise and approve the list. The approach carried out by 
Jordan can be considered to be wise; as it firstly assembled a therapeutic 
committee to develop Standard Treatment Guidelines, then developed the 
NEML based on the guidelines. In assembling the structure of the committees it 
was clear that pharmacists had a minor role on the committees and the 
selection of medicines was depended on the influence of physicians. 
4.3.7 Lebanon Essential Medicine List: 
 Lebanon is another of the countries in the Arab sphere of countries which 
has addressed to problem of medicines control.  It is a small country with a very 
diverse community, which is slightly different to the position in Kuwait, and over 
the years there has been considerable political instability. Despite this however 
the country has been able to move forward in terms of its healthcare services, 
to include the development of an Essential Medicines List and one was first 
published in 2002.  Although overall it took 12 years for the List to be 
appropriately reviewed and introduced and a more suitable list of medicines has 
been announced.  
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 However the early lists of medicines in Lebanon were exceptionally small 
in comparison to the list proposed by groups such as the WHO But the reason 
proposed was that they were mainly based on chronic conditions only and they 
included 71 Essential Medicines, divided into 14 sections. This list however 
remained the same for a long time but finally a new edition was published in 
2014, and a wide extension to cover many more health issues was introduced.  
As a result, the latest List of Medicines includes 310 medicines, but it only took 
a year to decide upon those which should be included when a group of experts 
became involved in the decision process. The new list is now seen as more 
organised and more appropriate to the needs of the country and contains two 
lists of medicines, a core list and a complementary list and it is containing of 30 
sections. There is some similarity to the WHO model List of Essential 
Medicines. But it is suggested that both the WHO suggested medicines and 
those particularly appropriate to Lebanon are included.   The list of medicines is 
arranged in three columns: 
1- INN of the medicine  
2- Dosage form and strength of the medicine  
3- Official Status of the medicine (List of Essential Medicines Lebanon – 
2014) 
 
 The medicines have symbols next to them to indicate the source of 
financing for each medicine, the following are the symbols used in the list: 
 NR: Non Registered drug in the Ministry of Public Health  
 R: Registered drug in the Ministry of Public Health  
 TB: included in the Tuberculosis Program  
 U: provided through UNICEF Program  
 Y: provided through YMCA Program  
 [a]: indicates that there is an age or weight restriction on use of the 
medicine (List of Essential Medicines Lebanon – 2014). 
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 The selection criteria was based on the WHO 18th model List of Essential 
Medicines.  
4.3.8 Morocco Essential Medicines List  
 Morocco is another country which can be considered to have some 
similarities to Kuwait, although the initial comparison is not particularly obvious 
as it is a mid-low income, Northern African Arabic country with a population of 
almost 33 million, of whom 19% live below the poverty line (WHO HAI. 2008). 
Morocco health expenditure is 6% of GDP (2011), (CIA World factbook. 2014).  
 Morocco has a National Essential Medicine List comprising of 270 
medicines and is written in French. The reason why it is mentioned here is 
because the Essential Medicine list is applied to the public sector where 
medicines are provided free of charge (WHO HAI. 2008). The nEML was 
published in 2008 and is a very straight forward list; it includes sections for drug 
classes then a section to identify medicines in codes, a section for medicine 
generic name and the dosage form available.  These developments are all 
areas where Kuwait may benefit.   
 There are however a number of areas where the MOH in Kuwait should 
take note and one is that the list doesn’t have any warning of age restrictions on 
the medicines proposed, and doesn’t have patient information leaflets to 
indicate any specific requirement or warning.  
4.3.9 Tunisian Essential Medicine List 
 Tunisia like Morocco is another mid-low income Northern African Arabic 
country with a population of almost 11 million (CIA World factbook. 2014). It is 
mentioned here because it has adopted slightly different proposals in its EML. 
 The Tunisian Government has constructed a team named the DPM, 
which was comprises of members of the Faculty of Pharmacy at Monastir 
University and a team of experts from the Tunisia Ministry of Health.   
 It is reported that the selection process was mainly based on the 
adaptation from the Belgium Drug Directory; where the work of DPM was to 
adapt the two lists in a manner that suited the health needs of Tunisia. The 
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MOH also introduced a procedure for enforcing its use which was based on the 
guidelines which had some similarity to the WHO Collaboration Centre 
proposals on registration and regulating of drugs. Although only in place for a 
small number of years it has recently been updated, which tends to show the 
commitment to the list, its practicality and efficiency in reality. 
 The aim of the list according to the Tunisian Directorate of Pharmacy 
was to promote Rational Drug Use; the Directorate believed that this was 
achievable if the health workers were provided with independent information on 
medicines registered in Tunisia (Tunisia EML 2008). One major point which 
comes out of this and others Lists is that the information provided in the 
discussion and decision was based upon both therapeutic and economical 
information. But in Tunisia one of the downsides was that there has been 
tendency from suggested reports for the recent information available to point to 
some medicine prescribing favouritism.  One aspect of this is that the 
prescribers have been suggested to base their selection on economic factors 
rather than quality and rationality.  
 In Tunisia the medicines in the list are divided into chapters based on 
their properties. Therapeutic and pharmacological, and some medicines have 
the letter H next to them which indicates that this medicine is for hospital use. In 
general the medicines themselves are divided into the following categories: 
 Vital Medicines 
 Essential 
 Intermediate   
 Comfort 
 
 Each chapter includes an introduction to give; direction in the use of the 
medicines, the medicine’s strength, dosage form and manufacturers. The idea 
behind including the manufacturer is a technique to promote generic medicine 
use resulting in better control over medicines expenditure.  These proposals 
also have merit and it is suggested that Kuwait should also to note of the 
reasons for going in this direction. 
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4.3.10 Bahrain Essential Medicine List: 
 Another of the gulf-countries is Bahrain which is located on a small 
archipelago of 33 islands, with the largest island being Bahrain Island (World 
Atlas. 2015). The population of Bahrain, in 2013, according to the CIA factbook, 
was almost 1.4 million.  
 In Bahrain the Essential Medicine list is part of the National Formulary.  
However; there were no separate lists found or any indication which points to 
the medicines in the Drug National Formulary as being Essential. The members 
of the selection committee are the same, as in Tunisia and comprises of two 
committees; the first one is the Drug Formulary Committee including 7 members 
and it was supported by an active participant team of 10 Pharmacists.  
 The number of Medicines on their list appears to be very large and is 
presently 1045. But the number is inflated as it includes medicines with both 
trade names and generic names, and the many different dosage forms for the 
same medicine.  
 One aspect of note is that there is no separation between the National 
Medicine formulary and the Essential Medicine list. Again it is something for the 
MOH in Kuwait to note as this practice can cause confusion and lack of 
adherence to quality and affordable medicines. It should also be noted that a 
National Medicine Formulary is a manual containing fundamental information on 
medicines but also pharmacological information to all the medicines available in 
the country, while an Essential Medicine List includes information on the 
minimum number for quality, safe and efficacious medicines that can satisfy the 
health requirement of a certain population (R. Laing and K. Tisocki. 2004).   
4.3.11 Iraq Essential Medicine List: 
 Iraq has gone through very large changes to its political identity 
throughout history; these changes were not gradual and didn’t happen 
peacefully. Iraq has gone through many wars and faced a number of political 
transformations resulting in very weak governmental sectors at all levels. 
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 It’s is still however classified as an upper-middle income, Middle Eastern 
country.  It, borders on the Arabian Gulf, Iran, Kuwait, Syria, Saudi Arabia, 
Jordan, Turkey and, currently Kurdistan, following the separation of this region 
from Iraq and it gained independence. As a result of this with such a large 
number of neighbours surrounding Iraq, the population is very diverse; and is 
composes of 75%-80% Arab, 15%-20% Kurds, and around 5% of various 
backgrounds to include Turkoman’s and Assyrian’s.  
 This diversity of the population, the conflict and the lack of organisation 
has had an impact on the healthcare services and expenditure in Iraq (CIA 
Factbook. 2015).  Recent data has indicated that the Health expenditure in 
2013 was 5.2 %( according to the CIA factbook).  Also although there has been 
discussion trying to reduce this expenditure, there are limited medicines 
structural formats in operation in Iraq.  
 The recent conflict problems in Iraq have however taken their toll, on the 
Health System.  But there has been efforts in the last 8 years to try to manage 
health expenditure and published its first List of Essential Medicines in 2010. 
The effective utilisation of such a list has not been explored yet and no literature 
is available to describe it.   
 The EML list which has been assembled has taken the following form 
and is divided into sections, which again may provide some structure for Kuwait 
to follow.: 
(Priority 1)  
 Medicines that need to be available at all times and circumstances. They 
are divided into 3 alternatives.  
 A: Medicine of first choice 
 A/a: alternative medicines 
 A/L: Essential but of limited use  
(Priority 2)  
 Medicines in this section are of verified quality and high safety margin 
with high cost. For this reason they are available on a limited scale and only 
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prescribed as a second line in case, if the medicines in the Priority list don’t 
work.  
 B: First choice Medicines (Best & expensive) 
 B/a: First choice alternative Medicines 
 B/L; First Choice Medicines of limited use 
(Priority 3) 
 Includes a complimentary list of medicines. 
 C: complimentary 
 C/a: alternative 
 B/L: limited use 
 
4.3.12 Saudi Arabia Essential Medicine List: 
 The last of the Arab Countries which was considered in the background 
study is the Kingdom of Saudi Arabia which is indicated to be a high income 
Middle Eastern country, bordering the Arabian Gulf from one side and the Red 
Sea on the other. Because of its oil wealth it is one of the richest countries in 
the world with a population of 28 million, and according to the CIA factbook the 
Health Expenditure is 3.2% of the GDP (CIA Factbook. 2015). The total annual 
expenditure on health (THE) in 2009 was 72.3 Billion Saudi Riyal (SAR) (US$ 
19.3 Billion), (Saudi FDA. 2012).  
 The Kingdom of Saudi Arabia has realised it is important to have a well 
organised Pharmaceutical Sector and appreciate the impact of such an 
organisation to the overall wellbeing of the population. For this reason the Saudi 
Ministry of Health has made a number of changes and improvements in the 
health sector in recent years to help provide better care.  
 One of the major pharmaceutical changes that has taken place is the 
implementation of an Essential Medicine List (nEML), which has played a 
crucial part in improvement of individuals right to good health and ensuring 
rational drug use. 
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 The list was last updated 4 years ago in 2011; and includes 183 of what 
is called Essential Medicines chosen in alliance with the National Standard 
Treatment Guidelines (Saudi MOH. 2009).     
 The list was constructed and compiled by the Pharmacy and 
Therapeutics Committee (PTC). It’s an advisory committee which gives 
recommendations in the formulation of health policies, medicine selection and 
the therapeutic use of medicines in hospital settings (MOH Formulary, drug list 
2012). The committee also has an educational unit; and they continue to 
provide health professionals with on-going training in the most recent advances 
in medicines and therapeutics. The committee has a continuous role by 
providing an updated version of the list, which was set at ideally every two 
years, but the latest one took 4 years to be updated. The update carried out 
deletion and/or addition of medicines, as appropriate and the final decision is 
made by the Committee and is based on the literature and evidence provided 
by international resources, and many public and/or independently funded 
National Drug & Poison Centres (Saudi FDA. 2012).    
 At this point it is useful to consider some of the points which relate to 
having a nEML in place.  One of these is the provision of improved rational drug 
use.   However although it is suggested that there should be an improvement at 
one level, unfortunately, there are no surveillance protocols to prevent or 
monitor the wide spread of antimicrobial resistance (Saudi FDA. 2012).   
 In addition a point which was uncovered is the very interesting fact which 
could be looked at, is that the Pharmacy and Therapeutics Committee (PTC), is 
found in each public sector hospital and it includes Physicians, Pharmacists, 
and Nurses as members; the committee is headed by a Physician (Alkelya M. et 
al 2015). It is suggested that these two facts can affect the decisions made, the 
reason being that Physicians can look at the concept of quality, cost-
effectiveness and Essential Medicines differently from Administratively trained 
pharmacist and Health Policy Administrators, there is a tendency among 
doctors to prefer a wider choice of medicines to prescribe from, which they tend 
to consider is a restriction.      
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 Considering all the facts mentioned earlier, it’s apparent that the duties of 
the PTC are large and intercalated. This situation can cause misperception of 
the committee roles and can cause collision between different committee’s 
decisions.   
 When contacting the Saudi FDA to ask for the official list, the response 
was concerning. The list has never been made public and not yet operational. 
All the literature states otherwise, especially as it was reviewed once, but never 
utilised. Such a situation has been seen in many policies in the GCC regions, 
the project starts and a specific budget gets allocated, then the policy never 
gets enforced officially due to many factors. Some of the reasons could be due 
to management changes, the new management finds this specific project not 
beneficial; another reason is lack of proper monitoring and involved members 
loose interest; resistant stakeholders to protect their welfare; running out of 
funds due to miss-management; issues related to Bureaucracy and the lengthy 
waiting period for getting approvals to each level of planning. These are some 
of the major reasons that might cause policies and new innovative programmes 
to halt; there are many others not so apparent and more specific to each 
situation.  
 In a situation like this, the overall management of the health system 
tends to suffer and loses its efficiency, therefore; it’s very important to ensure 
commitment and desire towards programmes that aim to enhance the health 
services. This is again a lesson for Kuwait. 
4.4 World Health Organisation Model List of Essential Medicines 
 In this section a brief comparison of the content of the WHO Model List of 
Essential Medicines against the needs of Kuwait is made and there is mention 
of how the structure and some details of the WHO List may be used for it health 
needs.  In addition there is discussion of the limitations of the WHO List when 
discussed alongside the needs of Kuwait.  
 The WHO Model List of Essential Medicines, provides an example which 
gives guidance to countries, on a country’s medicines needs, generally based 
on its economic situation, and whether there is a possibility that the 
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pharmaceutical sector is or may be capable of providing efficient and safe 
medicines.  
 The WHO has based their selection criterion on mainly; quality, safety, 
affordability and suitability. It should be noted that to have a list that contains 
these criterion; it is only conceivable when the country has a well-established 
health system combined with supportive and transparent health professionals 
and decision makers. Another important quality needed to be present, is 
satisfactory access to unbiased and well documented medicine information.     
 As indicated earlier in the Thesis the first WHO Model EML was 
published in 1977, and at that time the list included only 208 medicines, as time 
went by and medicine discovery advanced, the list doubled in size, but didn’t 
divert severely from the initial list. In the latest list, No19 from April 2015 WHO 
Model List, there were 410 medicines, a single chemical identity and 485 with 
repetitions. WHO made a list specific for children medicines, currently the 
children List of Essential Medicines is going through its 5th edition. In 20th Expert 
Committee on the Selection and Use of Essential Medicines there were 15 
expert members together with 4 temporary members. The latest list of Essential 
Medicines includes several new additions, an example of the new additions are 
as follows: 
 New treatments for hepatitis C 
 New treatments for breast cancer and leukaemia  
 Treatment for multi-drug resistant tuberculosis (TB), (WHO. 2015)  
 In totally, 36 new medicines have been added to the Model EML 
 In the children EML, there were 16 new medicines added (20th WHO 
Expert Committee. 2015). 
 The WHO Model List is divided into two sections, the first one is the Core 
List; which represents the minimum medicines suggested to be required for a 
basic healthcare system. Medicines on this list are suggested to be of high 
quality, safe, efficacious and cost-effective (WHO. 2015). 
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 The WHO Model EML comes with a secondary list, known as the 
Complementary List, this list aims to provide medicines for priority diseases; the 
diseases which are suggested by the WHO to be the ones that require specific 
health facilities, special training or special diagnostic tools. Other medicines 
included in the list; are medicines that need to be given in high doses to be 
effective and medicines that are relatively expensive. 
 From the discussions on the selected Arab countries’ National Lists of 
Essential Medicines which were discussed in the last section, some countries 
have chosen to select medicines which are on the WHO Model EML, and others 
have added a number which are outside the list, which was completed for a 
number of reasons as proposed. This is expected because the WHO Model is 
merely a suggestion and not obligatory and each country found their own way to 
select medicines and adapted their needs in a manner that was suitable to their 
own health needs and own health capabilities. It can be suggested that If the 
NEML is a complete adaptation of the WHO Model List, this would result in 
failure to reach the objective of the EML concept.  
 In addition the WHO has tended to tailor its List to the less privileged 
countries when building up the concept, therefore, the list contains a large 
number of Medicines to treat Tropical Diseases, and diseases of malnutrition. 
Currently, many countries with mid to high incomes who have used the concept, 
of the EML have managed to not only enhance medicine access but improve 
rational drug use and gave control over the inflation of medicine expenditure.     
There are therefore a number of variations between medicines on the 
WHO model EML and the Arab and other countries mentioned above. 
Variations are found between the sections of the anti-infective, the cytotoxic 
medicines and the dermatological medicines (Rianne van den Ham. 2009). 
 In the latest WHO model list of Essential Medicines, there are several 
medicines that are not in use currently in Kuwait or have been withdrawn or 
their use has been stopped. Another observation is that the WHO Model EML 
has several Anthelminthics, this is not really a major health concern in Kuwait; 
ring worms are relatively minor and curable with one available type of medicine 
named Mebendazole, trade name Vermox.  
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 In general the WHO model EML tends to focus on tropical diseases. 
Kuwait is a desert country with the only water source in Kuwait being the sea 
which needs treated carefully before supplying it to the population, therefore a 
large selection of Anthelminthics medicines are not required.    
4.4.1 WHO Model List of Essential Medicines for Children 
 In addition to the Medicines List for Adults, there has been a list 
suggested for Children in place for some time and it is strongly suggested that 
Kuwait also has a Medicines List specifically based around children up to the 
age of 12’s needs. It is clear worldwide that the importance of child health is a 
global priority.  The WHO Essential List of Medicines for Children was first 
approved in 2007 (S. Hill et al 2012). The lists from the WHO have since been 
updated and in April 2015, the 5th WHO List was completed.  The List focuses 
on medicines for childhood illnesses and has included those that are rarer and 
these are listed under what are known as Orphan Diseases and treated with 
Orphan Medicines.  
4.4.2 Selection of Orphan Drugs 
 EU legislation defines an orphan drug as one that could treat a disease 
with a prevalence of less than 5 per 10,000 of the population (S. Bojakowski, J. 
Spoors 2013). 
 Since Kuwait depends presently on many USA Food and Drug 
Administration decisions, it is sensible to give the USA FDA definition of an 
Orphan Drug, which is ‘a drug or biological product (“drug”) to treat a rare 
disease or condition upon request of a sponsor.’ (USA FDA, 20015).  The USA 
FDA goes on to define a rare disease as being; ‘A rare disease is generally 
defined as a disease which affects fewer than 200,000 Americans a year.’ 
(Gayatri R. Rao. 2015). 
 The decision on Orphan Drugs is however different between Europe and 
the USA which view rare diseases and Orphan medicines differently, and it is 
proposed that when an EML is discussed in Kuwait these differences should be 
considered and thus it may be the case that Kuwait develops its own definition.  
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 When contacting Kuwait Central Medical Stores, during the course of the 
Thesis study, who are the sole supplier of Public Sector Medicines, they 
responded by stating that the CMS have a link with Offices in London and the 
USA. These Offices deal with special cases and rare disease, the actual duty of 
these Offices is to order specific medicines for specific patients after going 
through the appropriate procedures. The medicines are then picked up from the 
suppliers quickly through a specific delivery company and immediately sent to 
the Health Centre in Kuwait for that specific patient. However at present this 
process doesn’t have a budget limit, it can be very costly and the regulations 
are not very specific.  It can depend solely on the discretion of the Head of the 
Office.  As has been indicated above it is another area which should be 
examined more closely and greater control actioned on the handle this process, 
with better written documentation and control.  
 This lack of control over prescribing in Kuwait is a wider issue than just 
for Orphan Medicines and is shown up in many of the requests and delivery 
processes in place in Kuwait today.  In particular practitioners are allowed to 
order any type of medicine, even if its safety profile has not been fully 
documented. Such practices are known to apply strains to the medicine budget, 
especially if a large percentage of the new medicines are very expensive.  
4.4.3 WHO Model list of Essential Medicines and Kuwait List of Medicines: 
 In this section there is a description of the differences found between the 
WHO Model List of Essential Medicines and Kuwait List of all medicines. 
 There are medicines widely used in Kuwait which, demonstrated quality, 
efficiency and safety but they are not available in the WHO model EML. For this 
reason it is proposed to be significant to look at prescribing statistics in Kuwait’s 
and medicine consumption rates when selecting medicines on Kuwait national 
EML.   
 The problem with this statement is that post-market efficiency evidence is 
not documented in Kuwait and the only way to reach this evidence is through 
practitioners and Pharmacists’ experiences. But this can be biased or not 
scientifically acceptable. Another option was to conduct a survey among 
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patients and compare it with the consumption rate of that particular medicine.  
But the problem could be that some patients might lack objectivity to provide a 
significant evidence of the medicines choices.  The reason could be due to the 
fact that some patients might be influenced by external factors, such as publicity 
campaigns to promote specific brand of medicines or the influence of fellow-
patients and follows their none-expert opinion on medicines and treatments 
preferences.   
 The table in the following page demonstrates some medicines that are 
on the WHO model EML and are not being used in Kuwait, and demonstrates 
other medicines being used in Kuwait which are not considered essential 
medicines by WHO., this type of table comparison might help in distinguishing 
the variances in the WHO Model EML and the health requirements in Kuwait. 
As mentioned earlier that the WHO Model EML is primarily presented with 
limited resources countries in mind, for this reason this list might not be suited 
as it is to Kuwait health requirements.    
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Table 4.8: Some examples of the differences between medicines on the WHO EML and the 
medicines used in Kuwait 
WHO EML Kuwait (common M) Only in KW (not on WHO). 
Senna deleted  
Charcoal, activated powder Only in private sector.  
potassium ferric hexacyano‐
ferrate(II) ‐ 2H2O(Prussian 
blue) 
deleted  
olefomepizole N/A  
sodium calcium edetate Not Available  
Anthelminthics (12 Medicines) Vermox (only one)  
clofazimine N/A  
ethambutol + isoniazid + 
pyrazinamide + rifampicin 
available Several combination available 
in WHO EML 
 
Capreomycin, cycloserine, 
delamanid, ethionamide, 
kanamycin, levofloxacin, 
linezolid, p‐aminosalicylic acid 
 Several anti TB combination 
and single compounds, 
Flucytosine (antifungal) N/A  
Antiretroviral medications (12 
medicines and 6 
combinations) 
 
3TC, 
Lopinavir+Ritonavir (Kaletra), 
Kivexa, 
Truvada, 
Efaverinz 200mg/600mg ( 
Stocrin) 
Etravirine 100mg (Intelence), 
Combivir ( 3tc+Azt), 
Abacavir (Ziagen) 
Atazanavir 200/150/ 100mg (3 
Strengths) 
Ritonavir 100mg (Norvir), 
Stavudine 40mg (Zerit), 
Tenofovir 300mg (Viread) 
Trizivir, 
(HIV )Rilpivirine, 
( HIV) Eviplera, 
(HIV) Maraviroc 300mg 
(Selzentry), 
(HIV) Darunavir) 
 
(HIV)Emtricitabine 200mg 
(Emtriva), Fosamprenavir 
700mg (Lexiva|Telzir), 
Amprenavir (Agenerase), 
Nelfinavir 250mg (Viracept), 
Neviapine 200mg (Viramune), 
Zidovudine 100mg (Retrovir), 
Gemifloxacin ( Factive) 
320mg, 
 
 
Anti-hepatitis 11 formulation and 
combination for Hepatitis 
Vaccine 
 
Diloxanide (Antiamoebic) N/A  
Miltefosine, Paromomycin, 
sodium stibogluconate 
(antiprotozoal) 
N/A  
Amodiaquine, artemether, 
artesunate, primaquine,   
(Antimalarial) 
N/A  
African trypanosomiasis 
treatment ( 8 medicines) 
Not available/ not required  
Japanese encephalitis 
vaccine 
N/A  
Source: the data were collected by the author from the WHO EML Library and Kuwait CMS drug 
catalogue  
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 As has been stated at the beginning of the Thesis, and based on the 
information gained from Kuwait MOH Central Medical stores, The State of 
Kuwait Ministry of Health does not have an exact form of Essential Medicines 
List.  The only record available is the Medicine Catalogue in an electronic form 
and this is available to the staff of Central Medical stores.  The comparative 
table above demonstrate the differences between the WHO Model List of EM 
and Kuwait Medicine Catalogue, and it’s evident that there are considerable 
variances between the two.  As has been said previously the reason can be 
explained in a way that the WHO works to target the less resourceful countries 
and these countries might faces challenges which are different from Kuwait, 
such as sanitation issues, lack of clean waters, malnutrition and some might 
suffer from a high level of HIV positive patients and differ in the none-
communicable diseases patterns. For instance, in the WHO model List, there 
are 12 different types of medicines to treat ringworm, whereas in Kuwait one 
type of medicines been regarded as sufficient.   
4.4.4 Kuwait M.O.H. Central Medical Stores Medicine Catalogue:  
 The following is a List of Medicines which is currently held within Kuwait 
and the Catalogue consists of 909 pages, and the pages are classified 
according to store number, and in accordance with the class of medicines or 
their usage.  
 There are 38 stores, which covers everything the M.O.H. requires in 
terms of medicines and medical appliances. The following are the numbers of 
each store and what it contains: 
 Store 01, Narcotic  
 Store 02, Injections 
 Store 03, Oncology 
 Store 04, Specialities 
 Store 05, Nutrition 
 Store 06, Vaccines 
 Store 07, Tablets 
 Store 08, Medicines for Diabetes 
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 Store 09, Surgical Dressing 
 Store 10, Intensive Care Anaesthesia 
 Store 11, Respiratory System 
 Store 12, missing 
 Store 13, Liquids & Chemicals 
 Store 14, Missing  
 Store 15, Forms and Lists 
 Store 16, Cardiovascular (largest with the most items) 
 Store 17, Sterilization Disposables 
 Store 18, Lab. Utensils 
 Store 19, Lab. Apparatus 
 Store 20, Lab. Analysis 
 Store 21, Lab. Liquids. INFL, Acids 
 Store 22, Lab. Media-Bacteriology 
 Store 23, Lab. Reagent-Cold Items 
 Store 24, Miscellaneous 
 Store 25, Dental 
 Store 26, Surgical Instruments 
 Store 27, X-Ray Films, Chemicals 
 Store 28, Orthopaedic 
 Store 29, Miscellaneous Disposables 
 Store 30, Sutures-Syringes-Needles 
 Store 31, Equipment’s Various Utensils. 
 Store 32, Psychotropic Drugs 
 Store 33, Dental Equipment’s 
 Store 34, Gases 
 Store 35, Artificial Kidney  
 Store 36, Reserved Items 
 Store 37, Insecticides 
 Store 38, Preparation Items 
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 The Kuwait Central Medical Stores deals with all health requirements for 
Kuwait, and the classification of each store is rather general, and would benefit 
from further justification of this arrangement.  
 It was indicated during the interview with the director of Kuwait CMS, that 
the actual running and logistics of the stores has being subcontracted out to a 
privately owned company called Agility Co. However there have been questions 
raised as to the value of this decision as the staff of this company, has limited 
medical or pharmaceutical experience. It has been suggested that the Store is 
been run on a format where the store keepers specific responsibilities being 
assigned to them by the medical staff at the CMS.  
 Therefore from the information found in the literature study so far there 
may be some concern for the choice, organisation, management, supply and 
medical usage of medicines.  These areas form the major topics in the research 
which was carried out. 
  In the following section, the medicine situation in Kuwait as found 
through this research is given.  As an initial part of the study the views of Health 
Professionals was pursued and the first research involved two questionnaires.  
These consisted of, a qualitative semi-structured interview protocol and an 
informal/conversational interview (no pre-set questions). The following is the 
outcome of this part of the study. 
4.5 Kuwait Health Situation 
 This stage is related to Kuwait Health; and is an introduction to help in 
understanding the actual medicine situation in Kuwait. Firstly a brief description 
is provided through the demographic of Kuwait, and includes a description of 
the healthcare system in Kuwait, including the pharmaceutical sector. It 
describes any available policy and future policies, the general budget of Kuwait 
MOH and the medicine budget changes over the years. In the last section of 
this chapter, the findings of the study conducted are included.  
 Kuwait is a small oil-wealthy country located at the Arabian Gulf; as from 
January 2016, the population of Kuwait was estimated to be 4 million, this is an 
increase of 4.79% from 2013. Two reasons caused this increase, one is the 
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reduced number of stillborn infants and the increased number of childbirths. The 
second, is due to an increase in the net migration for economic reasons. It was 
announced by Kuwait official resources that in 2015, 114 thousand people 
moved to Kuwait for work (Countrymeters, 2016). 
 This increase will possibly cause a strain on resources and services, and 
that includes Health and Medicines.  
 The ethnicity in Kuwait is very diverse, Kuwaiti people represents only 
31% of the population and the rest of the population are people who came to 
work in the country. Most of them are Asian at around 38% of the increased 
number, the next are the Arab workers which represents 28% of the total 
population. (The statistics for 2013 are provided by the U.S. Dept. of 
Commerce, 2015).  
 It’s important at this stage to discuss and explore the Kuwait Healthcare 
Public Sector. Kuwait is divided into six health districts: 
1. Al-Jahra Health District  
2. Hawalli Health District  
3. Farwaniya Health District  
4. Capital Health District  
5. Ahmadi Health District  
6. Al-Sabah Specialized Health District (Kuwait MOH 2016) 
The following map represents the geographical locations of these Health 
districts.  
172 
 
 
Figure 4.6: Kuwait Map demonstrating the various Health Districts 
 Some of the health districts in terms of land mass are very large and the 
reason is that Al-Jahra and Al-Ahmadi are less populated than the other Health 
Districts. Because of nature of the areas they cover and as they contain many 
of the oil companies, urbanization of these two districts has been found to be 
challenging due to the difficult geological structure of the sands and any 
buildings are generally very unstable.   
 The Healthcare Sector at Kuwait MOH is divided into three levels of care, 
the primary healthcare is represented by multiple polyclinics which are spread 
across the country and serve each region, the secondary healthcare service 
which is provided by the general hospitals, one in each health region and the 
tertiary system which consists of specialized healthcare hospitals, which are 
mainly located in Al-Sabah Region, which is the center for the tertiary health 
care region.  
 The treatment and health services are free for all Kuwaitis. But the 
expatriate’s in the country need to pay a yearly small health insurance fee to 
enjoy all the available health services.  They do however have to pay a small 
fee of one dinar equivalent to two pounds for admission to the  polyclinic, and  
double this fee to gain health support in the hospitals. But this small fee 
includes doctor visits, nurse care, medication regardless of the cost, and tests.  
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There is also a fee for expatriates when there is a need to use specialist 
medical services, such as MRI, but all other services are included in that small 
fee. 
 The system above was introduced; to try to reduce the number of 
unnecessary visits to the polyclinics.  Prior to the fee system being introduced, 
patients would try to bypass the polyclinic and aggressively demand 
prescriptions for ailments, even those of a minor nature such as a common cold 
medications or even minor pain killers.  Often their prime reason for doing this 
was to maintain a stock of these medicines for later use at home. But after the 
fee system was introduced the number of these patients has reduced 
dramatically. The introduction of the Fee payments also put pressure on the 
Medical Staff in the healthcare centers, because it led to a new problem of 
higher expectations of patients, who now suggested that because they are 
paying the fees they are entitled to get medication on prescription for all health 
problems, not just for the condition they are currently suffering from, but also 
medication for all future complaints. Because of these issues the Medicine and 
the overall MOH budget for healthcare did not reduce, but continued to increase 
(Kuwait FDA, 2015).  
 The following figure shows the increase in the MOH budget from 1995 
until 2013. 
 
Figure 4.7: Kuwait MOH Budget from 1995 until 2013 
 Sourced from Kuwait e-Government website: http;//www.e.gov.kw/ 
And U.S. Department of Commerce/ international Trade Administration 
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It’s evident that the Budget inflation kept on increasing strongly from the turn of 
the millennium, and there was a particular, large jump, in 2009 then continuous 
large inflation after that year. The Compounded Growth Rate (CAGR) is 
demonstrated in the following table  
Table 4.9: Kuwait The Compounded Growth Rate (CAGR) from 1995-2013 
Compounded Growth Rate % 
95-00 1.05 
00-05 7.59 
05-10 16.79 
10-13 15.65 
05-13 16.36 
95-13 9.48 
Sourced from Kuwait e-Government website accessible: http;//www.e.gov.kw/ 
And U.S. Department of Commerce/ international Trade Administration 
  
From financial forecasts (U.S. Department of commerce} carried out in 
recent years it is expected by projecting the statistics shown above, that if the 
Compounded Growth Rate (CAGR) stabilizes at 7% which is about average 
using todays increases, the budget of Kuwait MOH will be USD 18 billion by the 
year 2030. That is extremely large for a country with a relatively small 
population close to 4 million and such a financial cost is likely to cause serious 
probably uncontrollable strains on the MOH budget and the overall total 
government budget.   
 Therefore it is suggested to be important to look closely before major 
issues arise, by comparing the increase with the actual general budget of the 
state of Kuwait, and how they may fit together. 
 The following bar chart was sourced from the Kuwait Ministry of Health 
website (www.moh.gov.kw), it demonstrates how the MOH budget fits with the 
general budget of Kuwait from 1995 until 2013. 
 The bar-chart in figure 17 shows that the Government of Kuwait has kept 
the percentage of the budget allocated to the health services almost constant 
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Figure 4.8:  sourced by author from the official Kuwait Ministry of Finance 
data 
and the government of Kuwait is the sole funder of Kuwait MOH budget, the 
maximum it reached was 7.4% in 2010, and the least was in 2009 with 5.3% 
and 2007 with 5.2%. Therefore, the increase of the MOH budget was due to an 
increase in the total government budget, which is related to the oil situation and 
Oil revenue, what is meant by this is that when the Oil income increases the 
total government budget increase and vice versa.   
 
 
 
At this point, from the information above it is safe to say that the budgets 
of the MOH and for Medicines from the main Government budget are almost 
stable, but the main budget is the one that is inflating drastically, and it is this 
that needs control and deliberation. In other words it’s a national effort and 
serious studies and policies need to be operated to control future situations.  
 How has the problem been dealt with, the simplest method when oil 
revenues are high has been for the Government of Kuwait to attempt to 
enhance the health services has allocated a large amount of money which has 
particularly improved the healthcare centers. It has allocated 4.4 billion U.S 
dollars for the expansion of several secondary healthcare hospitals to keep up 
with the demands, and to provide more beds. 
 This move is a great attempt to provide improved health to the 
population, but there are other options such as giving the primary polyclinic 
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more authority to treat late stages of chronic diseases, rather than referring to 
them to the secondary healthcare hospitals and increase the pressure of 
demands. Looking closely at this move it is however suggested it would be 
better to encourage a number of initiatives, such as more preventive care rather 
than curative care, spending some funds to enhance the public awareness to 
health matters and educating them on healthy life choices should reduce the 
demands on the health services and provide a healthier population with suitable 
knowledge of healthy life choices. 
 Another way which could be used to try to enhance the health services is 
by trying to find and reduce the area(s) that drains most of the funds, and to try 
to come up with the most appropriate policy to overcome and control the 
situation. There are a number of areas where the MOH resources are being 
drained.  One major reduction could be a program to deal with the costs of 
treating Kuwaiti patients outside of Kuwait. This program has been very 
expensive and has caused a major strain on the budget.  Once the patient is 
back in the country, the costs have not however finished and the 
Pharmaceutical sector is responsible to provide that patient with possibly all 
kind of new medications some of which are very costly and may not have been 
fully studied post-market. This has been a very big additional cost on the 
Medicines budget. 
 Another source of MOH budget drainage could be from, what is known 
as the Visiting Visa Patients, those are non-residents and non- Kuwaiti patients, 
who travel to Kuwait to enjoy the almost free health services and gain access to 
very expensive medicines at the cost of one Kuwaiti Dinar which is an 
equivalent of two pounds only.  As a costly example some prescriptions for 
organ transplant patients might cost in the region of 500 Kuwaiti Dinar which a 
little more over a thousand pound, and the visiting patients can get access to 
these medicines for as little as only 2 pounds. It can be the case that these 
visiting non-Kuwaiti patients come to the country every three months for 
prescription refills. In some healthcare centers, these outside patients can 
receive a 6 months’ supply of medicines.  This leads to a very high cost for the 
MOH and it’s like the Kuwait medicine budget is not only allocated to the 
population of Kuwait, but it has also to cover the high cost of non-Kuwaitis who 
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only appear to come to the country to receive unlimited costly medicines.  In 
addition other international patients can get access to the service (Kuwait MOH, 
2015). These situations are of concern to the people in the MOH and to the 
people of Kuwait and it is suggested through this research work that it is 
something which needs further study and possible curtailment. 
 In discussions during the Thesis study it was indicated that the Kuwait 
MOH realizes that this situation needs to be resolved and have tried to find a 
solution.  One step taken was to increase the polyclinic admission fees for non-
residents to five Kuwaiti Dinar which is close to 10 pounds and for hospital visits 
it’s been increased to ten Kuwaiti Dinar which is equivalent to 20 pounds But 
against the actual cost the return is low and for outsiders it is an increase which 
is still worth paying to get the extremely expensive medication. Therefore, the 
problem is still there and was not discouraged by the administration of the 5 
KWD and 10 KWD admission fees.  
 Reflecting on the discussion above, it’s apparent that the budget inflation 
is to many aspects and from the information obtained through the research 
study there is a question around the lack of efficient planning and there should 
be considerations relating to management. It has been found that there are 
limited clear policies in place, and policies that in place often go into a holding 
format with every change of the Health Minister, which can occur regularly. A 
typical example was the launch of the Pharmacovigilance Department and the 
Medicine Index Department in 2013 and subsequent stalling of the work of 
these Departments in two policies that will be discussed later in the Chapter. 
 Following the fieldwork in Kuwait, it demonstrated that Kuwait’s 
Pharmaceutical Sector follows a very complex approach. This could be due to 
several factors but the several interviews carried out with senior managers at 
Kuwait MOH and Kuwait FDA it gave some evidence to an impression that, the 
Pharmaceutical sector lacks proper policies and follows very dated regulations 
that have not changed much over the years and has had many additions made 
to it, some might seem very contradictory to the original (Kuwait FDA, 2014).  
 Through on-site observation of the work carried out in Kuwait, it became 
noticeable that the staffs are following some regulations that are released 
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separately and not gathered in one written document. This has resulted in 
missing out on some of the procedures and causes the inability to make a full 
confidant decision, in case another declaration came out to cancel the current 
one they are already following, this information was gained following the field 
work conducted and after the interviews conducted with the Kuwait FDA staff 
that been assigned new roles to carry out new innovative policies but then been 
stopped pending further instructions.  
4.5.1 Medicine Registration Department: 
 Located at the Kuwait FDA building, it includes 12 pharmacists and a 
head of Medicine Registration Department. The duties of this department are to 
register new medicines by conducting a study on any new medicines that 
requires marketing in Kuwait, or a pre-registered medicine that had some 
changes. Another part of these department duties is to update the registration of 
already existing medicines. The department is also responsible for following any 
medicine errors that might come up post-market and the withdrawal of unsafe 
medicines.  
 The number of staff is rather small in comparison to the amount of work 
needed to be carried out; the result is a very slow productivity which causes 
frustration to the recipients.  
4.5.2 Deletion of Medicines or Withdrawal of Defected Batch or 
Manufacturing Error 
 Kuwait Food and Drug Administration (Kuwait FDA), is responsible for 
the detection of any medicine errors post-market, there are several reasons why 
a medicine or a batch of medicines may need to be withdrawn. The following 
are some of the reasons as described by the staff at the drug registration 
department at Kuwait FDA: 
- Applying changes without obtaining the right licence, such changes are 
as follows; 
 Changes in one or more active ingredient(s). 
 Addition of new active ingredients. 
 Removal of any existing active ingredients. 
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 Changes in quantity of any active ingredients  
- The manufacturing company may have detected some fault, vulnerability 
or defect and sent a request of withdrawal for the medicine or a specific 
batch of medicine from the market. 
- They may have received a warning from the WHO for specific medicines 
for being troublesome, or problematic. 
- They may have received a warning from the USA FDA or EMEA to 
withdraw a specific medicine after post-market use. 
 Once the warning is received or the announcement is made by the USA 
FDA or EMEA, the medicine should be suspended and a recall sent out. This is 
followed by a meeting at Kuwait FDA to determine the extent of the problem 
and what is the right course of action that needs to be carried out. Once this is 
done, the action can lead to either temporary withdrawal until the problem is 
resolved or a permanent withdrawal and total cancelation of the product license.  
 There is a division within the Kuwait Medicines Registration Department 
that deals with such situations, entitled the Quality Assurance Department, and 
they carry out daily searches of the FDA and EMEA sites to explore any new 
problems or warnings.   
 However the Kuwait FDA generally depends solely on the 
announcements made internationally and has no type of an internal national 
system to follow the medicine situation locally.  The issues around this practice 
is that Health Regulators in different countries and different ethnicities react 
differently to medication, what might be considered as safe to one community it 
might be hazardous to another and vice versa. Although the Kuwait FDA has 
realise the importance of having a suitable monitoring system and has tried to 
come up with some solutions and the following describes the attempts that have 
been made by Kuwait FDA to organise the medicine situation in Kuwait.  
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4.5.3 New Policies  
 From the information gained during the study and experience as a 
managing pharmacist, new and younger pharmacists, many of which have been 
educated outside the country, are suggesting a number of developments to 
enhance the standards of the Pharmaceutical sector.  These include 
suggestions to modify the current structure and make it comparable with the 
surrounding countries who have more developed structures and with the more 
developed countries.  It’s now quite typical in Kuwait within the Health Groups, 
to see a very high level of excitement and encouragement once a suggestion of 
new policy comes up.  But unfortunately the level of excitement can drop down 
quickly with time.  The result is often that the new Policy stays pending with no 
direct order to proceed (Kuwait MOH, 2013). The following are examples of two 
important policies that are long overdue and have come to a halt.   
4.5.4 Pharmacovigilance Department  
4.5.4.1 Interview with the Head of Pharmacovigilance Department in 
Kuwait FDA 
Following the fieldwork visit to the Kuwait Food and Drugs Authority, and 
the Medicines Registration Departments, one of the areas of concentration was 
to discuss Policy Development through a closer inspection, with regards to two 
policies that are supposed to be of added value to the pharmaceutical sector in 
Kuwait.  The interview with the Head was carried out with the pharmacist in 
charge of the Medicine Index Policy and then later the discussion moved onto 
the Pharmacovigilance Policy. 
The interview was initially non-formal, and more of a conversational 
interview without prepared questions, but had a specific purpose in mind. The 
purpose was to find out the several types of policies available at Kuwait MOH, 
the process of launching new policies, and policy adaptation and 
implementation.  
 The outcome of the interview which gives an example of the lack of full 
development of ideas for improvement in Policy and Operations was as follows: 
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The Pharmacist stated,  
“The Department is five years old but the number of staff is only two and 
they are in reality not following the international guidelines”  
And further added that,  
“They are waiting for new operation regulations that follows the 
international guidelines.” 
The Department which is actually named the Quality Assurance 
Department was then changed into the Pharmacovigilance Department, the 
person who was to develop the Department was given the approval from his 
Senior Colleague to start the Department but no actual plan has been agreed 
which relates to the structure of the Development and on the duties to be 
carried out and there has been no discussion of the expected contribution to 
general health.  
The MOH did not focus on the development of the Quality Assurance 
Department and the later changed into the Pharmacovigilance department, The 
Ministry of Health in general and the none-pharmaceutical senior managers at 
the ministry of health, thinks that medicine quality assurance can be tracked by 
other departments.  
 It could be suggested that the Pharmacist should have been more pre-
active in developing a Plan.  However from the interview they gave the reason 
for not having an operation plan by stating, 
“It’s assumed that we are waiting for the Arabic Standard Guidelines on 
Pharmacovigilance to follow from the proposal, but nothing has been 
announced yet.” 
However, although the duties of the two-staffed Department are not yet 
fully assigned, from the interview it was clear that they have started to plan and 
are effectively using their own initiative, although the direction followed may be 
unstructured and have assigned some non- official duties to themselves. These 
includes a check daily on-line for any announcements of adverse drug reactions 
from International Pharmaceutical Companies, and in addition have the self-
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assigned responsibility of checking the USA FDA announcements for medicine 
label changes or warnings on issues such as side effects.  This job is already 
scheduled to be done by specifically assigned staff members at the Medicine 
Registration Department.  Thus there is an indication of inefficiency through the 
clashing of duties between two Departments and the interpretation is related to 
the fact that the Pharmacovigilance Department staff has no written job 
description.   
 However although the  aspect carried out above does need resolution 
there is one job being done, which is actually related to the duties of this as yet 
non-structured  sub-section of the Quality Assurance Department, and that is 
the production of a newsletter that carries any instruction or special 
requirements for any medicine. Example of these requirements can be a form of 
instructions to the prescribers to perform pre-testing or post-testing of patient’s 
vitals after taking certain medicines that has a narrow therapeutic window or 
medicines with narrow safety profile, or instruction for medicines that changed 
in quality or have new safety profile.  
 Although this newsletter is sent to all healthcare facilities and centers at 
all levels, the Department still remains anonymous to most pharmacists at 
Kuwait MOH, this was observed when contacting various pharmaceutical 
department at the three level of healthcare in Kuwait and the response of the 
staff where lack of awareness to the newsletter. This might propose that this 
Newsletter work is unclear or inaccessible to the relevant audience. 
The department staff further adds that,  
“Kuwait has no local postmark vigilance, in Kuwait, it all depends on 
international warnings and instructions” 
  This is a problem because each country has its unique genetic 
disposition and react differently to medicines, therefore; what is harmless to one 
specific genetic profile isn’t necessary safe to another.  
 One important statement declared by the pharmacovigilance pharmacist 
is that, 
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“This department is not efficiently performing because of lack of ministerial act, 
if one strong ministerial act comes out, it will be required by law to have specific 
duties for this department and it will perform better” 
 The interviewed staff mentioned that they are ready to take the job 
especially that they are trained and attended a number of workshops and 
presentations from private companies.  
 This is one example of an innovative policy paused for several reasons 
that will be discussed later; the next policy is having a drug index with the main 
objective of having a more organized process of classifying medicines in 
Kuwait.   
4.5.4.2 Kuwait Drug Index 
 The Drug Index plan started around the first quarter of 2015, two 
pharmacists have been selected to carryout feeding the hard-copies of drug 
monograms into a computer programme. The work has slowed down a bit and 
one of the allocated pharmacists has been moved to a new division, this might 
be an indication that the enthusiasm towards the programme and the support 
has been lost, the deficiency of interest in the Drug Index plan was observed 
following the in-charged staff comments stating that, 
“The Drug Index plan, was not discussed anymore in meetings, and no further 
instructions were given to keep going” 
 There is another issue that caused this policy to slow down. This issue is 
that the pharmacists involved have not been given any form of written 
guidelines or procedures to follow, and no training on the concept of a Drug 
Index design or medicine formulary guidelines. All they got instructed to do was 
to feed a computer package with monograms of medicines without any thought 
to the process. With such unplanned protocol, it might be expected for the 
policy to pause awaiting instructions, the two staffs’ in-charge of the Drug Index 
did ask for training and further instructions but still waiting for a reply from the 
head of the department.     
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 It seems, from these two attempts to enhance the medicine situation at 
the State of Kuwait MOH, that the process of implementing had not in these 
cases has not been efficiently planned and not for various reasons been 
supported by the strong decision makers to ensure its continuous execution.  
 Although these examples are only two, from experience and from the 
other interviews and during other  fieldwork, it could initially be suggested that 
there may  need to be more direct attention to the development of proposals 
which on the face of it appear to be important initiatives within the MOH. For this 
reason, it is proposed that it may be significant to include the support of high-
level decision makers at Kuwait MOH and to be more organised and have a 
general plan for policy implementation across many facets of the MOH 
administrative service.  With such a structure in place, it could be believed that if 
the new policy is proposed and gets support, then there should be a structure to 
support the development with a strong steering group which should improve 
and might enhance its success rate Furthermore, leading from the study carried 
out here it might be worthwhile to look more closely at the training and 
experience required to carry out such developments and to use experienced 
people, possibly from outside of Kuwait to conduct an initial detailed study, to 
add positive value to the new policy undergoing implementation.  
 The following is a description of 6 interviews that been conducted with 6 
Health Executives at various levels of management. The section describes the 
interviewees’ views on the EML concept in general and what they might think is 
a suitable process of implementing EML at the state of Kuwait. The choices of 
the participants at the interviews were based in the strong leading role of the 
participants in managing the Ministry of Health pharmaceutical sector and the 
broad knowledge in health managements and development, it is expected that 
the participants might be the individuals that can provide a useful and 
meaningful data to any health related innovation.   
4.5.5 Thematic Analysis of 6 Senior Health Executives Interviews.  
This section includes the description of 6 interviews carried out with 
senior managers at the Ministry of Health in Kuwait and one from Kuwait 
University, Faculty of Pharmacy. The participants were selected based on their 
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important part in the procurement of medicines and their decision-making 
strength in the medicine selection process.  
 
 The transcripts and field notes were imported into the qualitative analysis 
software package N-Vivo for coding and data management. The prime aim of 
using this software is to organize complex research data into different segments 
to carry out a complex search to meet the aims and objectives of the research. 
However, this is not an interpretative device and thus the interpretation of the 
data is carried out after organizing the data with the aid of this device. It is used 
to work effectively with extensive data and a suitable coding scheme. 
 
4.5.5.1 Generation of Themes and Coding 
 
 The themes were generated by using the template analysis procedures 
and the broad themes identified for the research were named as codes. Each 
broad theme was analysed with the help of data provided by the participants of 
the interviews. The codes used for the study were meaningful, regarding the 
research objectives and questions. The codes that were created for this study 
are concepts, feasibility, gains, and drawbacks. The participants had a broad 
range of views on the concept of Essential Medicines.  
 
4.5.6 Understanding the Concept of Essential Medicine List.  
 
 The responses in regards to the concept of EML in general were 
somehow similar, all the participants answered that they have gained sufficient 
knowledge about the concept of the essential medicine and the benefits of 
implementing this concept in the medicinal field. In addition, they also have the 
information about the benefits achieved through implementation of this program. 
However, two participants noted that the principle is semi-available in Kuwait, 
those were the undersecretary of medicines and medical appliances and the 
undersecretary of development and quality at Kuwait Ministry of Health. This is 
understandable for individuals of that level of management not to declare sides 
or views before getting a grasp of the complete topic.   
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4.5.6.1 The View of the Concept of EML in Relation to Kuwait Health 
Situation. 
 
The general view was that the concept is excellent but it needs to be 
implemented carefully; there were some differences in the responses,  
Dr. Omar, who is The Assistant undersecretary of Pharmaceutical and medical 
appliances expressed his thoughts in the concept as follows;  
 
“It’s a list of Medicines with fewer items and more focus on generic medicines. 
It’s very similar to what we practice in out pharmaceutical services, but we 
established the system our self’s” 
 
In Dr. Omar statements, he focused on the fact that EML encourages 
Generic medicines but he further added that the Pharmaceutical sector has a 
similar system, it does demonstrate a basic understanding of the concept but 
the EML does not only focus on Generics it goes further to includes some 
relatively high cost-effective medicines that Dr. Omar didn’t get grasp of it fully, 
it is understandable since the concept of EML is not available in Kuwait and this 
was the first time Dr. Omar get an idea about it, therefore in Dr. Omar statement 
that the system is similar to what is already present in Kuwait is not very 
accurate.   
The second interviewee was DR Al-Falah, who is the Assistant 
Undersecretary of the Ministry of Health for the Planning and quality Affairs 
thought that the concept of EML is; 
 
“I think that the concept is suitable to my Department which is Planning and 
quality Affairs” 
 
The response represents a link between Dr. Al-Falah department with 
the innovation process and since Dr. Al-Falah is not related directly with the 
medicines procurement, he was unable to give a clear indication of the EML 
concept in details but managed to find the link of the EML to its Department 
duties in relation to enhancing the quality of health services and he believed 
that the EML will fit well with his department work. 
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 The third interviewee was chosen based on his work in academia and 
might be the first introduction of the system to young pharmacists if the system 
get implemented, Dr. Waheedi is the Associate dean of the Faculty of 
Pharmacy, Kuwait University, his thought on the concept were very 
methodological and his statement was as follows; 
 
“It’s a national drug list, updated every two years” 
 
 His response was very brief, precise and practical at this early stage of 
the interview. He did not comment further on the EML concept benefits but he 
further explained it at a later stage of the interview that will be quoted later in 
this chapter under different theme.  
 The fourth participant was Dr. Al-Qattan, who works as the Head of 
Specialties Drug section at Kuwait CMS. His response was very brief only one 
word, this could be because he was extremely busy and there were several 
interruptions to the interview that was impossible to control, his response was;  
 
“Excellent” 
 
 The response doesn’t ensure his clear understanding of the concept, but 
it might indicate that he think it’s a suitable mean to innovate or maybe be he 
doesn’t fully acknowledge it and gave a brief comment, when the interviewee 
were asked to elaborate, he did not add any further comment.  
   
 The fifth interviewee was selected based on his position in a tertiary 
healthcare and direct interaction with medicine supply and procurement, he was 
the Head Pharmacists of Psychiatric Hospital, and he thought in his own word 
as follows; 
 
“Good, saves money if fully applied, transparency is a must” 
 
 The response establishes a broad understanding to the concept and 
being able to express the fact that implementing EML requires transparency is a 
good indication to the desire to innovate and minimize medicines corruption. 
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 The last participant Pharmacist Asma Al-Mutairi was preferred because 
of her work with the primary healthcare level and she is directly involved with 
the procurement and usage of medicines and because the primary healthcare is 
the first level that deals with healthcare recipients. Her thought on the concept 
were as follows; 
“Good, enhance pharmacist role in healthcare” 
 
 The response is interesting and referred to a further positive role to the 
pharmacist in healthcare, this could indicate the well to be more active and the 
desire to enhance healthcare.  
 
4.5.6.2 The Views on the Possibilities of the Implementation of EML 
 
The code of this section was Feasibility and it was noted that hesitancy 
was present, and most of the interviewees had concerns, the general theme 
was that it is possible but requires support at a higher level and needs a 
ministerial act.  
Dr. Omar thought that; 
 
“The regulations in the ministry of health are very rigid and will hinder the 
application of this system, we need new law to start the policy and getting new 
law in place is very difficult. 
Such policy need to get the approval of the government National 
Assembly (the Parliament) that’s a very long process then needs to be passed 
to the Ministers Council once both approved the law will be stated then it’s in 
the hand of the Minister of Health to regulate it and draw the plan to its various 
sections.  
A special ministerial decree need to be declared from the legal 
department at the Ministry of Health then it has to go through a committee to 
implement it.  
In short, it’s very long, very exhausting and time consuming process”  
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The response is important, it gives directions to what might be expected, 
to carry any new policy work, and it states that a lot of time and efforts are 
expected.  
 
Another high-ranking interviewee Dr. Al-falah thought; 
 
“It requires time and careful deliberation of the whole concept and need 
very careful planning. It will make a lot of doctors feeling restricted.” 
 
 
This comment was shared with CMS staff Dr. Fahad, who deals with 
physician requests daily; his statement was as follows; 
 
“Doctors work in a different way; they will question the withdrawal of 
some drugs and will protest against the limitation to the drugs they are allowed 
to prescribe” 
   
 This is another important matter that requires to be included in the plan, if 
the EML of Kuwait get adopted, it requires to include physicians during the 
course of the implementation. This type of involvement might help in easing the 
way to introduce the concept; it might be useful to gain the support of the 
physicians early to enhance the success rate of the concept.  
 
Another important thought, stated from an academic point of view by Dr. 
Waheedi when he was asked whether he thinks that the EML concept can be 
operational at the MOH, his response was; 
 
“Probably yes, with concerns being that the MOH committees when under 
taking an assignment they tend to take it as an administrative task rather than 
scientifically based” 
 
Dr. Waheedi stated an important thought that requires to be considered if 
the EML concept get implemented, and medicine selection process and 
medicines policies in general requires the support of a sound scientific 
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background and good pharmaceutical experience for it to be efficient, basing 
the work on administrative staff might not be a good way to go.   
 
4.5.6.3 EML Gains 
 
 The response was almost unanimous; all the respondents thought it will 
control cost, enhance medicine access and provide rational drug use.  
The CMS staff had further thoughts;  
 
“Save on cost, saves on storage spaces, saves on paper work, decrease drug 
error, decrease doctors’ confusion towards the massive medicine list and 
makes them more aware of the medicines available. Focus on good quality 
medicines and eliminate low quality. Prevent stacking of a lot of different 
generics” 
 
Dr Essam of the tertiary Health centre, thought that;  
 
“Control Medicines prices, control counterfeit medicines, patient satisfaction 
with the availability of treatment, pharmacist familiarity and knowledge with 
medicines will increase. Doctor / pharmacist work relationship will be easier and 
better, because everyone knows its place and role. This will lead to better work 
ethics and increase the standards of work” 
 
 The statement by Dr Essam includes an important advantage to be 
considered, which is medicine knowledge enhancement and improved trust 
between doctors, pharmacists and patients, this kind of trust between the 
healthcare providers and healthcare recipients is always an improvement, and 
the harmony in the interaction might results positively on the general health.   
 
 Reviewing the responses, each respondent saw the impact to their actual 
work and related the concept to it, this is a constructive way of looking at the 
concept, it might demonstrate an initial acceptance to the concept and 
willingness to move forward in the healthcare services.     
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4.5.6.4 Drawbacks of the EML 
 
 The responses in regards to the drawbacks and interruptions that might 
cause an complication while implementing the EML concept in Kuwait was 
diverse, but each interviewee regarded the obstacles from own experience and 
how it relates to the interviewee work field, the main difficulty felt by most 
respondents is the resistance from the local big pharmaceutical companies; the 
following quotation from Dr Essam presents this finding; 
 
“Wholesalers will have concerns” 
 
Dr. Al-Falah had a similar but broader view on the matter, his statement were; 
 
“Very difficult to change the current culture and the current system has been the 
same since the beginning of the Pharmaceutical services, I expect there will be 
a lot of resistance but it’s achievable” 
 
 Both participants shared concerns in regards to the resistance to the 
concept, it is understandable concern and might be useful to figure out what 
might cause an impediment to the concept at an early stage, it is believed that 
by doing so, it will help to be ready for any upcoming opposition during the 
introduction, adaptation and implementation of the concept.   
 
 Another view was common along some of the participants, the fact that 
the process might take a long time; 
Dr. Omar stated,  
 
“The law enforcement is very long process, and the minister of Health frequently 
changes that might bring the whole policy to a halt, when a new Minister of 
Health get appointed” 
 
And Pharmacist Asma also held similar thought to Dr. Omar; the following is her 
statement;  
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“Difficult to implement, takes long time and efforts” 
  
 The view shared by Dr Omar and Pharmacist Asma are significant, and 
it’s predicted that a concept with a large scale would requires time to be 
implemented effectively. 
       
 In the other hand, Dr. Waheedi had a different view on the matter, he 
focused on the healthcare providers and healthcare recipients and his 
statement was as follows; 
 
“Mainly felt by physicians, and patients. Patients usually have high expectation 
for treatments received and the whole healthcare experience” 
 
 Dr. Waheedi intended in his statement that the downside to the EML 
concept in his own view and based on his limited knowledge of the concept, 
might be felt by the healthcare recipients and healthcare providers more and the 
reason could be explained by the fact that both would like a full and extensive 
list of medicines to choose from, in reality this practice can be viewed as 
inappropriate, and multiple-prescribing of different medicines under similar 
therapeutic class could be unsafe. 
 
 Dr. Fahad from the CMS, had different view on the matter and he thought 
that there might be a major disadvantage to the concept if it gets implemented, 
the reason in his opinion that the concept encourages generic medicines and 
since the generic manufacturing companies are able to deliver the supply faster, 
he worries that the end results might be all generic medicines and no branded 
medicines at the CMS. His statement was as follow; 
  
“Larger branded company takes long time to supply, generic manufacturers are 
faster and cheaper, therefore, CMS buy generic. Generics are more variable 
and reliable. The CMS Will end up with generics medicines only. 
Senior MOH managers will resist the implementation” 
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 It is true that the EML concept encourages the procurement of quality 
generics, but it doesn’t limit the medicine selection to it. What Dr. Fahad has 
stated is an important point that requires consideration, if the EML concept get 
adopted and implemented at Kuwait MOH, it might be wise to include some 
criteria on the medicine selection procedure to distinguish when it’s preferable 
to select generics and when it’s more appropriate to select branded medicines. 
Another impression coming out of this statement is that there might be 
important to have written and clear procedures to follow during the process of 
implementing the EML concept. This practice of having clear and well-written 
documents might help in clearing confusion on medicine selection and it can be 
considered as being a well-planned reference to refer to when making decisions 
relating to the EML.    
 
 Overall, the disadvantages or what might make it difficult to operate the 
EML concept efficiently came down to the long managerial process of getting 
the concept approved, then the fear of not being able to follow it up 
competently, the resistance from the healthcare providers and recipients, from 
the high level management at the MOH and from the major pharmaceutical 
suppliers at Kuwait.  
  
 It’s important and valid points and it might be useful to carefully 
deliberate on them and take these thoughts in consideration, if Kuwait MOH 
decided to adopt the concept of EML.  
  
 The last two points that were part of the interviews were related to 
whether the interviewee like the EML concept to be present in Kuwait and if that 
was the case would they like to take part in the process.  
The responses were as follows 
 
4.5.6.5 Implementing EML in Kuwait and Being Part of the Process 
 
 All participants agreed on implementing the EML and would like to take 
part in the process. The Assistant Undersecretary of the Ministry of Health for 
the Planning and Quality Affairs stated  
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‘I would like to see it implemented but it requires a specific modification to suit 
Kuwait health’ 
 
 This a very reasonable thought and it demonstrated deeper 
understanding of the concept. On the other hand, the Assistant Undersecretary 
of Pharmaceutical and Medical Appliances stated that; 
 
‘A big policy such as the Essential Medicine List will require the appropriate 
committee to get it operational and that must be chaired by the relevant 
Undersecretary, and in this case will be the Undersecretary of Pharmaceuticals.  
After all, if anything goes wrong or any inappropriate decisions are made I will 
be responsible for it.’ 
 
 This is a very important addition and gives an idea of the local protocol 
that needs to be followed in order for the EML to be launched.   
 
 The outcome of the interviews were positive, with concerns of resistance 
from various stakeholders, such as drug companies, physicians with particular 
interest to specific treatments, patients thinking they are receiving a poor quality 
of medicine when they get prescribed generic medicines and other people who 
loses financially from such a concept. The overall thought is that, all support the 
concept but apprehensive that it might get diffused and halted like previous 
policies that didn’t get implemented correctly and didn’t follow the most 
appropriate method of execution.  
 
 The following part is relating to the medicine situation in Kuwait, it will 
include the outcome of the two questioners carried out in Kuwait; the first 
questionnaire was conducted to extract knowledge of the overall medicine 
satisfaction level at the public sector in Kuwait.  
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4.5.7 Kuwait Medicine Situation Evaluation 
 
 83 participants were involved in the evaluation of the medicine supply 
system questionnaire; the following table represents the different professions 
that took part in the questionnaire.   
 
Table 4.10:  Job title of the participants  
 Frequency Percent Valid Percent Cumulative Percent 
Valid Physicians 27 32.5 32.5 32.5 
Academic Staff 7 8.4 8.4 41.0 
CMS Staff 8 9.6 9.6 50.6 
Public Pharmacist 41 49.4 49.4 100.0 
Total 83 100.0 100.0  
 
 The population of the study chosen based on their direct involvement 
with the medicine supply cycle. The questions within the questionnaire were 
aimed to view the degree of satisfaction towards the current medicine supply 
system and try to identify what issues the health professionals might have with 
the system. For this reason, different levels of work experience were chosen to 
ensure diversity in opinions and the following table represents the range. 
 
Table 4.11: Work experience 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 1-5 Years 21 25.3 25.3 25.3 
6-10 Years 31 37.3 37.3 62.7 
over 11 years 31 37.3 37.3 100.0 
Total 83 100.0 100.0  
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Figure 4.9: the percentage of participants work experience 
 The majority of the respondents had work experience of over 5 years, 
this is important to ensure a valid view and good knowledge of the current 
medicine situation, but it is still important to include the younger healthcare 
providers to view their ideas and get younger and fresher thoughts.   
 
 Looking at the level of satisfaction with the medicine supply system at 
Kuwait MOH, almost half of the participants were unsatisfied with the current 
system, and 56% thought that there is room for improvement to the regulations 
and the system.   
 
 
Figure 4.10: Bar chart to demonstrate the participant’s satisfaction with the 
Medicine supply cycle at Kuwait MOH. 
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Table 4.12: Satisfaction with MS 
 Frequency Percent Valid Percent Cumulative Percent 
Valid Yes 22 26.5 26.8 26.8 
No 47 56.6 57.3 84.1 
No Comment 13 15.7 15.9 100.0 
Total 82 98.8 100.0  
Missing 999 1 1.2   
Total 83 100.0   
 
 The previous bar-chart and table 22 shows low level and almost lack of 
satisfaction of the current medicine supply situation, this condition is alarming 
and requires a serious stand and deliberation, there is a need to understand the 
reason behind such a response and since half of the staff at MOH that took part 
in the questionnaire have concerns with the medicine situation, the question at 
this stage is why nothing has been done about it.  
 
 This state of dissatisfaction with the medicines situation might 
demonstrates a level of lack of communication between the clinical staff who 
are dealing with health and medicine affairs directly and the administrative staff 
at Kuwait MOH, as they are not capable of resolving the concerns causing the 
clinical staff to be unsatisfied with the current medicine situation. This attitude 
was apparent when 60% thought that there is room for improvements within the 
MOH Medicine regulations. This response is demonstrated in the following bar-
chart and table 24. 
 
 
 
 
Table 4.13: How well regulated the MS 
 Frequency Percent 
Valid Not well regulated 19 22.9 
Appropriately regulated 5 6.0 
Room for improvement 50 60.2 
No Comment 9 10.8 
Total 83 100.0 
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Figure 4.11: Bar chart to demonstrate the participant’s thoughts on the regulatory 
statues of the medicine situation at Kuwait MOH. 
 
 From the results obtained above it is clear that there are very few 
number of health professionals who are involved directly with medicines that 
think the medicine situation is well regulated. This outcome complements the 
previous results; it’s obvious that the medicine situation is inadequate in the 
view of the healthcare providers that took part in the survey. Such situation 
might cause the staff to be distressed and work in a very sub-standard 
environment. The outcome of working in poor work environment could be an 
unsatisfactory healthcare regardless of the strength of the human resources, if 
the regulations and policies are not robust; the strength of the workers is 
inadequate to provide a suitable level of healthcare.   
 
 At this point a serious system of organisation might be useful, and 
supporting the healthcare system with strong regulations to ensure its 
endurance and operation could be of added value to enhance the overall health 
of the population.    
 
 When the EML concept was explained to the participants, almost all the 
participants strongly agreed on the establishment of an EML in the State of 
Kuwait. Only 4.8% had no strong feelings towards EML.  
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Figure 4.12:  Respondents Views on the EML concept Bar-Chart 
 
Table 4.14: View on EML 
 Frequency Percent 
Valid Strongly agree 49 59.0 
I agree 30 36.1 
   
No strong feelings 4 4.8 
Total 83 100.0 
 
 
 
A cross-tabulation was carried out to compare the experience level 
against the views on EML, the reason for this cross-comparison is to establish a 
connection between the level of experience and the desire to innovate, it is 
believed that the more experienced healthcare providers would be more aware 
of the healthcare system and the medicine situation and might be able to 
provide a meaningful data to help in understanding the medicine situation 
efficiency at the state of Kuwait, the outcome of this cross-comparison is 
demonstrated in the following table and Bar Chart. 
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Table 4.15: Work experience against View on EML Cross-tabulation 
 View on EML 
Strongly 
agree 
I 
agree 
No strong 
feelings 
Work 
experience 
1-5 Years Count 10 8 3 
% within View on 
EML 
20.4% 26.7% 75.0% 
6-10 Years Count 20 10 1 
% within View on 
EML 
40.8% 33.3% 25.0% 
over 11 
years 
Count 19 12 0 
% within View on 
EML 
38.8% 40.0% 0.0% 
Total Count 
 
49 30 4 
     
 
Figure 4.13: Cross-comparative bar-chart for the views of EML against work 
Experience 
 
 The Cross-Comparison demonstrated that the less experienced health 
professionals are the ones who couldn’t form a complete opinion towards the 
EML concept, whereas the group that served over 11 years made an opinion 
that either agreed or strongly agreed with the concept, this response can be 
justified by the fact that the more experienced healthcare providers are more 
aware of the medicine situation in Kuwait Healthcare public sector and can form 
a solid opinion, in the other hand the less experienced staff might be less aware 
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and don’t have a broader awareness of the medicine system, and that might 
explain the reason behind their response.  
 
 The next part of the questionnaire tried to view what the healthcare 
providers thoughts on generics, because EML encourages the utilisation of high 
quality generic medicines, the prescribers were asked in what situations would 
they be willing to prescribe generic medicines to their patients. The responses 
varied, each prescriber saw it from a different perspective, the outcome of the 
thoughts on generics were described on the following table and bar-chart. 
Table 4.16: Generic prescribing (Dr Only) 
 Frequency Percent 
Valid Always 3 3.6 
If patient happy to take it 10 12.0 
If no brand 13 15.7 
sometime 1 1.2 
Total 27 32.5 
Missing 999 56 67.5 
Total 83 100.0 
 
 
Figure 4.14: Participants prescribing protocol in relation to Generic medicines. 
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 The responses to the question were that the prescriber that took part in 
the questionnaire, will only prescribe generics based on patient choice and if 
there were lack of the branded medicines; and thus these are the two main 
situations in which the prescriber would recommend generic medicines to its 
patients. 
 
 This type of prescribing practice demonstrates that even doctors are not 
fully agreeing on prescribing generics and this needs further investigation to 
understand their rationale for such practice. But generally speaking, generics 
has a bad reputation among patients who think that generics are of less quality 
than branded medicines; this assumption is based on the fact that the cost of 
generics are a lot less than branded medicines.  
 
 Generic medicines are defined by WHO as ‘a pharmaceutical product, 
usually intended to be interchangeable with an innovator product, that is 
manufactured without a licence from the innovator company and marketed after 
the expiry date of the patent or other exclusive rights’ (WHO.2016). Basically, 
the generic medicines have the same active ingredient as the branded 
medicines, but have different product names and different inactive ingredients, 
the results have different excipients. The generic medicines could have a 
different texture, appearance, taste or even smell from the branded equivalent. 
Such changes make patients doubt the quality, and they refuse to comply with 
the treatment. This doubt of generic medicine quality might be due to lack of 
proper patient education; it’s an important matter that needs to be considered 
when implementing EML. Otherwise, patients will refuse the choices of 
essential medicines on the EML and that would lead to failure in the 
implementation process.  
 
 Looking at the results of the questionnaire, it’s clear that there is almost 
an agreement on the dissatisfaction level with the medicine supply system 
among the health professions who are directly involved with the medicine 
supply cycle. The health professions appear to think that there is an immediate 
need for reregulating the medicine supply system. Almost all the participants 
thought that the implementation of an EML would have a positive influence to 
203 
 
the medicine supply system. One finding, which should raises concerns, was 
the fact that generic prescribing is not very popular and it would only be carried 
out in the case of a lack of branded medicines.  
 The next segment will include the findings of the Standard Treatment 
Guidelines Questionnaire. STGs are a very important tool that supports the 
essential medicines selection process, for this reason it’s important to learn the 
available guidelines.  
4.6 Standard Treatment Guidelines (STGs) Questionnaire 
 The questionnaire was designed to view the STGs being currently 
followed at Kuwait healthcare facilities. This is prepared because the medicine 
selection on EML should conform to STGs being followed. For this part of the 
research work, 90 medical doctors were surveyed, the study included multi-
centres, varied almost evenly, between primary, secondary and tertiary 
healthcare facilities. Almost half of the participating doctors had 6-10 years’ 
work experience.  
 The following table represents the distribution of the questionnaire 
participants according to their work place.  
Table 4.17: healthcare facility type Frequency Percent 
Valid primary healthcare facility 26 28.9 
Secondary healthcare facility 30 33.3 
Tertiary Healthcare Facility 34 37.8 
Total 90 100.0 
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Figure 4.15: The distribution of the participants over the three level of healthcare at 
Kuwait MOH 
 
 Most of the participants had 6-10 years’ experience and the rest are 
divided into those with less than 5 years and over 11 years. The following table 
and chart represents the distribution of the participants. 
Table 4.18: Work experience 
in years 
Frequency Percent 
Valid 1-5 Years 22 24.4 
6-10 Years 42 46.7 
11 Years 26 28.9 
Total 90 100.0 
 
 
 
 
 
 
 
 
Figure 4.16: participants work experience distribution  
 The awareness level of the existence of STGs was 85%, very high, but 
it’s very worrying that there are a few doctors who were unsure or had a slight 
awareness of the available STGs, the question at this stage is what are the 
treatment protocol the unaware doctors are following and how are they treating 
the patients.  
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Figure 4.17: the participant’s level of awareness with the existing of STG 
 
 
Table 4.19: STG awareness 
 Frequency Percent Valid Percent Cumulative Percent 
Valid Yes 76 84.4 84.4 84.4 
Not Sure 8 8.9 8.9 93.3 
Slightly aware 6 6.7 6.7 100.0 
Total 90 100.0 100.0  
 
 Only 40% of the respondents were using local national STG, the rest 
varied on the STG following on their prescribing regimen. A large percentage 
used international STG, and 13% used their own designed STG.  
 
 
 
 
 
 
Table 4.20: The type of STG being followed by the participants  
 Frequency Percent 
Valid Local 40 44.4 
Own 12 13.3 
International 34 37.8 
Total 86 95.6 
Missing 9999 4 4.4 
Total 90 100.0 
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Figure 4.18: Participants STG type 
 Prescribers using their own designed STGs, and not following a well-
desighned treatment regimen is considered as a lack of Good Prescribing 
Practice, because prescribing needs to adhere to well documented guidelines to 
allow a standardised treatment throughout the healthcare system. This way 
prescribers will have a clear idea of how patients are being treated and other 
doctors can follow other patients without disturbing there treatment regimen, 
this leads to improved therapeutic skills.  
 It is believed that having national Standard Treatment Guidelines will 
allow better medicine utilisation and will lead to better procurement practice, this 
is the case because all parties that are involved in procurement and prescribing 
will be able to predict what medicines are required and the amount that need to 
be available to cover the healthcare requirements. On the other hand, lack of 
uniformity in the guidelines being followed, will result in undesirable patient 
confusion, conflict in deciding how to proceed, loss of doctor reliability in patient 
views, morbidity due to adverse drug reactions, and all this would result in 
patient lack of compliances; waste of resources is another point which needs to 
be considered, because inappropriate medicine use causes medicine waste. An 
important example of misuse of medicines is antimicrobial resistance, due to 
over use or basically mixed use of multiple antimicrobials. 
 Another important finding is that only 26% of respondants were aware of 
other colleagues STG, the rest had no idea or were unsure; the results are 
described below. Such situation might lead to inability of other prescribers to 
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cooperate in patient treatment, and might be unable to help patients other than 
their own.  
 
 
                                                             
                                                        
                                                                                              
 
 
 
 
 
 
 
 Figure 4.19: The awareness level of the respondents with their peers 
STG   
 Respondents explained the choices in various ways, half of them are 
using the official STG of the healthcare centre, but 22% were using STG from 
their training abroad. This situation might be inappropriate because, Kuwait has 
a different health profile than others and the genetic disposition of Kuwait 
ethnicity not necessarily similar to other countries. For this reason using STG 
from other countries might be unsuitable and maybe harmful. 
Table 4.21: Similarity of the STG with colleagues  
 Frequency Percent 
Valid Yes 26 28.9 
No 4 4.4 
Maybe 50 55.6 
Not Sure 10 11.1 
Total 90 100.0 
Table 4.22: Reason for using this particular STG Frequency Percent 
       Valid Knowledge from previous 
 University training 
8 8.9 
Conveyed from previous 
 training at different country 
22 24.4 
Official guideline  
of healthcare centre 
50 55.6 
instructed by  6 6.7 
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Figure 4.20: the participant’s reason for following a particular STG 
 
A cross-comparison between the work experience and the type of STGs 
being used was conducted to view any significant finding in relation to how the 
new prescribers would react towards treatment options and compare it with the 
way the more experienced prescribers handle prescribing.   
  
previous colleague 
Others 4 4.4 
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 The following table and Bar-Char demonstrate the relation. 
Figure 4.21: Work experience in years Vs STG Type Cross-comparison 
 The comparison of the work experience and the type of STGs being used 
revealed that the new doctors are more committed to the local guidelines, but 
some are using the guidelines they learned during their international training, 
and none of them are coming up with own guidelines. It makes sense, 
especially that doctors with less than 5 years’ experience, might lack the skill to 
design their own STG. What is noticeable is the fact that more experienced 
doctors follow the international STG, this can be explained by the fact that the 
more experienced doctors go to a lot of international conferences and 
international workshops. This may be one reason for them adopting an 
international approach in prescribing treatments.  
Table 4.23: Work experience in years Vs STG Type Cross-tabulation 
Count   
 STG Type Total 
Local Own International 
Work 
experience  
in years 
1-5 Years 14 0 6 20 
6-10 Years 22 10 10 42 
11 Years 4 2 18 24 
Total 40 12 34 86 
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 The most used STGs are the local STGs and the Canadian Guidelines; 
there are two reasons for such high usage of the Canadian Guidelines. The first 
one is that most doctors get their speciality training in Canada, and that’s why 
they use the Canadian Guidelines. The second reason is because Kuwait MOH 
is trying to start a standardisation protocol by adopting the Canadian process 
and has a Canadian team of healthcare experts in Kuwait MOH to change the 
current policies at The MOH. Table 34, sum up all the different types of STG 
followed by the participants. 
  
 Another important point that needs to be recognised is the fact that there 
is no monitoring to STG being used, no follow-up, and it’s been observed that 
the existing guidelines are based on the current and earlier practice rather than 
evidence based; there isn’t any kind of update or even evaluation for the 
currently used STGs.  
 
  
Table 4.24: STG types being followed by the respondents  
STG Number % 
NICE 2 4.4 
Internet search 1 2.2 
International Guidelines 6 13.3 
Canadian STG 11 24.4 
American Medical Association Web Site 5 11.1 
Evidence-Based Practice  2 4.4 
Uptodate.com 1 2.2 
Maudsley Prescribing Guidelines “The Maudsley 
Prescribing Guidelines (also known by the abbreviation 
MPG) is a referenced prescribing guideline for psychotropic 
drugs” 
1 2.2 
Kuwaiti Board Training 4 8.8 
Healthcare facility Own STG 12 26.6 
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Chapter Five 
Discussion 
Recommendations and Policy Implications 
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5.0 Introduction 
 This chapter contains the findings discussion, in the context of exiting 
research on the concept of the Essential Medicines and the suitability of this 
concept to Kuwait’s public sector healthcare situation. Based on the findings of 
the study, the practicality and appropriateness of the medicine policy that it is 
consisted mainly of the Essential Medicine List and the Standard Treatment 
Guidelines will be demonstrated. This chapter will answer the research 
questions based on the outcome of the studies conducted, it will justify the 
approach used to answer the research questions and it will demonstrate the 
limitation of the approach.  
 Thesis discussions conventionally put the findings that have been 
experimentally determined, in perspective with the findings made by the 
previous researcher. For this particular research, it is not possible to do this 
comparison. The major reason for this is because there are no previous works 
in the topic relating to Kuwait, and if we like to compare the findings of this 
research with other studies conducted to other countries that have similar health 
profiles to Kuwait, that is again not a possibility. The reason is that Kuwait’s 
situation is unique; it's certainly a high-income country where the GDP (PPP) 
per capita is USD 70686 (ranks 5th). It's human development index is high 
(0.816) and ranked 47th. However, it does not appear on the many lists that 
state the developed nations. 
 
 Kuwait has a place on the World Bank's high income countries list, but 
neither on the lists of the International Monetary Fund, Development Assistance 
Committee nor the Newsweek's World's Best Countries (20, with intensive 
access to resources and has great availability of health technologies which are 
comparable to advanced countries, but Kuwait on the other hand, is similar to 
limited resource countries in terms of organisation, some type of health 
corruption and serious bureaucracy difficulties. Consequently, Kuwait’s unique 
health system has no direct parallels against which to compare.  
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 What has been done in relation to this research work was to compare 
various Kuwait health aspects with several countries, each aspect compared 
with a different country’s situation.    
This research work aims to answer the research questions systematically by the 
way of the proposition emerged from four different methods of study, each 
stage of the research answered one of the research questions, however, the 
research work outcomes will give directions on the recommendations needed to 
be considered if the concept of Essential Medicines gets implemented at the 
health public sector in the State of Kuwait. 
5.1 Research Question One and Two 
“What is an Essential Medicine List and why do countries need it?” 
“What are the characteristics of an effective EML Programme?” 
 The first two research questions seek to investigate the WHO concept of 
EML, how it’s defined, the method of implementation, the update of the EML 
over the years, the percentage of adapting the EML by the member countries, 
and the suitability of the EML to high-income countries. This information is 
important to establish whether the EML is suited to Kuwait, or if it’s only valid for 
low income countries. But first it’s important to understand its objectives and 
aims to be fully aware of its implication.  
 The general focus of the WHO Model List of Essential Medicines is 
medicine quality and access, the two terms are interchangeable, no patient 
should get access to medicine unless it’s of established quality, otherwise, the 
concept fails to achieve its target which is the general wellbeing of the 
population. 
 Another focus for EML is cost, this term is relevant to each country’s 
available funds, and how much any government is able to spend on medicines 
and the available health reimbursements schemes. In a country like Kuwait, the 
funds are available but the process of utilising the funds efficiently and 
transparently is not clearly defined. Medicines are prescribed to patients in the 
public sector free of charge, and a three month supply is provided and in some 
cases a six month supply is given, another form of medicines drainage were 
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found in the visiting visa patients, that only pay a small amount of ten Kuwaiti 
dinar and get prescribed medicines with a very high cost.  
 This policy of medicine prescribing causes drainage to the medicine 
resources, especially the six month supply of medicines, where patients are 
stopped from using the current treatment regimen and moved to a new regime, 
the massive supply of medicines will be disposed and wasted, and this is a 
massive drainage of medicines.  
 If Kuwait public health system followed a more organised prescribing, 
procurement concept, such approach might reflect positively on the overall 
health and the might even deliver a system of control over cost. Kuwait requires 
a system that will be able to deliver a solution to the massive number of 
medicines on the CMS; this massive number gave rise to high cost, medicines 
procurement challenges, it might go further to include a system that will 
enhance the prescribing protocol and such system would eventually provide 
better health.  
 One proposition is to adopt the concept established by the WHO of 
Essential Medicine List; the WHO EML is suggested by the WHO to member 
countries to help them to deliver some type of an organisation to the medicine 
situation in each country, the work of the WHO is not a mandatory and the 
WHO does not impose its adaptation, it is merely a guide to aid country in their 
medicines related innovation. The work of the WHO was directed towards 
countries with limit access to resources and countries with issues with sanitation 
and have difficulties with access of clean water, for this reason the WHO Model 
EM included a number of medicines related to infectious diseases, in the more 
resourceful countries the health requirements are different, the diseases profile 
are more directed towards life style and modern none-communicable diseases, 
for this reason the WHO Model List of Essential Medicines are not a suitable 
form to be adopted in the exact layout by the higher income countries. The 
medicine choices on any newly designed nEML is required to be complying with 
the health situation, the affordability level of the population and the country 
adopting the concept, and the availability of suitable healthcare facilities to 
provide the required health level using the selected Essential Medicines.     
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 The selection process of medicines on the WHO Model EML is based on 
the WHO Standard Treatment Guidelines, it’s considered a good practice to 
have STG to follow and the STG needs to be suitable to country’s health needs 
and medicine capabilities.  
 The WHO Model EML has gone through rigorous scrutiny over the years; 
it started as a list of drugs aimed at limited income countries, but over the years 
the List direction changed and more higher income countries has adopted the 
concept in different forms, the expanding number of countries adopting the 
Model EML concept resulted in different disease profile and different health 
requirements, for this reason the Model EML has evolved and several changes 
has taken places, the revised Model EML included medicines that are more 
expensive and due to the availability of the world Pharmacovigilance 
programmes and the widespread of quality medicine information, the selection 
of these medicines moved from experimental based choices onto more of post-
market evidence based choices.  
 The updating of the list was crucial to keep up with the advancements in 
medicine technologies and the change of diseases patterns. The list currently 
includes more expensive medicines, which are considered to be cost-effective, 
such as antiretroviral medicines.  
 The major indication of EML concept success is demonstrated in the 
WHO Model EML continuance since 1977; it has been adopted by many 
international none-profitable organisations. Another evidence that might be 
considered as a type of success confirmation of the Model EML is the fact that 
over time a large number of countries, with various standards of livings, are 
adopting the EML concept and adjusting it to suit each country’s health 
requirements. The keyword at this stage is adjustment; the EML concept 
adaptation requires alteration to suits the national health requirements of each 
country, the medicines on each national EML vary and for a national EML to 
succeed it needs to be tailored to each country’s health needs, financial 
resources and the available Standard Treatment Guidelines. 
 The general timeline of the WHO Model EML started in 1970 as general 
idea and the WHO expert advisory Committee met in 1975 and published a 
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model List of EML in 1977 with 208 medicines. The list got updated every two 
years, in 1981 the WHO established the WHO Action Programme on Essential 
Medicines to support the EML concept, until 2009 there were over 156 countries 
with an EML. Looking at the map below, it demonstrates countries from different 
levels of income and each country is adopting the list for different reasons. The 
map demonstrates as well, that most of the countries adopted the EML concept 
in less than 5 years; it’s an indication of the recent popularity of the EML 
concept. Many high-income countries are seeing useful utilisation to the EML, 
not only in terms of cost reduction and enhancing medicine access but also in 
providing more medicine and distribution organisation and control over the 
medicine list.   
 
Figure 5.1: Countries with an official selective list for training, supply, reimbursement. 
Some countries have state/provincial lists instead of or in addition to national lists.  
Source: WHO, World Drug Situation Survey, 1999 
 
 The WHO provided support to countries to start their own policy of 
Essential Medicines to 113, of which 22 benefited from comprehensive 
programmes (WHO, 2016). 
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The following figure 32, demonstrates the percentage of the countries 
benefiting from the WHO assistance, the figure also demonstrates that there are 
22 countries benefiting from full support of the WHO to start medicine policy and 
EML, other countries are getting more of a technical support. 
Figure 5.2: the distribution of countries benefiting from the help of the WHO in 
designing their nEML     
  
 At the turn of the century, the EML became more beneficial to wider 
range of countries. The EML became valuable to the industrialised countries, 
because the medicine expenditure shows unsustainable growth of 12-18% per 
year, emphasising need for prioritisation and rational medicine selection (WHO 
Annual Report, 2003).     
 The EML has provided other practical usage beside access to quality 
affordable medicine, an additional importance of the EML concept was found in 
helping the public sector in medicine procurement and distribution, it can be 
seen as a monitoring system for medicine availability and pricing, enhances the 
in-service training of healthcare providers, enhances medicine transparency 
and decreases antibiotic resistance when rational drug use is followed. 
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 From the information gained, it’s apparent that the EML started as a 
means to control cost and quality, but as time passed, the Model EML 
progressed and had further role as an instrument to enhance several aspects of 
the medicine situation in many countries, regardless of the income level.    
 Overall the EML based on the number of countries adopting it has 
become universally accepted, it became widely utilised in low and middle 
income countries and in recent years it’s been widely implemented in the high-
income countries. The EML had several other uses other than enhancement in 
medicine access and cost control, it’s been used in health provider training, in 
medicine supply and reimbursement, enhancing procurements and medicine 
quality control.  
 Generally, the EML can be considered a success in meeting the 
proposed objectives set by the WHO Expert Advisory Committee and might 
even went further to be a valuable tool in medicine control and Rational Drug 
Use and the general enhancement of the overall health.  
 The overall framework of an effective and successful EML, is to design a 
list of a reasonable and controllable number of medicines, the medicines on the 
list need to follow the cost-effectiveness concept carefully, the selection process 
is required to be carefully suited to the country’s health requirements and the 
process of implementation needs to be transparent and frequently monitored 
and updated.      
 
5.2 Research Questions Three  
“To what extent have other countries succeeded in their implementation of an 
EML?” 
 The third research question aims to gain experience from the process of 
implementing EML by other countries, it’s to give a perception of what to expect 
and what to evade if the list became available in Kuwait.  
 To answer the question, two studies were conducted, one was 
conducted at an international level, studying 5 countries with various income 
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levels, out of the five countries studied, two have a high income namely; 
Norway and Australia. 
 Norway has the highest income level in the world; it’s similar to Kuwait in-
relation to the fact that patient expectations are high, and Norway is considered 
to have one of the highest healthcare expenditures in the world. The spending 
has grown in Norway more than any other OECD country and this is 
demonstrated in figure 33.  
The following table demonstrates how much is being spent by Norway on 
health.      
Table 5.1: Norway Health Expenditure Statistics 
 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
% from the 
Government 
total budget 
9.38 8.97 8.46 8.04 8.20 8.11 9.25 9.07 8.94 8.89 
Health care expenditure by financing agent sourced from Eurostat: Statistics Explained. 
Last update: 11-05-2015 
             
 
Chart sourced from: OECD Health Statistics 2015 
 In 2013, Norway had a lower expenditure than the rest of the OECD 
countries; this is because it adopted a system to lower pharmaceutical 
expenditure. They adopted a system of long-term care and increased the 
spending on that by 30% (OEDC Health Statistics, 2015). It can be deducted 
from this attempt by the Norwegian healthcare services, that if the medicines 
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budget get condensed and the money get forwarded to another preventive care 
it might have a deficit effect on the total healthcare budget.  
The bar-chart demonstrate an increase in 2014 of the Health expenditure 
in Norway, reviewing the studies conducted by the OECD Reviews of Health 
Care Quality, there appears to be broad consensus across stakeholders over 
the direction of the health system, even when this entails significant challenges 
or adjustments, for example there has generally been agreement over the 
direction taken by the Coordination Reform. However, beyond this broad 
consensus there is a lack of consistent meaningful engagement between key 
stakeholders (for example, discussion and negotiation between GPs, 
municipalities, hospitals, mental health services) which is an obstacle to the 
successful implementation of some impressive aspirations for improvement, 
particularly around increasing co-ordination (OECD, 2014). 
 The Norwegian Health Services director was considered as the EML 
concept builder, his aim was not only to control cost but also enhance rational 
drug use. Although Norway is a high-income country, it still found it important to 
practice control over the increasing medicine budget. Norway faced oppositions 
from the Pharmaceutical industry and has been accused of restricting the free 
trade of medicines. 
 Such objection is understandable; the pharmaceutical industry would 
prefer to have the total freedom over selling newer medicines and more 
expensive medicines and from a business point of view, would like to have 
more control over medicine prices. This is not happening otherwise the 
Norwegian Health services would be faced with a serious medicine budget 
issue and this is the major reason for adopting EML by the Norwegian Health 
services.     
 The second-high income country that adopted EML is Australia, it had 
the lowest cost of medicines in the world in the past, but in recent years the 
prices went up. The Australian Health services adopted the concept of EML and 
made the system of reimbursement based on it. 
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 The concept of basing the reimbursements of medicines on the EML is 
commendable, but the actual application of it is not accomplished, it’s been 
found out, through a study conducted by Duong (2015)  that the decision 
makers at the Australian Health Services have a confused perception of what is 
considered an essential medicine. The stakeholders mixed up the essential 
medicines with the reimbursed medicines, and thought that the selection of the 
essential medicines is based on consumer demand. This is could be an 
indication that the concept of EML has not been fully explained to the whole of 
healthcare providers and for it to be operating efficiently, a suitable education 
programme might be useful to provide a suitable level of EML implementation 
and efficient utilisation of the concept.   
 Rational drug use is a major criterion on the objectives of Australia for 
adopting EML, and the second objective is to control and maintain a suitable 
pharmaceutical industry.  
 The third country, with many attempts to start an EML, is India; it’s a 
lower middle income country, it is one of the first countries to start EML in the 
third world countries, with several failed efforts. The main issues with the 
medicine situation in India were the unverified medicine quality, lack of price 
control, weak pharmaceutical regulations and weak enforcement of the 
regulations, problems with irrational drug use and a major problem with what is 
known as the witch doctors and the untrained pharmacists.  
 India attempted lots of policies to try and resolve the issues, but all failed. 
The failure can be related to lack of focus on the Essential Medicines, and the 
procurement didn’t get based on EML. Another reason is that the medicine 
selection didn’t get based on the actual health needs but the major reason for 
the failure of all attempts, was due to the strong opposition by the very powerful 
pharmaceutical industry in India. 
 Such a situation requires a strong transparent government that would not 
get influenced by incentives from the rich pharmaceutical industry, but this is 
difficult for a country with extremely limited resources, referring back to Kuwait 
such a situation shouldn’t be applied but unfortunately similar situations do 
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happen in Kuwait. The pharmaceutical industry in Kuwait is very limited and 
most of the medicines get imported, but there are a lot of incentives given to the 
healthcare providers to ensure that a specific supplier wins the bid of a bid 
tender. This might be considered as a form of lack of transparency or an 
ignorant form of medicine corruption that is draining the health budget. 
 It’s a serious matter and if not fought and controlled, no policy would be 
strong enough to endure such corruption and lack of transparency, the term 
corruption is a strong term to be stated but it comes in various level and the 
type that is present in Kuwait Healthcare Services is an invisible type and most 
of the Healthcare providers are unaware of it as being a form of medicine 
corruption, it might be presented at a very small level, by posting a specific 
medicines posters at any healthcare facility that would be viewed by patients all 
the time and the result would gain preference over peer medicines, another 
form of medicines corruption is accepting incentives from pharmaceutical 
suppliers in return to prescribe a specific medicines, this form of practice might 
seem harmless but it can be alarming and requires careful deliberation, 
because prescribing is required to be based on medicine post market evidence 
of effectiveness and quality rather than advertisement and enforcing the 
medicines.  
 In relation to Kuwait, it was ranked 66 in 2012 at the transparency rank, 
but in the latest 2015 ranking, Kuwait had moved up to be at 55, which is a 
good improvement considering the current unstable political situation in the 
region (U.S. Dept. of Commerce, 2015) (Transparency International, 2016).   
The following table demonstrates how Kuwait ranked in the Corruption 
Perception Index from 2012 until 2015. 
Table 5.2: Kuwait ranked in the Corruption Perception Index from 2012 until 2015. 
Year 2015 Score 2014 Score 2013 Score 2012 Score 
Rank 49 44 43 44 
Sourced from Transparency International Official website, 2016 
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 The Transparency International defines the rank which has been used as 
‘the score indicates the perceived level of public sector corruption on a scale of 
0 (highly corrupt) to 100 (very clean). A country's rank indicates its position 
relative to the other countries in the index. This year's index includes 168 
countries and territories.’ (Transparency International. 2016).    
 Kuwait comes just a few ranks before Oman, but is the most corrupted 
country among the rest of the GCC countries, if this is the case that might 
reflect negatively on the process of innovation, which might be faced with 
serious hindrances, generally, careful transparent approaches are required to 
any innovative process including health related and medicines innovations.  
 This score shouldn’t be taken lightly, especially with a country that has a 
great deal of funds which can bring the country to a very high standard of living, 
if the corruption gets controlled. Further to this fact, Kuwait is considered a 
literacy-free country, because according to the World Bank Adult Literacy rate, it 
states that 96% of Kuwaitis are able to read and write (World Bank, 2016). 
Considering these two facts the corruption level in Kuwait should be less and 
measures are needed to contain the situation.  
 Since Pharmaceutical products take a large portion of the health sector 
budget, it’s vulnerable to corruption. Corruption can be defined in the general 
way as being ‘the abuse of public office for private gain’ (World Bank. 2016). 
Pharmaceutical corruption is more specific and can exist in several forms; major 
forms of pharmaceutical corruption found in questionable medicine quality, lack 
of medicine access; some forms found in the Kuwait health sector, that is 
considered as corruption when refereeing to the definition of medicine 
corruption, but the healthcare providers in Kuwait are unaware of it as being so. 
One type is the over prescribing of medicines to some patients, another form is 
some medicines go missing, or even queue-jumping which is an occurring 
event, and the last corruption form is sadly practiced by many levels of 
authorities in Kuwait public sector.  
 Transparency International suggests that, all members of the community, 
at all levels, have an important role in corruption control, it suggests that 
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accountability from all health professionals and administrators need to be 
demanded (Transparency Int. 2016).       
 The U.S Energy Information Administration, rank Kuwait as holding 6% 
of the world reserves in oil, and it estimates that Kuwait will remain as one of 
the world’s top oil producers (U.S. Energy Info. Adm. 2016).  As a step to 
improve the country and to explore other resources other than oil, the Kuwait 
Parliament approved a USD 110 Billion National Development Plan; part of this 
fund is allocated to improve the health sector (Kuwait MOH, 2016).   
 In Seri-Lanka, the situation was different; the Seri-Lankan public 
healthcare wanted to adopt the concept but failed because of the changing 
health political climate. Such situation is common in the developing countries 
and as a result of this political climate change, the high level management 
changes frequently and decisions made by previous managers stop and new 
ones get put in place until the next group of high ranking decision makers joins 
and so on. Such scenarios are found in Kuwait, new Ministers of health are 
frequently appointed, and the decision made by the previous Minister gets 
stopped by the next appointed Minister. 
 This is a major point and needs to be closely deliberated, if the concept 
of EML gets implemented in Kuwait, there should be strong regulations that 
wouldn’t be affected by the changing of managements, and the regulations 
need to be stated to enforce EML use and implementation regardless of who is 
in charge of the ministry at that point.    
 A good scheme to do so is by assigning a specific committee of qualified 
health professionals and there interests should be clearly declared, 
transparency must be applied at all levels. The committee members should not 
be chosen based on favouritism. The members should not receive any financial 
or none-financial incentives by participating in the committee, the committee 
members are required to be independent decision makers and be fully aware of 
the concept and the selection process. If any of the above doesn’t get fulfilled 
the concept will face the same fate as all the previous third world countries, a 
inadequate none-operational concept. 
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 Kuwait might face a similar situation as Bangladesh when it tried to 
attempt the EML concept. Since the seventies Bangladesh made several 
attempts but all failed and the main reason was bureaucracy and bias, the 
selection committee members were pharmacists and the actual health needs 
were unknown by the appointed expert committee members.  
 One attempt of Bangladesh to implement EML was based on the 
international selection criteria of medicines and this failed as well, the reason is 
that each country has unique health needs and should not copy other countries’ 
EML, it will not satisfy the current needs of the country. This fact needs to be 
considered when the concept of EML gets implemented in Kuwait.  
 Therefore, the EML concept is a good tool to control budget and provide 
quality relevant medicines to the population, but what is equally as important as 
the concept itself is full knowledge of it, its process of implementing, involving all 
stakeholders and educating them on the gains of the concept. 
 Opposition is expected, but care needs to be practiced to understand 
their reasons and try to bring them on board, full careful explanations of the 
EML need to be introduced to all opposing parties, once this is done, their views 
for opposing the implementation of the EML need to be stated, preferably in 
writing, once this is done, each concern needs to deliberated and answered. 
Enforcing a concept with a lot of opposition will cause its failure, it is important 
to take as many supporters as possible to ensure utilisation and adherence.  
 At an Arabic level, there are 12 Arabic countries with EML, the standard 
of living varies among the Arab countries, some have limited resources others 
are undergoing serious political and war situations which is stopping all types of 
innovation and bringing the country to a very bad era.  
 The Arabic world has gone through lots of changes since the start of 
what is known internationally as ‘the Arabic Spring’, terminology widely refused 
by the Arabic community. Simply because this term indicates the start of a good 
era, but the Arabic spring caused a lot of distress and chaos. This has been 
apparent in the health services and medicine supply in countries undergoing 
conflict. It also caused a social and economic inequity, lack of accountability 
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and the elevation of corruption level. The request of reforms by the civilians was 
faced with the use of force and that is very clear in countries like Syria, Bahrain 
and Iraq. The disturbed Arabic political climate has created what is known by 
political scientists as, fractionalisation, it’s a term used to describe a situation 
when countries undergo division in their own lands. Powell-Jackson et al (2011) 
suggests that countries undergoing fractionalisation have reduced access to 
healthcare among other services (Powell-Jackson et al, 2011).   
 Going back to the research question of whether other countries have 
succeeded in there adaptation of the concept, the answer is not so straight 
forward, the system seems to be in place, many efforts have been attempted to 
ensure its continuity but it’s not clear if it’s actually totally operational.  
 It’s apparent that having a list doesn’t necessary mean that the EML is 
being employed efficiently, and it is proposed to consider the utilisation 
efficiency level when adopting the concept, it is proposed that the concept  
requires serious commitment by all the decision makers to make the concept 
work.  It needs a suitable timeframe and effort for it to be effective.  
 Having a well-designed EML, even if it’s appropriate to the needs of the 
country doesn’t necessarily guarantee its success. Many factors need to be 
taken on-board, transparency is key, corruption control is very important, 
declare of interest when selecting specific medicines is important, educating the 
health providers with the concept is an important component. But these are not 
all the efforts that need to be carried forward, it’s very important to get the 
healthcare recipients involved as well, this is achievable, by providing a suitable 
level of education in the process, be transparent, get them involved and gain 
insight to their thoughts on the matter.  
 There is a general belief among healthcare recipients and some of the 
healthcare providers that the generic medicines are of weak quality and not 
effective. These thoughts have been the result of lower quality generics, for this 
reason it’s important to re-evaluate the quality of existing generic medicine and 
only accept those with suitable quality. The healthcare recipients might benefit 
of a suitable level of education with generics; this will help in regaining the trust 
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with the generic medicines and make generic medicine more acceptable to 
patients. The process of educating the public can be done in several means, it 
can be visual in the form of television advertisements, internet awareness 
campaigns, flyers and leaflets handed out to people in public and in health 
regions. It can be done through an awareness programme at the local primary 
healthcare centres and local community centres. 
 The major issues that have been observed with the EML relating to the 
Arabic countries are the change of the health requirements due to the disturbed 
political climate. There are a lot of injuries and deformities due to war and 
protests that cause increased demands on emergency medicines, pain control 
therapy and surgery related medicines. This is evident in places like Syria, Iraq, 
Yemen, and Libya. The result of such situations is that the essential medicines 
cannot be accessed and the EML is not being updated to fit the new health 
changes. The Arabic uprising has diverted the efforts from focusing on health 
and medicine access to trying to control the disorder that is increasing in the 
region.        
 When comparing the various EML of countries with various standards of 
living, the outcome of this comparison was very interesting. Some countries 
adopted the exact WHO Model List of Essential Medicines, where other 
countries have used it as a guideline and made appropriate changes to suit 
their own health circumstances.  Adopting an EML of another country is a very 
major misconduct in the implementation of the EML, simply because different 
countries have different health requirements. This situation was found in 
Tunisia; the Tunisian EML was published with the aid of three international 
organisations, the WHO, the Italian Technical Cooperation and the Belgium 
Drug Directory, the results of such cooperation is an EML that is relatively 
similar to the Belgium List. It’s clear that Belgium has different access to 
resources and different health needs. Such adaptation of the EML by Tunisia is 
destined for failure, because one of the major criteria of an EML is to be 
relevant to the health needs of the country and the relevance to the standard of 
living of each country.  
228 
 
 Another important observation was the fact that many Arabic countries 
adopted the EML a while ago but completely ignored the concept and not fully 
continued with the updating until very recent years. This was the case with 
Egypt, the Egyptian’s first EML were published in 1998, then no updates until 
2006. It’s a very long period to leave an EML unrevised. In Bahrain the first EML 
were published in 2009 and seven years later no updates until now. In the 
Kingdom of Saudi Arabia, the situation was different, the SA MOH had multiple 
committees taking part in medicine selection of the first EML, but when the 
Saudi Arabian FDA staff were contacted for clarification for the process of 
utilising the SA EML, the response was that they had heard about it but they are 
not aware of its utilisation and they have no access to it. This is a total 
disappointment to the EML, the list needs to be accessible by all healthcare 
providers and it needs to be utilised in all aspects of pharmaceutical service 
works.  
  When examining the different lists closely, it was apparent that the 
concept of cost-effectiveness is relative and is country-specific, what is 
considered costly in one country is not necessary costly in another. The rules 
used to examine the cost-effectiveness of particular medicines are different 
from one country to another.  
 The list varies depending on various factors, it can differ in accordance 
with the Standard Treatment Guidelines used by a particular country, it can 
change due to different health requirements, and the selection of medicines can 
vary depending on the practicality of obtaining a specific medicine, whether it 
requires special handling, or special storage or even special transportation. 
Another consideration when selecting medicines is to obviously consider cost 
and quality and consider how it is possible to maintain the quality of medicine 
during the whole shelf-life and during handling and storage. 
 Overall, having an EML doesn’t necessarily guarantee its success, the 
list needs to be adopted correctly, following suitable guidelines with the 
assistance of the international guidelines but not a total adaptation of the 
international guidelines, the list needs to comply with the national Standard 
Treatments Guidelines to ensure its relevance to the health profile and disease 
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burdens of each country. The cost-effectiveness concept needs to be related 
closely and deliberated carefully to suite the available health funds, the expert 
committee members need to be chosen carefully and be independent decision 
makers that don’t follow any specific organisation or have any type of interest in 
the medicine selection. The selection of medicine needs to be based on post-
market evidence of quality and efficacy, for this reason a strong 
pharmacovigilance programme is urgently required to be started in the Arabic 
region and connecting it with the international pharmacovigilance resources is 
proposed to increase its efficiency.  
 In terms of generic medicines, it would be considered as good practice to 
re-examine generics’ quality, and re-license them, then a good process of 
education for the healthcare providers and recipients with generics concept and 
its benefits might help in accepting the generics perception. 
 Opposition is expected with any new changes and reforms, the EML 
faced opposition from various sources, the doctors found it restrictive and 
patients found it limiting, therefore, it’s very important to educate both parties. A 
related and suitable educational program is needed to explain the EML concept 
and the benefits of it should be considered when the concept is about to be 
launched.  
 The other form of opposition is found through the strong pharmaceutical 
industry and the medicine wholesalers, they are the main force of opposition, 
because they are the majority stakeholders that will lose a lot when the 
medicine situation gets organised. Ignoring such strong stakeholders is not a 
good practice, they need to be involved and faced with the reality of the 
implementation and adaptation of the EML concept, the incentives they usually 
giveaway to healthcare providers should be stopped, reduced to a minimum or 
have an organised method to deal with such practice.  
 The relationship between the pharmaceutical industry and the healthcare 
providers needs to have a form of control as well, any member of the medicine 
selection committee that have a direct or indirect interest with any kind of 
medicine should either abstain from providing an opinion on the matter of 
his/her interest or maybe be completely replaced by someone with no interest.  
230 
 
 The list has gone underutilised by many countries, it’s been found that 
having a well thought and well-designed EML doesn’t necessarily ensure its 
effective implementation and usage. Many countries have made the efforts of 
planning and providing a suitable EML but the list failed to achieve its 
objectives, simply because there weren’t any forms of regulation to enforcing its 
usage. For this reason, it is proposed that having a strong ministerial act might 
give strength to the implementation and utilisation of the EML, it is proposed 
that if the new regulation to enforce the utilisation of EML solid enough, it might 
be sturdy enough to endure the frequently changing political climates at the 
Ministry of Health in a third world country situation.   
4.3 Research Questions Four 
The last research question that has been investigated in this research is as 
follows: 
“What are the contextual factors in Kuwait which would assist or hinder effective 
implementation of EML?” 
 The fourth research question was aimed to investigate what is available 
as health policies at Kuwait MOH in relation to the pharmaceutical sector. It 
aimed to find out whether these policies have been effectively implemented or 
was not so successful; it aimed to find out what is the continuous effect of the 
available medicine policies, and how these policies have been dealt with.  
 The question was answered through several interviews conducted with 
senior managers at Kuwait MOH, head of departments at Kuwait FDA and 
Kuwait University, Faculty of Pharmacy.  
 The outcome of the interview revealed that there were several attempts 
by the staff of Kuwait FDA to start several medicine related policies, but 
unfortunately, none of them were completed, and one of these is still paused 
and waiting further instructions.  
 The process of adopting any new policy is not well thought of, and the 
instructions are not clear. The problem as mentioned by Dr Wahede, Associate 
Dean, at the Faculty of Pharmacy at Kuwait University, is that the MOH in 
Kuwait deals with any policy as an administrative task rather than a scientific 
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based work, or a pharmaceutical based work. What is meant by this statement 
is that when a policy needs to be implemented, the committee meets and thinks 
of it in a rigid administrative form, by issuing all the relevant circular, that 
sometimes goes by the Minister of Health and other times it doesn’t, thinking it’s 
an internal pharmaceutical affair and no need to get any ministerial level 
approval. In such situations the policy gets diffused and paused. This obviously 
time consuming, wastes valuable health resources and further strains on the 
budget. This is the case because when any decision made when starting a 
policy, the assigned staff moves completely to that policy and stops doing any 
other tasks, and since the policy undergoing implementations doesn’t have any 
clear instructions on what to do, the staff involved get paid for not doing 
anything and that’s a form of masked unemployment and consequently drains 
the budget.  
 Another form of wasting MOH budget is found in the process of sending 
the assigned staff to training courses and workshops which cost money and not 
employing the experiences gained from their training effectively and 
productively.  
 It’s been observed that there is a power struggle between the ministry of 
health pharmaceutical staff and the Kuwait Pharmaceutical Association. The 
power struggle was detected when Kuwait FDA tried to start the Kuwait Drug 
Index, at the same time, Kuwait Pharmaceutical Association came up with an 
edition called ‘100 Common Drugs’ and are having an updated version 
published soon titled ‘200 Common Drugs’. The publication had 8 pharmacists 
working on it, the information was basically copied from the British National 
formulary, NICE, and Electronic Medical Compendium. The book was aimed to 
be a manual for new graduates to assist them in dispensing and can be used as 
a quick reference. The ranking and categorising of the book was based on the 
information gained from Kuwait MOH. The manual is a good attempt to organise 
information provided to the pharmacists, but it did not go through any monitoring 
nor revision, and the accuracy and validity of the information is not 
demonstrated.  
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 There were no guidelines followed when the manual was being prepared. 
This situation indicates the fact that MOH managers and the pharmacists in 
general, are unaware of the fact that there are international tools to help them 
with policy planning and health innovations.  
 One explanation for such a situation is that managerial level are awarded 
based on the length of time at the job and not based on qualification, capability 
and excellency in the job. This method of allocating managers and team leaders 
has two sides to it, it is good in regards to the fact that everyone gets an equal 
chance to get promoted, but the down side to it, is that spending longer years in 
a job doesn’t guarantee efficiency and competency in managing the team or the 
department. This process requires restructuring and extremely delicate 
deliberation.   
 The continuous attempts to innovate is a demonstration of the effort that 
needed to be in Kuwait a long time ago, but even when attempts were made to 
start a new policy, it failed and the interest diverted to another policy. This 
situation is apparent in several aspects at Kuwait MOH, but in relation to this 
research it has been demonstrated when an attempt was made to launch the 
Kuwait Drug Index which is similar to what is known internationally as the 
National Medicine Formulary, then the interest moved towards the 
establishment of the Pharmacovigilance Department. Although both of the 
policies are strongly needed and should be adopted, both are not being 
executed, the concept is available on papers but the actual operational part of it 
is not in place. This is another form of time and resource wastage.   
 Other than the lack of knowledge, bureaucracy is another reason for the 
absence of advancement and innovation in the pharmaceutical sector at the 
State of Kuwait. This statement came after analysing the responses gained 
from interviewing high ranking and managerial level staff members, they were 
all happy with the concept of EML, but they were all concerned that it will face 
other policies destiny and it will fade away.   
 The interviews gave a good insight into Kuwait’s current medicine 
situation, and it gave an indication on how the system works in the MOH, the 
general understanding of the concept was available, and all agreed that it will 
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be of added value to the medicine situation in Kuwait MOH. There were 
however, concerns with the actual process of implementation, none of 
respondents were encouraged or had a positive view of the success of the 
implementation process, the concerns varied from the fact that the EML can 
work if it’s implemented in a transparent manner; it’s an obvious requirement, 
lack of transparency will destine the EML to failure, as happened with several 
developing countries. Another obstacle is the process of gaining official 
approval which is time consuming and exhausting, and that is a reason why 
some policies get implemented without the official governmental approval and 
then get stopped or dismissed. All are valid concerns and need to be 
considered when the EML gets implemented. 
 The positive impact of the EML concept on the MOH Budget was 
recognised by the participants, it will enhance the control of the escalating 
medicine budget, but it needs to be considered that the actual percentage of the 
medicine budget from the total MOH budget has not changed over the years. 
It’s the actual MOH budget that increased, therefore, the MOH needs a general 
concept of redistributing the allocated budget and try to invest in preventive care 
rather than the current system of curative care. 
 The survey conducted revealed the lack of organisation in terms of 
prescribing, the physicians don’t have a specific national protocol when 
prescribing to patients, each physician uses their own protocol based on 
experience, previous training or own initiative. Such a situation is not acceptable 
and causes a lot of confusions, especially among patients, this is the case 
because diseases can be treated in several ways using several regimen and 
sometimes the physicians can’t necessarily remember each regime used with 
each patient. In the case of Kuwait, doctors are using several European, 
American and British treatment protocols that vary in the types of medicine that 
is available in each country, and the result of this none-unified treatment 
guideline is a more extensive list of medicines and consequently a bigger 
medicine budget.   
 The availability of STGs is of added value at several levels, the 
healthcare providers will have a standard guide on prescribing, it enables the 
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healthcare providers to provide quality care, the prescribers will be more aware 
of the prescribed medicines, since they follow well thought out guidelines that 
include suitable and quality essential medicines. 
 There is a positive impact to manage funds more efficiently, especially 
when there is previous knowledge of the required medicine, having a suitable 
STGs will enhance procurement and will help in better management for the 
medicine supply cycle. But the main beneficiary are patients, the STGs will 
provide the best option of treatment  patients should receive, all patients at all 
levels of healthcare will be treated similarly, having a known STGs will enhance 
the availability of medicines, and consequently better patient compliances and 
satisfaction.  
 The second survey in regards to the views of the healthcare providers on 
Kuwait’s medicine situation were interesting, all demonstrated the desire to 
improve the system, a large number are unhappy with the current system, and 
all are very happy with the concept of EML and would like to see it get 
implemented. Such thoughts and responses are clear indications that the 
healthcare providers are keen to innovate and would like to see the medicine 
situation in Kuwait improve and get transformed to a better and more advanced 
situation.  
 Another point worth considering is the fact that physicians don’t prefer to 
prescribe generic medicines and this reflected on patient’s opinion of generic 
medicines. The general thought is that generic medicines are of less quality and 
manufactured in a lower standard than the branded medicines. The general 
misconception has been demonstrated through the health carer recipients, 
partly because there are some local generics in Kuwait that are not up to the 
required standards and patients did not have a pleasant experience using them, 
and partly because some patients mix the concept of  generic medicines with 
counterfeit medicines. Therefore, it’s very important to educate the patients of 
the concept of generic medicines and retest and re-establish the quality of 
already available generics.  
 Quality generic medicines can be considered as a useful tool to enhance 
medicine access and control funds, according to Chief Pharmacist Fahad Al-
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Qatan, Special Medicines Department Manager at the CMS. Generic medicine 
arrives faster to the CMS, the suppliers do not complicate the process of 
purchasing and delivery, therefore, generics are not only less expensive, but 
also save time in procurement as well. Therefore, it’s important to establish trust 
in generic medicines and make them more acceptable to patients, because the 
impact on health and the general wellbeing is good, and it will enhance 
medicine supply and control the funds.  
 This is one of the points that needs attention if the concept of EML gets 
implemented at Kuwait MOH, there are several conceptual factors that might 
hinder the implementation of any policy in Kuwait, and those factors will affect 
the process of implementing EML as well. Such general conceptual factors are 
competition among the high level management to claim the new innovative 
ideas as their own, lack of commitment and loss of interest is present to any 
new plan, the inexperience of the assigned staff to carry forward the new policy 
and the results of being unable to implement the new policy effectively, a large 
number of healthcare providers lack the awareness of the international 
guidelines and the results are placing a policy that is weak and inefficient.   
 One major and frequently occurring factor that might hinder the process 
of innovation is the long excessively complicated administrative procedure that 
needs to be followed every time an improvement or change needs to occur. 
This bureaucracy is a major hindering factor and causes loss of motivation and 
eventually lose of the policy. 
 In relation to the Kuwait situation, the main and most apparent reason for 
the slow innovation process in Kuwait MOH is the fear of losing personal 
incentives if any change occurs, therefore, higher level staff are always vigilant 
to any new concept and make sure it won’t affect them personally in an 
undesirable manner.   
 The mentioned conceptual factors that might hinder the effective 
implementation of the EML at the state of Kuwait needs to be carefully 
approached and resolved before attempting the concept of EML 
implementation. If that has not been considered, the EML will face a similar fate 
to all the previous policies that have been attempted previously and failed.   
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5.4 Recommendations for the Kuwaiti Government   
 The following recommendations are formulated for the process of 
implementing EML, and are considered important factors in the process of EML 
launch.  
 The intensive list of medicine that is available at Kuwait MOH, needs to 
be revised and updated and only medicines that are prescribed frequently need 
to be included. Anything less than frequently prescribed, needs to be 
considered as an orphan medicine and specific rules should be applied to 
provide it. 
 The problem of the drainage of medicine to none-resident patients’ 
needs to be emphasised and very restricting and clear policies need to be in 
place. 
 The open access of consultants, to order any medicine, is proposed to 
go through reregulating and it would be more beneficial if it get limited to 
extremely special cases.  
 Transparency is key; it should be practiced at all health aspects and 
especially in the medicine supply. If transparency gets implemented effectively, 
it’s proposed that the medicine corruption level might drop and this could 
enhance the public confidence in the pharmaceutical sector.  
 Educating the healthcare providers and healthcare recipients is very 
important; all should be included and considered, education programmes can 
start at a school level up to the public in the local clinics. Workshops and 
training programmes should be conducted at all levels to healthcare providers 
and recipients. The programmes need to be provided by suitable and 
knowledgeable staff, and preferable no financial incentives to be given to 
eliminate the competition of the people who are after financial gain rather than 
sharing knowledge and educating the public.   
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 Policy makers and the decision makers in Kuwait MOH have a duty to 
examine and assess the current level of government bureaucratic procedures 
towards any health innovation ideas or plans.  
 In more medicine, related work, several medicine related policies can be 
started in Kuwait such as Pharmacovigilance, Standard Treatments Guidelines, 
Health Providers and Recipient Education Programmes and a major change to 
the management structure would be beneficial to be considered.  
 Standard Treatment Guidelines are almost none-existing, STG are an 
important part in the medicine selection process in the EML and therefore, 
serious work needs to be done in planning and making Kuwait-specific STG. 
This is achievable by establishing a STG committee, which will develop a 
comprehensive plan for the guidelines. The committee will select the format, 
recruit contributors, and reviewers to establish the STG. When deciding on the 
most appropriate treatment option, it is important to consider using few 
medicines, bearing in mind the cost-effectiveness of the choices being made, 
base the selection on the Essential Medicines, and clearly indicate what is the 
first, second, and third line therapy is, and the treatment course should be 
clearly described. It is worthwhile to refer to the WHO guidelines when planning 
the local STG. Once the STG are decided, it is advisable to pilot it and test it 
before publishing it. Once it’s ready, the STG needs to be implemented in an 
appropriate mode, continuous staff training is vital, and regular monitoring is 
essential as well, plus the guidelines should be regularly revised and updated.   
There is a major need to organise the health sector at the state of Kuwait 
in general and the Pharmaceutical sector in particular, it might be useful to 
include a more knowledgeable staff and give them further suitable 
responsibilities to perform and innovate. The Pharmaceutical infrastructure 
needs to be reconstructed, this can only be achieved by having well-qualified 
staff and experts design an information sharing and  reporting system, at a 
national level and connect it with the available international resources, and 
having a transparent and experienced advisory committee.  
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The inflated MOH general budget and the inflated medicine budget, 
needs to be prioritised, plans and policies that have been used by other 
countries, to provide control over these countries’ budget, need to be 
considered and adopted, the EML concept has proven over time its 
effectiveness as a tool to organise funds and enhance medicine access. 
The EML can only fulfil its objectives if it’s been implemented 
transparently, it should follow the international guideline but should not be an 
exact version of the international EML or any other country’s national EML. The 
government needs to create an awareness of the concept of Essential 
Medicines among health recipients and providers, the MOH should consider 
reregulating the registration of new medicines and adopt a suitable system to 
ensure the quality of medicines that is available.   
The Kuwait national EML can have a different structure to the WHO Model 
EML, a common practice observed by other countries is to combine the STG 
with the EML as a single document or include the STG in the comments section 
of some essential medicines.   
Several general factors would affect the implementation process, these 
factors need to be deliberated in advance to avoid future obstacles or even the 
termination of the process of implementation of EML. The factors are the 
available pricing policy, access of essential medicines, reimbursement scenario, 
government initiatives in supporting implementation, patent and licensing 
scenario and healthcare infrastructure. Some of these factors have no impact in 
Kuwait because they are not available; such as the reimbursement scheme, 
other factors are very important and require careful deliberation. The pricing of 
medicine is usually the main concern to some countries, in Kuwait, pricing is not 
a major one and this might be one of the reasons for the inflated budget of 
pharmaceuticals in Kuwait, therefore it’s important to adopt a suitable system 
for pricing and maybe follow the footsteps of some middle-income countries and 
have a price ceiling for high-priced medicines.  
Shortage of some medicines might be present in Kuwait MOH, this is the 
case because of the intensive list of medicines that need to be procured at all 
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the time. If the focus moved from attempting to provide all of the over 7000 
medicines on the CMS list of medicines, and only focused on a more 
reasonable list of essential medicines, medicine access might be enhanced. 
This is not the only factor that needs to be considered, the government needs to 
support the concept of EML and provide sufficient planning but this won’t be 
possible unless a serious restructuring of the pharmaceutical infrastructure 
occurs. It has been noticed in Kuwait a number of patients can’t get access to 
certain medicines and end up buying from the private sector which will result in 
an increase in the out-of-pocket expenses; this could be the results of poor 
management or inefficient procurement process.   
The entire above factor needs to be considered to be able to have an 
operational and useful EML that would enhance the general health and control 
the inflated medicine budget. 
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 5.5 Limitations of the Study 
One main limitation to this study is the lack of similar published studies, the 
other limitation is the inaccessibility of Kuwait health resources and the lack of 
secondary data relating to any aspects of Kuwait health. 
This study is a first of its kind in regards to Kuwait, the methodology employed 
is specifically designed to this particular study, unless an exact study should be 
attempted, this study can’t be generalised nor transferred, and this is another 
limitation to this study.  
5.6 Recommendations for Future Research 
The study suggested a number of directions for future research, it’s important to 
research the health corruption level and the level of actual transparency at 
Kuwait Ministry of Health. It would be of added value to study the reason behind 
the current bureaucracy at the government sector and what are the appropriate 
methods to evade it.  
Since there are no actual studies in regards to Kuwait health needs and there is 
no published data to support any further research, it’s proposed to research the 
reason for the lack of appropriate medicine related research in relation to 
Kuwait.  
5.7 Final Comments 
Through the research results, it’s been found that the Essential Medicine List is 
a valuable tool to perform medicine control and organise the medicine situation 
in a given healthcare centre regardless of the budget limitation and the amount 
of the available resources, providing there is an appropriate utilisation of the 
concept. 
It’s been found, through research conducted, that having a well-planned and 
well thought EML doesn’t necessarily ensure its efficient utilisation. The EML 
needs to be supported by regulatory and human support, as well as having a 
good monitoring and updating system, it’s important as well to have a 
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transparent process of medicine selection and medicine selection committee 
members with no interest in the selected medicines.  
EML is an efficient tool in enhancing medicine access in limited resource 
countries, but it went further with its significance to include further benefits to 
high income countries in terms of budget control, medicine control, good 
procurement practice, medicine corruption control, reimbursement scheme and 
many other values depending on each country’s situation. 
The survey conducted in Kuwait MOH revealed the eagerness of the healthcare 
providers towards health and medicine innovation, as they see new 
international policies as a suitable method for employing control and 
organisation at the MOH in Kuwait. The concerns were that such innovations 
might be faced with opposition from the stakeholders who might lose interest if 
the current organisational culture changes, such situations need careful 
deliberation and each opposing suggestion or thought needs to be explained 
and clarified before moving forward.   
The survey demonstrated the lack of trust in generic medicine quality and 
efficiency, it’s important at this stage to restore the confidence back to generic 
medicines and explain the actual meaning of generics to the whole population 
through various types of health educational programmes. 
The EML can be of added value to the Kuwait medicine situation if 
implemented, handled correctly and appropriately. The EML implementation 
process in Kuwait needs to follow very careful footsteps, the health needs of 
Kuwait needs to be clearly established, the selection of medicines needs to be 
carefully executed, the process of introducing the EML to the healthcare 
recipients and providers needs to be carefully attempted and a suitable plan 
needs to be in place for the overall implementation process.  
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Establishing an essential Medicine List at the state of Kuwait 
 
 
Nadyah Alayadhi 
n.y.alayad@student.ac.uk 
University of Bradford 
Richmond building 
BD7 1DP 
 
 
 
 Please Initial Box 
 
1. I confirm that I have read and understand the information 
sheet for the above study and have had the opportunity to 
ask questions. 
 
  
2. I understand that my participation is voluntary and that I  
 am free to withdraw at any time, without giving reason. 
 
 
3. I agree to take part in the above study. 
 
 
  
 
 
 
 
Name of Participant    Date    Signature 
 
 
 
 
Name of Researcher    Date    Signature 
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Appendix II  
Assessments of the current medicine supply system in the 
State of Kuwait, and the medicines regulatory system. 
Healthcare providers views on the concept of Essential 
Medicines list 
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Assessments of the current medicine supply system in the State of 
Kuwait, and the medicines regulatory system. 
Healthcare providers views on the concept of Essential Medicines list 
 
 
The purpose of the study is to measure the current medicines supply system 
and what visions healthcare providers might have toward having an Essential 
Medicine List. This study forms part of PhD research programme in 
developments, economic studies and pharmaceutical innovations, which is 
under the supervision of Dr John Lawler and Prof B.J. Clark, University of 
Bradford, UK. 
 
 Please complete the questionnaire and return it to me in the sealed 
envelope provided. 
 All responses will be dealt with strict confidence and anonymously.  
 please direct questions or comments to  
 
 
Nadyah Alayadhi 
SISS and School of Life Sciences 
University of Bradford  
Bradford, West Yorkshire, UK 
n.y.alayad@student.bradford.ac.uk. 
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1. Demographic data 
1.1 How long have you been working as a healthcare provider? 
 1-5 years 
 6-10 years 
 11 years and over 
1.2 Speciality 
 Physicians 
 Academic staff (university, PAAET) 
 CMS staff 
 Public Pharmacists 
 Private Pharmacist 
 Legal Staff 
 
2. Medicine supply system 
2.1 Are you satisfied with the current medicine supply system? 
 Yes   
 No 
 No Comment 
2.2 Do you think the medicine supply system is well regulated? 
 No 
 Appropriately regulated 
 Room for improvement 
 No comment 
2.3 In your own words, how do you think the medicine supply system can 
be improved? 
....................................................................................................................
....................................................................................................................
....................................................................................................................
....................................................................................................................
....................................................................................................................
......................................................................................................... 
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3. Generic Medicines 
3.1 If a generic drug has proven to have good quality and efficacy, to 
what extent would you prescribe it? 
 Always prescribe it 
 Prescribe it, if the patient happy to take it   
 Prescribe it, if no brand available  
 Prescribe it, some of the times  
 Never prescribe it  
 Don’t Know 
 
4. Essential Medicine List  
 
 
The WHO essential medicine list defined as " drugs that satisfy the 
health care needs of the majority of the population; they should therefore 
be available at all times in adequate amounts and in appropriate dosage 
forms, at a price the community can afford." it has been adopted by over 
150 countries worldwide.  
 
4.1 What are your views on the establishment of 'Essential Medicine List’ 
program 
 at the state of Kuwait? 
 I would strongly agree with its establishing   
 I would agree with its establishing 
 I have no strong feelings either way  
 I would disagree with its establishing  
 I would strongly disagree with its establishing 
 
Comments………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
270 
 
……………………………………………………………………………………………
………………………… 
Appendix III 
Assessment of the availability of Standard treatment guidelines 
in Kuwait healthcare facilities 
 
 
 
  
271 
 
 
Assessment of the availability of Standard treatment guidelines in Kuwait 
healthcare facilities 
 
 
The purpose of the study is to measure the current medicines supply system 
and what visions healthcare providers might have toward having an Essential 
Medicine List. This study forms part of PhD research programme in 
developments, economic studies and pharmaceutical innovations, which is 
under the supervision of Prof B.J. Clark and Dr John Lawler, University of 
Bradford, UK. 
 
 Please complete the questionnaire and return it to me in the sealed 
envelope provided 
 All responses will be dealt with strict confidence 
 Please direct questions or comments to  
 
 
Nadyah Alayadhi 
SISS and School of Life Sciences 
University of Bradford  
Bradford, West Yorkshire, UK 
n.y.alayad@student.bradford.ac.uk. 
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Healthcare facility type  
 Primary healthcare facility 
 Secondary healthcare facility 
 Tertiary healthcare facility  
 
Duration of work experience at current healthcare facility. 
 1-5 years 
 6-10 years 
 11 years and over 
 
Are you aware of the Standard Treatments Guidelines of your centre?  
 
 Yes 
 No 
 Not sure 
 Briefly 
 
 
What type of STG do you use? 
……………………………………………………………………………………………
……………………………………………………………………………………………
………………………………………………………………………………………… 
 
Are you using the same as your colleagues? 
 
 Yes 
 No 
 Maybe 
 Not sure 
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Why do you use this kind of STG? 
 Learned at university. 
 Conveyed from previous training at different country. 
 The official guidelines used by current centre. 
 Instructed by previous colleague to follow this STG. 
 Others, (please specify) 
……………………………………………………………………………………
……………………………………………………………………………………
……………………………………………………………………………………
………… 
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Appendix IV 
Point to be covered when meeting with Senior Health Managers  
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Name:  
Position:  
Date: 
After Reading the information provided, do you understand the concept of 
Essential Medicine List programme? 
What are your views? 
 Concept:   
 
 Feasibility:  
 
 Gains: 
 
 Drawbacks: 
 
Would you like EML programme to be implemented in the state of Kuwait? 
 
 
Would you like to be part of the process of executing EML? 
 
 
 
 
 
 
